



(51) International Patent Classification:
C12N 15/10 (2006.01)

(21) International Application Number:
PCT/US2015/058304

(22) International Filing Date:
30 October 2015 (30.10.2015)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
62/073,126 31 October 2014 (31.10.2014) US
62/166,302 26 May 2015 (26.05.2015) US

(71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).

(72) Inventors: LU, Timothy, Kuan-Ta; 1 Harvard Place, Charlestown, MA 02129 (US). WONG, Alan Siu, Lun; 334 Harvard Street, Apt. A2, Cambridge, MA 02139 (US). CHOI, Ching, Gee; 334 Harvard Street, Apt. A2, Cambridge, MA 02139 (US).

(74) Agent: DIPIETRANTONIO, Heather, J.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR

(57) Abstract: Described herein are methods and compositions that enable rapid generation of high-order combinations of genetic elements comprising a CRISPR guide sequence and a scaffold sequence, and a barcode for rapid identification of the combination of genetic elements encoded within a single cell or a pooled population. Also described herein compositions of inhibitors of epigenetic genes and methods for reducing cell proliferation and/or treating cancer.




FIG. 15

WO 2016/070037 A2



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR

RELATED APPLICATIONS

5 This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application number 62/073,126, filed October 31, 2014 and U.S. provisional application number 62/166,302, filed May 26, 2015, each of which is incorporated by reference herein in its entirety.

GOVERNMENT FUNDING

10 This invention was made with government funding support under Grant No. OD008435 awarded by National Institutes of Health. The government has certain rights in this invention.

FIELD OF INVENTION

15 The invention relates to methods and compositions for the rapid generation of high-order combinations of genetic elements comprising a CRISPR guide sequence and scaffold sequence, and the identification of said genetic elements. The invention also relates to compositions of inhibitors that target epigenetic genes to inhibit cell proliferation and related methods.

20

BACKGROUND

The clustered regularly interspaced short palindromic repeats (CRISPR) / Cas system was initially discovered in bacterial and archaeal species as a defense mechanism against foreign genetic material (*e.g.*, plasmids and bacteriophages). The naturally occurring CRISPR / Cas systems rely on expression of three components: a guide RNA sequence that is complementary to a target sequence, scaffold RNA that aids in recruiting the third component, an endonuclease, to the site. Though in many bacterial and archaeal species CRISPR / Cas systems are used to degrade foreign genetic material, the system has been adapted for use in a wide variety of prokaryotic and eukaryotic organisms and have been used for many methods including gene knockout, mutagenesis, and expression activation or repression (Hsu, et al. *Cell* (2014) 157(6):1262-1278). In genetically engineered CRISPR / Cas systems, the requirement for three independent components can be circumvented by expression of a small guide RNA (sgRNA) that contains both the CRISPR guide RNA sequence for binding a target sequence and the scaffold RNA that together mimics the

30

structure formed by the individual guide RNA sequence and scaffold sequence and is sufficient to recruit the endonuclease to the appropriate target site (Jinek, et al. *Science* (2012) 337(6096):816-821).

5

SUMMARY

Generation of vectors and genetic elements for the expression of multiple CRISPR systems comprising more than one sgRNA (guide sequence and scaffold sequence) is very laborious, and the complexity of libraries of CRISPR systems built using traditional cloning methods is very limited. The methods described herein allow for the generation of vectors comprising multiple sgRNAs each comprising a CRISPR guide sequences and a scaffold sequence, and concatenated barcode elements that can be detected and used as indicators of the identity of the CRISPR guide sequence(s). The methods also provide simple and rapid generation of highly complex libraries of vectors.

Aspects of the present invention provide genetic constructs comprising a first DNA element comprising a CRISPR guide sequence and a scaffold sequence; a first compatible end element and a second compatible end element flanking the first DNA element, wherein the first and second compatible end elements are capable of annealing to each other; a barcode element; a third compatible end element and a fourth compatible end element flanking the barcode element, wherein the third and fourth compatible end elements are capable of annealing to each other but are not capable of annealing to the first or second compatible end elements; and a separation site located between the fourth compatible end element and the first compatible end element, wherein the DNA element, first compatible end element, and second compatible end element are on one side of the separation site, and the barcode element, the third compatible end element, and the fourth compatible end element are on the other side of the separation site.

In some embodiments, the genetic construct further comprises a promoter element upstream of the first DNA element.

Aspects provide vectors comprising any of the genetic constructs provided herein.

Other aspects provide genetic constructs comprising a plurality of DNA elements, wherein each DNA element of the plurality of DNA element comprises a CRISPR guide sequence and a scaffold sequence; a first compatible end element and a second compatible end element flanking the plurality of DNA elements, wherein the first and second compatible end elements are capable of annealing to each other; a plurality of barcode elements; a third compatible end element and a fourth compatible end element flanking the plurality of

barcode elements, wherein the third and fourth compatible end elements are capable of annealing to each other but are not capable of annealing to the first or second compatible end elements; and a separation site located between the plurality of DNA elements and the plurality of barcode elements.

5 Other aspects provide vectors comprising any of the genetic constructs provided herein and a promoter sequence located upstream of each of the CRISPR guide sequences.

Yet other aspects provide methods for generating a combinatorial vector, comprising (a) providing a vector containing a first genetic construct comprising a CRISPR guide sequence; a second compatible end element and a first recognition site for a first restriction enzyme flanking the CRISPR guide sequence; a barcode element; and a third compatible end element and a second recognition site for a second restriction enzyme flanking the barcode element; (b) cleaving the first genetic construct at the first recognition site, resulting in a fifth compatible end element, and cleaving the vector at the second recognition site, resulting in a sixth compatible end element; (c) providing a scaffold element comprising a scaffold sequence; a separation site comprising a first compatible end element and a fourth compatible end element; and a seventh compatible end element and an eighth compatible end element flanking the scaffold element, wherein the seventh compatible end element is capable of annealing to the fifth compatible end element and the eighth compatible end element is capable of annealing to the sixth compatible end element; and (d) annealing the scaffold element to the cleaved first genetic construct, wherein the annealing occurs at compatible end elements within the vector and the scaffold element that are capable of annealing to each other, and wherein after the annealing, the scaffold element is integrated between the CRISPR guide sequence and the barcode element, and wherein the separation site is located between the scaffold sequence and the barcode element, creating a combinatorial vector.

25 In some embodiments, the method further comprises (a) providing any of the combinatorial vector as described herein; (b) cleaving the vector at the separation site within the scaffold element, resulting in a first compatible end element and a fourth compatible end element; (c) providing a second genetic construct comprising a CRISPR guide sequence; a scaffold sequence; a barcode element; and a second compatible end element and a third compatible end element flanking the second genetic construct, wherein the second compatible end element of the second genetic construct is capable of annealing with the first compatible end element of the vector and the third compatible end element of the second genetic construct is capable of annealing to the fourth compatible end element of the vector; and (d) annealing the second genetic construct to the cleaved vector, wherein the annealing occurs at

compatible end elements within the second genetic construct and the vector that are capable of annealing to each other, and wherein after annealing, the second genetic construct is integrated into the vector, creating a combinatorial vector comprising concatenated barcode elements and concatenated CRISPR guide and scaffold sequences.

5 In some embodiments, the combinatorial vector further comprises one or more promoter upstream of the CRISPR guide sequence. In some embodiments, the method is iterative. In some embodiments, the first recognition site and the second recognition sites have the same recognition site sequence, and the first restriction enzyme and the second restriction enzyme are the same restriction enzymes.

10 Other aspects of the invention provide genetic constructs comprising at least two CRISPR guide sequences; a barcode element; and a restriction recognition site located between each CRISPR guide sequence and between the barcode element and the CRISPR guide sequence nearest to the barcode element.

Other aspects provide genetic constructs comprising a plurality of DNA elements, each comprising a CRISPR guide sequence and a scaffold sequence; a barcode element; and a promoter sequence located upstream of each of the DNA elements of the plurality of DNA elements. In some embodiments, the barcode element is located at the 5' end of the genetic construct. In some embodiments, the barcode element is located at the 3' end of the genetic construct.

20 Other aspects provide vectors comprising any of the genetic constructs described herein.

Yet other aspects provide methods for generating a combinatorial vector, comprising (a) providing a vector comprising: a plurality of CRISPR guide sequences; a barcode element, wherein the barcode element is located downstream of the plurality of CRISPR guide sequences; optionally a promoter sequence located upstream of at least one of the plurality of CRISPR guide sequences; and a plurality of recognition sites for a plurality of restriction enzymes, wherein each of the plurality of recognition sites is located downstream of one of the plurality of CRISPR guide sequences; (b) cleaving the vector at at least one of the plurality of recognition sites with at least one of the plurality of restriction enzymes, resulting in a first compatible end element and a second compatible end element; (c) providing a first scaffold element comprising: a scaffold sequence, optionally a promoter sequence, and a third compatible end element and fourth compatible end element flanking the first scaffold element, wherein the third compatible end element is capable of annealing to the first compatible end element of the cleaved vector and the fourth compatible end element is

capable of annealing to the second compatible end element of the cleaved vector; and (d) annealing the first scaffold element to the cleaved vector, wherein the annealing occurs at compatible end elements within the first scaffold element and the cleaved vector, and wherein after annealing, the first scaffold element is integrated downstream of one of the plurality of CRISPR guide sequences, thereby producing a combinatorial vector. In some embodiments, the method is iterative.

Other aspects provide methods for generating a combinatorial vector comprising (a) providing a vector comprising: a plurality of CRISPR guide sequences, a barcode element, wherein the barcode element is located upstream of the plurality of CRISPR guide sequences; optionally a promoter sequence located upstream of at least one of the plurality of CRISPR guide sequences; and a plurality of recognition sites for a plurality of restriction enzymes, wherein each of the plurality of recognition sites is located upstream of one of the plurality of CRISPR guide sequences; (b) cleaving the vector at least one of the plurality of recognition sites with at least one of the plurality of restriction enzymes, resulting in a first compatible end element and a second compatible end element; (c) providing a first scaffold element comprising optionally a scaffold sequence, a promoter sequence, and a third compatible end element and fourth compatible end element flanking the first scaffold element, wherein the third compatible end element is capable of annealing to the first compatible end element of the cleaved vector and the fourth compatible end element is capable of annealing to the second compatible end element of the cleaved vector; (d) annealing the first scaffold element to the cleaved vector, wherein the annealing occurs at compatible end elements within the first scaffold element and the cleaved vector, and wherein after annealing, the first scaffold element is integrated upstream of one of the plurality of CRISPR guide sequences, thereby producing a combinatorial vector. In some embodiments, the method is iterative.

Aspects of the invention provide compositions comprising two or more inhibitors targeting two or more epigenetic genes selected from the combinations of epigenetic genes set forth in Table 2. In some embodiments, each of the two or more inhibitors reduce or prevent expression of an epigenetic gene or reduce or prevent activity of a protein encoded by the epigenetic gene. In some embodiments, each of the inhibitors is selected from the group consisting of a CRISPR guide sequence and scaffold sequence; an shRNA; and a small molecule. In some embodiments, at least one of the inhibitors is a CRISPR guide sequence and scaffold sequence; and the composition further comprises or encodes a Cas9 endonuclease. In some embodiments, the CRISPR guide sequence or shRNA is expressed from a recombinant expression vector. In some embodiments, the combination of epigenetic

genes comprises BRD4 and KDM4C or BRD4 and KDM6B. In some embodiments, the inhibitor of BRD4 is JQ1 ((6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester). In some
5 embodiments, the inhibitor of KDM4C is SD70 (N-(furan-2-yl(8-hydroxyquinolin-7-yl)methyl)isobutyramide). In some embodiments, the inhibitor of KDM6B is GSK-J4 (ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride).

Other aspects provide methods for reducing proliferation of a cell, comprising contacting the cell with a combination of two or more inhibitors targeting two or more
10 epigenetic genes selected from the combinations of epigenetic genes set forth in Table 2. In some embodiments, the cell is a cancer cell. In some embodiments, the cancer cell is an ovarian cancer cell. In some embodiments, each of the two or more inhibitors reduce or prevent expression of an epigenetic gene or reduce or prevent activity of a protein encoded by the epigenetic gene. In some embodiments, each of the inhibitors is selected from the group
15 consisting of a CRISPR guide sequence and scaffold sequence; an shRNA; and a small molecule. In some embodiments, at least one of the inhibitors is a CRISPR guide sequence and scaffold sequence; and the composition further comprises or encodes a Cas9 endonuclease. In some embodiments, the CRISPR guide sequence or shRNA is expressed from a recombinant expression vector. In some embodiments, the combination of epigenetic
20 genes comprises BRD4 and KDM4C or BRD4 and KDM6B. In some embodiments, the inhibitor of BRD4 is JQ1 ((6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester). In some embodiments, the inhibitor of KDM4C is SD70 (N-(furan-2-yl(8-hydroxyquinolin-7-yl)methyl)isobutyramide). In some embodiments, the inhibitor of KDM6B is GSK-J4 (ethyl
25 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride).

Other aspects provide methods for treating cancer in a subject comprising administering to the subject a combination of two or more inhibitors targeting two or more
30 epigenetic genes selected from the combinations of epigenetic genes set forth in Table 2, wherein each of the two or more inhibitors are administered in an effective amount. In some embodiments, each of the inhibitors is selected from the group consisting of a CRISPR guide sequence, an shRNA, and a small molecule. In some embodiments, the effective amount of each of the two or more inhibitors administered in the combination is less than the effective amount of the inhibitor when not administered in the combination. In some embodiments,

each of the two or more inhibitors reduce or prevent expression of an epigenetic gene or reduce or prevent activity of a protein encoded by the epigenetic gene. In some embodiments, each of the inhibitors is selected from the group consisting of a CRISPR guide sequence and scaffold sequence; an shRNA; and a small molecule. In some embodiments, at least one of the inhibitors is a CRISPR guide sequence and scaffold sequence; and the composition further comprises or encodes a Cas9 endonuclease. In some embodiments, the CRISPR guide sequence or shRNA is expressed from a recombinant expression vector. In some embodiments, the combination of epigenetic genes comprises BRD4 and KDM4C or BRD4 and KDM6B. In some embodiments, the inhibitor of BRD4 is JQ1 ((6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester). In some embodiments, the inhibitor of KDM4C is SD70 (N-(furan-2-yl(8-hydroxyquinolin-7-yl)methyl)isobutyramide). In some embodiments, the inhibitor of KDM6B is GSK-J4 (ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride).

Other aspects provide methods for identifying a combination of inhibitors of epigenetic genes that reduces proliferation of a cell comprising contacting a first population of cells and a second population of cells with a plurality of combinations of two or more CRISPR guide sequences and scaffold sequences and a Cas9 endonuclease; culturing the first population of cells and the second population of cells such that the second population of cells is cultured for a longer duration compared to the first population of cells; identifying the combinations of two or more CRISPR guide sequences and scaffold sequences in the first population of cells and the combinations of two or more CRISPR guide sequences and scaffold sequences in the second population of cells; comparing the abundance of each combination of two or more CRISPR guide sequences and scaffold sequences in the first population of cells to the abundance of each combination of two or more CRISPR guide sequences and scaffold sequences in the second population of cells; and identifying a combination of two or more CRISPR guide sequences and scaffold sequences that is absent from or in reduced abundance in the second population of cells but present in or in increased abundance in the first population of cells as a combination of CRISPR guide sequences and scaffold sequences that reduces cell proliferation.

Yet other aspects provide methods for identifying a combination of genes to be inhibited to reduce proliferation of a cell comprising contacting a first population of cells and a second population of cells with a plurality of combinations of two or more CRISPR guide sequences and scaffold sequences and a Cas9 endonuclease; culturing the first population of

cells and the second population of cells such that the second population of cells is cultured for a longer duration compared to the first population of cells; identifying the combinations of two or more CRISPR guide sequences and scaffold sequences in the first population of cells and the combinations of two or more CRISPR guide sequences and scaffold sequences in the
5 second population of cells; comparing the abundance of each combination of two or more CRISPR guide sequences and scaffold sequences in the first population of cells to the abundance of each combination of two or more CRISPR guide sequences and scaffold sequences in the second population of cells; and identifying a combination of two or more CRISPR guide sequences and scaffold sequences that is absent from or in reduced abundance
10 in the second population of cells but present in or in increased abundance in the first population of cells as a combination of genes to be inhibited to reduce proliferation.

These and other aspects of the invention, as well as various embodiments thereof, will become more apparent in reference to the drawings and detailed description of the invention.

Each of the limitations of the invention can encompass various embodiments of the
15 invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combination of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being
20 carried out in various ways.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are not intended to be drawn to scale. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:

25

FIG. 1 presents a schematic depicting a non-limiting embodiment of the invention. In steps 1 and 2, an oligonucleotide library is synthesized and corresponding oligonucleotide pairs are annealed together. Each oligonucleotide contains a CRISPR guide sequence, two BbsI restriction recognition sites, and a barcode element. In step 3, the oligonucleotides are
30 ligated into a storage vector in a one-pot ligation reaction resulting in a vector containing the oligonucleotide. In step 4, the vector is digested at the BbsI restriction recognition sites to allow for insertion of a scaffold sequence as well as a separation site formed by BamHI and EcoRI restriction recognition sites. The barcoded guide RNA library can be iteratively digested at the separation site for insertion of additional elements containing a CRISPR guide

sequence, scaffold sequence, separation site, and barcode element, resulting in a complex guide RNA library with concatenated barcode elements. The sequences, from top to bottom, correspond to SEQ ID NOs: 364-366.

5 FIGs. 2A and 2B present schematics depicting non-limiting embodiments of the invention. In step 1 of FIG. 2A, oligonucleotides are synthesized, each containing multiple CRISPR guide sequences and a single barcode element downstream of the CRISPR guide sequences. Restriction recognition sites (RE) are present following each of the CRISPR guide sequences. In step 2, the pooled synthesized oligonucleotides are ligated into a
10 destination vector in a one-pot ligation reaction. As shown in step 3, the vector can be sequentially digested at each of the restriction recognition sites following each CRISPR guide sequence with different restriction enzymes, allowing for insertion of a scaffold element, and in some cases a promoter element to drive expression of a downstream CRISPR guide sequence, resulting in a barcoded combinatorial guide RNA library encoding multiple
15 CRISPR guide sequences and scaffold sequences with a single barcode element. In step 1 of FIG. 2B, oligonucleotides are synthesized, each containing multiple CRISPR guide sequences and a single barcode element upstream of the CRISPR guide sequences. Restriction recognition sites (RE) are present following each of the CRISPR guide sequences. In step 2, the pooled synthesized oligonucleotides are ligated into a destination vector in a
20 one-pot ligation reaction. As shown in step 3, the vector can be sequentially digested at each of the restriction recognition sites following each CRISPR guide sequence with different restriction enzymes, allowing for insertion of a scaffold element, and in some cases a promoter element to drive expression of a downstream CRISPR guide sequence, resulting in a barcoded combinatorial guide RNA library encoding multiple CRISPR guide sequences and
25 scaffold sequences with a single barcode element.

FIGs. 3A-3D show generation of a high-coverage combinatorial gRNA library and efficient delivery of the library to human cells. FIG. 3A presents the cumulative distributions of barcode reads for a one-wise gRNA library in the plasmid pool extracted from *E. coli*
30 indicating full coverage for all expected combinations. FIG. 3B presents the two-wise gRNA library in both the plasmid pool and the lentivirus-infected OVCAR8-ADR-Cas9 cell pool indicating near-full coverage for all expected combinations. Most barcoded gRNA combinations were detected within a 5-fold range from the mean barcode reads per combination (highlighted by the shaded areas and indicated by the arrows). FIG. 3C shows a

high correlation between barcode representations (\log_2 values of normalized barcode counts) within the plasmid pool and the infected OVCAR8-ADR-Cas9 cell pool, indicating efficient lentiviral delivery of the two-wise library into human cells. FIGs. 3D shows high reproducibility for barcode representations between two biological replicates in OVCAR8-ADR-Cas9 cells cultured for 5-days post-infection with the two-wise gRNA library. R is the Pearson correlation coefficient.

FIGs. 4A-4C show identification of gRNA combinations that inhibit cancer cell proliferation using a high-throughput screening. FIG. 4A shows a schematic of the high-throughput screen in which OVCAR8-ADR-Cas9 cells were infected with the barcoded two-wise gRNA library and cultured for 15 or 20 days. Barcode representations within the cell pools were identified and quantified using Illumina HiSeq and compared between the two pools. FIG. 4B (right panel) shows two-wise gRNA combinations that were found to modulate cell proliferation ranked by \log_2 ratios between the normalized barcode count in 20-day versus 15-day cultured cells. FIG. 4B (left panel) shows the same gRNAs paired with control gRNAs. Combinations with control gRNA pairs are highlighted in open triangles. The anti-proliferative effects of gRNA combinations that were confirmed in another biological replicate are highlighted in open circles (see FIG. 12). The labeled gRNA combinations were further validated. FIG. 4C presents validation of two-wise combinations that modulate cancer cell proliferation. OVCAR8-ADR-Cas9 cell populations were infected with the indicated two-wise gRNA combinations and cultured for 15 days. Equal numbers of cells were then re-plated and cultured for additional time periods as indicated. Cell viability was measured using the MTT assay and characterized by absorbance measurements ($OD_{570} - OD_{650}$) ($n = 3$). Data represent the mean \pm standard deviation (SD).

25

FIGs. 5A-5D show combinatorial inhibition of KDM4C and BRD4 or KDM6B and BRD4 inhibits human ovarian cancer cell growth. FIG. 5A shows the fold change in cell viability of OVCAR8-ADR-Cas9 cells infected with lentiviruses expressing the indicated single or combinatorial gRNAs relative to cells infected with lentiviruses expressing control gRNA. Cells were cultured for 15 days, then equal numbers of infected cells were then re-plated and cultured for 5 additional days. FIG. 5B shows the fold change in cell viability of OVCAR8-ADR cells co-infected with lentiviruses expressing the indicated shRNAs relative to cells infected with lentiviruses expressing control shRNA. Cells were cultured for 9 days, then equal numbers of infected cells were re-plated and cultured for 4 additional days. FIG.

30

5C shows the percentage of cell growth inhibition of OVCAR8-ADR cells treated with SD70 and JQ1 at the indicated concentrations for 5 days relative to control cells that did not receive drug. The calculated excess inhibition over the predicted Bliss independence and HSA models are also shown for the combination of SD70 and JQ1 (center and right panels). FIG. 5D shows the percentage of cell growth inhibition of OVCAR8-ADR cells treated with GSK-J4 and JQ1 at the indicated concentrations for 7 days relative to control cells that did not receive drug. The calculated excess inhibition over the predicted Bliss independence and HSA models are also shown for the combination of GSK-J4 and JQ1 (center and right panels). Cell viability was determined by MTT assay. Data represent mean \pm SD (n =3 for (FIG. 5A); n = 6 for (FIGs. 5B-5D)). The asterisk (*P < 0.05) and hash (#P < 0.05) represent significant differences between the indicated samples and between drug-treated versus no drug control samples, respectively.

FIGs. 6A-6E show lentiviral delivery of combinatorial gRNA expression constructs provides efficient target gene repression. FIG. 6A presents a schematic of a strategy for testing lentiviral combinatorial gRNA expression constructs in human cells. Lentiviruses were generated that contained genes encoding RFP and GFP expressed under control of UBC and CMV promoters, respectively, and tandem U6 promoter-driven expression cassettes of gRNAs targeting RFP (RFP-sg1 or RFP-sg2) and GFP (GFP-sg1) sequences. The lentiviruses were used to infect OVCAR8-ADR or OVCAR8-ADR-Cas9 cells, and GFP and RFP expression were assessed using flow cytometry and fluorescence microscopy. FIG. 6B shows flow cytometry scatter plots assessing GFP and RFP expression in cells infected with lentiviruses encoding the indicated gRNA expression constructs for 4 days. Lentiviruses encoding combinatorial gRNA expression constructs reduced the percentage of cells positive for RFP and GFP fluorescence in OVCAR8-ADR-Cas9 cells but not OVCAR8-ADR cells. FIG. 6C presents the percentage of cells positive for GFP (left columns) and RFP (right columns) at day 4 post-infection with lentiviruses encoding the indicated gRNA expression constructs. FIG. 6D presents the percentage of cells positive for GFP (left columns) and RFP (right columns) at day 8 post-infection with lentiviruses encoding the indicated gRNA expression constructs. Limited cross-reactivity between gRNAs targeting RFP and GFP was detected. Data in FIG. 6B represents flow cytometry measurements for cells infected for 4 days, while quantifications in FIGs. 6C and 6D represent the mean \pm standard deviation (n = 3). FIG. 6E presents representative fluorescence micrographs demonstrating that

combinatorial gRNA expression constructs effectively repressed RFP and GFP fluorescence levels in OVCAR8-ADR-Cas9 cells but not in OVCAR8-ADR cells at day 3 post-infection.

FIGs. 7A-7C show the cleavage efficiency of gRNAs of targeted genes in OVCAR8-ADR-Cas9 cells. FIG. 7A presents a summary table showing the indel percentages detected in OVCAR8-ADR-Cas9 cells, using the Surveyor assay. Cells were infected with 8 different gRNAs randomly-selected from the screening library for 8 or 12 days. The expected sizes of the uncleaved and cleaved PCR products detected for the Surveyor assay are listed in base pairs. FIGs. 7B and 7C present agarose gels showing the Surveyor assay results for DNA cleavage efficiency in OVCAR8-ADR-Cas9 cells that were either uninfected or infected with the indicated gRNAs for 8 or 12 days.

FIGs. 8A and 8B show the cleavage efficiency of dual-gRNA expression constructs at targeted genes in OVCAR8-ADR-Cas9 cells. FIG. 8A presents the expected sizes of the uncleaved and cleaved PCR products detected for the Surveyor assay listed in base pairs (upper panel). The agarose gel shows the indel percentages detected in OVCAR8-ADR-Cas9 cells infected with the indicated single or dual-gRNA expression constructs for 12 days using the Surveyor assay (lower panel). FIG. 8B is an immunoblot analysis showing protein levels in OVCAR8-ADR-Cas9 cells that were either infected with vector control, or the indicated single- or dual- gRNA constructs for 15 days.

FIGs. 9A-9C present DNA alignments of targeted alleles for single-cell-derived OVCAR8-ADR-Cas9 clones infected with dual-gRNA expression constructs. FIG. 9A shows alignments of sequences from OVCAR8-ADR-Cas9 cells infected with lentiviruses expressing sgRNAs targeting BMI1 and PHF8. The sequences, from top to bottom, correspond to SEQ ID NOs: 203, 204, 203, 203, 204, 204, 203, 205, 206, 206, 203, 203, 204, 207, 208, 209, 204, 210, 208, 208, 210, 210, 203, 219, 206, 206, 208, 208, 220, 220, 221, 222, 204, 204, 223, 224, 204, 204, 203, 203, 204, and 204, respectively. FIG. 9B shows alignments of sequences from OVCAR8-ADR-Cas9 cells infected with lentiviruses expressing gRNAs targeting BRD4 and KDM4C. The OVCAR8-ADR-Cas9 cells were infected with lentiviruses for 12 days and plated as single cells. Genomic DNA for each single cell-expanded clone was extracted. The targeted alleles were amplified by PCR and inserted into the TOPO vector by TA cloning for Sanger sequencing. The sequences for the two alleles of each clone are shown. Mutations and insertions of nucleotides are in bold,

while deletions are indicated as “-”. Wildtype (WT) sequences for the targeted genes are shown as references, with the 20 bp gRNA target underlined and PAM sequences in bold italics. The sequences, from top to bottom, correspond to SEQ ID NOs: 211,212, 211, 211, 213, 213, 211, 211, 214, 214, 211, 215, 212, 216, 211, 211, 217, 218, 211, 211, 212, 212, 5 211, 211, 225, 226, 211, 211, 226, 227, 211, 211, 212, 212, 211, 228, 226, 229, 211, 211, 229, 226, 211, 211, 230, and 226, respectively. FIG. 9C is a Venn diagram showing the frequency of single- and dual- gene-edited cells. OVCAR8-ADR-Cas9 cells harboring the indicated dual-gRNA expression constructs were plated as single cells by FACS. The targeted alleles were sequenced from 40 whole genome-amplified single cells with Illumina 10 MiSeq. 75% (i.e., 30/40) and 80% (i.e., 32/40) of the single cells harbored at least one mutant allele at the targeted BMI1 and PHF8 loci, respectively. 62.5% (i.e., 25/40) of the single cells contained at least one mutant allele in both BMI1 and PHF8 genes. The sequences for the two alleles of each single cell are shown in Table 6. Similar mutant allele frequencies determined from the single-cell-derived clones by Sanger sequencing (FIG. 9B) and whole-genome- 15 amplified single cells by Illumina MiSeq (FIG. 9C) were observed.

FIGs. 10A and 10B show high reproducibility of barcode quantitation between biological replicates for the combinatorial gRNA screen. FIG. 10A presents a scatter plot comparing barcode representations (\log_2 number of normalized barcode counts) between two biological replicates for OVCAR8-ADR-Cas9 cells cultured for 15 days post-infection with 20 the two-wise gRNA library. FIG. 10B presents a scatter plot comparing barcode representations (\log_2 number of normalized barcode counts) between two biological replicates for OVCAR8-ADR-Cas9 cells cultured for 20 days post-infection with the two-wise gRNA library. R is the Pearson correlation coefficient.

25 FIG. 11 shows consistent fold-changes in barcodes quantitation among the same gRNA combinations arranged in different orders within the expression constructs. The coefficient of variation (CV; defined as SD /mean of the fold changes of normalized barcode counts for 20-day versus 15-day cultured OVCAR8-ADR-Cas9 cells) was determined for each two-wise gRNA combination arranged in different orders (i.e., sgRNA-A + sgRNA-B 30 and sgRNA-B + sgRNA-A). Over 82% of the two-wise gRNA combinations had a CV of <0.2 , and 95% of two-wise gRNA combinations had a CV of <0.4 , respectively, in the cell-proliferation screen.

FIGs. 12A-12C show biological replicates for the combinatorial screen identifying gRNA pairs that inhibit cancer cell proliferation. FIG. 12A shows \log_2 fold change for OVCAR8-ADR-Cas9 cells infected with the same two-wise gRNA library used in FIG. 4B. Combinations of guide RNA pairs (right panel) and their gRNA + control counterparts (i.e., gene-targeting gRNA + control gRNA; left panel) that modulated proliferation were ranked by the \log_2 ratios of the normalized barcode count for 20-day compared to 15-day cultured cells. The anti-proliferative effects of gRNA combinations that were confirmed in another biological replicate are highlighted in open circles (FIG. 4B), while combinations with control gRNA pairs are highlighted in open triangles. Labeled gRNA combinations were further validated in FIG. 4C. FIG. 12B presents a scatter plot showing the \log_2 ratios of the normalized barcode counts for 20-day versus 15-day cultured cell between two biological replicates of OVCAR8-ADR-Cas9 cells infected with the two-wise gRNA library. FIG. 12C shows the frequency distribution of \log_2 ratios for the gRNA combinations in the pooled screen. \log_2 ratios shown were calculated from the mean of two biological replicates.

15

FIG. 13 shows high consistency between individual hits in the pooled screen and in the validation data. For each two-wise gRNA combination, the fold-change in the normalized barcode count for 20-day versus 15-day cultured cells, obtained from the pooled screening data ('Screen phenotype') was plotted against its relative cell viability compared to the vector control determined from the individual cell-proliferation assays ('Validation phenotype') ($R = 0.932$). Data for the screen phenotype are the mean of two biological replicates; the individual validation phenotype represents the mean of three independent experiments. R is the Pearson correlation coefficient.

25

FIGs. 14A-14F show shRNA-mediated knockdown of targeted genes in OVCAR8-ADR cells. FIG. 14A presents the relative mRNA levels of KDM4C in OVCAR8-ADR cells expressing control shRNA or shRNA targeting KDM4C. FIG. 14B presents the relative mRNA levels of BRD4 in OVCAR8-ADR cells expressing control shRNA or shRNA targeting BRD4. FIG. 14C presents the relative mRNA levels of KDM6B in OVCAR8-ADR cells expressing control shRNA or shRNA targeting KDM6B. mRNA levels were quantified by qRT-PCR and normalized to actin mRNA levels. Data represent the mean \pm SD ($n = 3$). FIGs. 14D-14F show Western blot analysis of relative protein levels in OVCAR8-ADR cells expressing control shRNA or shRNAs targeting *KDM4C*, *BRD4*, or *KDM6B*. Measured protein levels were normalized to actin levels, normalized to the control shRNA samples, and

30

plot as the relative protein level in the graphs below. The asterisk (* $P < 0.05$) represents a significant difference in mRNA or protein levels between cells expressing the gene-targeting shRNA versus control shRNA.

5 FIG. 15 shows a strategy for assembling barcoded combinatorial gRNA libraries. Barcoded gRNA oligo pairs were synthesized, annealed, and cloned in storage vectors in pooled format. Oligos with the gRNA scaffold sequence were inserted into the pooled storage vector library to create the barcoded sgRNA library. Detailed assembly steps are shown in FIG. 1. The CombiGEM strategy was used to build the combinatorial gRNA
10 library. Pooled barcoded sgRNA inserts prepared from the sgRNA library with BglIII and MfeI digestion were ligated via compatible overhangs generated in the destination vectors with BamHI and EcoRI digestion. Iterative one-pot ligation created (n)-wise gRNA libraries with unique barcodes corresponding to the gRNAs concatenated at one end, thus enabling tracking of individual combinatorial members within pooled populations via next-generation
15 sequencing.

 FIGs. 16A-16E present the results from deep sequencing for indel analysis at gRNA-at targeted genomic loci in OVCAR8-ADR-Cas9 cells. Cells were infected with the indicated sgRNAs for 15 days and then subjected to deep sequencing. FIG. 16A presents the
20 indel frequency. FIG. 16B shows the percentage of frameshift and in-frame mutations. FIG. 16C shows the distribution of indel sizes. FIG. 16D shows the distribution of indels analyzed by deep sequencing of the targeted genomic loci in OVCAR8-ADR-Cas9 cells that were infected for 15 days with either the single sgRNAs (KDM4C or BRD4), top graphs, or dual-gRNA expression constructs (KDM4 and BRD4), bottom graphs. FIG. 16E shows the
25 distribution of indels analyzed by deep sequencing of the targeted genomic loci in OVCAR8-ADR-Cas9 cells that were infected for 15 days with either the single sgRNAs (PHF8 or BMI1), top graphs, or dual-gRNA expression constructs (PHF8 and BMI1), bottom graphs.

 FIGs. 17A-17C show mathematical modeling of the frequency of a pro-proliferative
30 gRNA and an anti-proliferative gRNA within a mixed cell population. FIG. 17A shows simulation of the relative frequencies of a pro-proliferative gRNA and an anti-proliferative gRNA in a cell population with different fractions (*i.e.*, 2, 5, or 10%) of cells that contain the anti-proliferative gRNA (f_s) and the pro-proliferative (f_p) gRNA initially. The relative frequency is defined as the barcode abundance at a given time compared to the initial time

point. In this example, the fraction of cells with the modified growth rate due to genetic perturbations by the CRISPR-Cas9 system (p) is set as 1.0 (i.e., 100%), and the doubling time of the anti-proliferative clone ($T_{doubling,m}$) is 48 hours. FIGs. 17B and 17C show modeled relative frequencies of an anti-proliferative gRNA in a mixed cell population with regard to variations in the parameters: p , $T_{doubling,m}$, f_s , and f_f . In each graph of FIGs. 17B and 17C, lines represent $p=0.2$, $p=0.4$, $p=0.6$, $p=0.8$, and $p=1.0$, from top to bottom. In FIGs. 17A-17C, the doubling time of the pro-proliferative clone is set as 12 hours. Detailed definitions are described in Example 3.

FIG. 18 shows pooled screen and validation data for individual gRNA combinations. For each gRNA combination, the fold-change in the normalized barcode count for 20-day versus 15-day cultured cells obtained from the pooled screening data ('Screen phenotype') was plotted against its relative cell viability compared to the vector control determined from the individual cell-proliferation assays ('Validation phenotype'). The Screen phenotype of each individual sgRNA was averaged from the fold-change of the corresponding sgRNA paired with each of the three control sgRNAs. Data for the screening data are the mean of two biological replicates, while the individual validation data represent the mean \pm SD ($n \geq 3$).

FIG. 19 presents the measurement of on-target and off-target indel generation rates for gRNAs targeting KDM4C, KDM6B, and BRD4. Each row represents a genomic locus corresponding to a 20 bp guide sequence (in black) followed by a 3 bp PAM sequence (in gray). Sequences in bold black font represent the gRNA's on-target genomic sequence. Below each dashed line for KDM4C-sg1, KDM6B-sg2, and BRD4-sg3 are all the predicted exonic off-target genomic sequences identified using the CRISPR design (Ran, et al. *Nature Protocols* (2013) 8:2281-2308) and CCTop (Stemmer, *PLoS One* (2015) 10:e0124633) tools. Five exonic/intronic off-target sites predicted for BRD4-sg2 were also evaluated. Underlined nucleotides highlight the differences in the off-target sequences from the on-target sequence. Each genomic locus was PCR amplified from $\sim 10,000$ cells and deep sequenced with >4.2 million reads. n.d. indicates that PCR of the genomic sequence failed to provide specific amplicons for sequencing. The sequences, from top to bottom, correspond to SEQ ID NOs: 368-393.

FIGs. 20A-20B show the reduced growth in OVCAR8-ADR-Cas9 cells harboring both KDM4C and BRD4 frameshift mutations. FIG. 20A depicts a cell growth assay on a single-cell-expanded OVCAR8-ADR-Cas9 mutant clone with both *KDM4C* and *BRD4* frameshift mutations (i.e., derived from Clone #3 shown in FIG. 9B). Equal numbers of cells were plated and cultured for 5 days before MTT assay. Data represent mean \pm SD (n = 3) of absorbance measurements ($OD_{570} - OD_{650}$) relative to control OVCAR8-ADR-Cas9 cells. The asterisk (*P < 0.01) represents significant difference between the control and mutant cells. FIG. 20B presents an immunoblot analysis of protein levels in the control and mutant cells from FIG. 20A.

10

FIGs. 21A-21B show RNA-sequencing analysis of OVCAR8-ADR-Cas9 cells infected with gRNA expression constructs. FIG. 21A presents representative heatmaps showing the relative expression levels of each gene transcript (rows) in each sample (column) for OVCAR8-ADR-Cas9 cells targeted by the respective single or dual gRNAs. Transcripts that were identified as significantly differentially expressed in OVCAR8-ADR-Cas9 cells infected with the indicated gRNA(s), when compared to the vector control, are included in the heatmaps. Values are \log_2 -transformed FPKM measured using RNA-Seq, and mean-centered by the transcript. Hierarchical clustering of transcripts and samples was performed based on the Pearson's correlation. FIG. 21B shows the top ten enriched gene sets of biological processes for the differentially expressed genes identified in OVCAR8-ADR-Cas9 cells infected with the indicated gRNAs when compared to the vector control (Q-value < 0.05). Subsets of the differentially expressed genes (x-axes) that are associated with the gene sets (y-axes) are shaded in gray in the tables.

25

FIGs. 22A-22B show the effect of KDM4C and BRD4, as well as KDM6B and BRD4, on cell growth for additional cancer cell lines. FIG. 22A shows that combinatorial gRNA expression constructs effectively repressed targeted fluorescence genes in breast cancer MDA-MB231-Cas9 and pancreatic cancer Bx-PC3-Cas9 cells. Lentiviral vectors that contained RFP and GFP genes expressed from constitutive promoters, with or without tandem U6 promoter-driven expression cassettes of gRNAs targeting RFP and GFP sequences, were delivered to MDA-MB231-Cas9 and Bx-PC3-Cas9 cells for analysis of GFP and RFP expression under flow cytometry. Detailed strategy is described in FIG. 6. Lentiviruses encoding combinatorial gRNA expression constructs reduced the percentage of cells positive for RFP and GFP fluorescence at day 4 post-infection. FIG. 22B shows MDA-

30

MB231-Cas9 and Bx-PC3-Cas9 cells infected with lentiviruses expressing the indicated single or combinatorial gRNAs were cultured for 14 days. Equal numbers of infected cells were then re-plated and cultured for additional 5 days. Cell viabilities relative to control sgRNA were determined by the MTT assay. Data represent mean \pm SD (n =6) from 5 biological replicates. The asterisk (*P < 0.05) represents significant differences between the indicated samples. These results indicate that combinatorial gRNA targeting of epigenetic genes can have variable phenotypes depending on the cellular background.

DETAILED DESCRIPTION

10 Generation of vectors and genetic elements for the expression of multiple CRISPR systems comprising more than one sgRNA (guide sequence and scaffold sequence) is very laborious, and the complexity of libraries of CRISPR systems built using traditional cloning methods is very limited. The methods described herein result in vectors with concatenated barcodes and CRISPR guide sequences and scaffold sequences. The methods are potentially 15 highly efficient for building large libraries for combinatorial genetic screening and leverage the fact that large numbers of oligonucleotides can be readily printed and that guide sequences with target specificity determining regions can be printed onto these oligonucleotides because the guide sequences and barcode elements are of short lengths.

The Massively Parallel Combinatorial Genetics approach to generating CRISPR 20 constructs and vectors described herein allows the rapid generation of combinatorial sets of genetic constructs comprising components of the CRISPR system (CRISPR guide sequences and scaffold sequences) capable of targeting nucleic acid of a host cell. The methods also enable the pooled screening of multiple combination orders (*e.g.*, pairwise, tri-wise, and n-wise combination can be pooled and screened together simultaneously), identifying minimal 25 combinations needed for a given application. Combinatorial sets of genetic constructs, such as those generated using the methods described herein, may be useful for the identification of genes and genetic pathways that interact synergistically to regulate a cellular process or phenotype, such as cancer cell growth. Also described herein are novel combinations of epigenetic genes identified, using combinatorial CRISPR constructs described herein that, 30 when inhibited together, have anti-cancer effects, such as reducing proliferation of cells.

Aspects of the present disclosure relate to genetic constructs, vectors comprising genetic constructs, combinatorial vectors, and methods of generating combinatorial vectors using in the Massively Parallel Combinatorial Genetics approach, which can be found in PCT

Publication No. WO2014/00542, herein incorporated by reference in its entirety. As used herein, a “genetic construct” refers to one or more DNA element(s) comprising a CRISPR guide sequence and a scaffold sequence and a barcode element, such that each DNA element is associated with a barcode element. As used herein, association between a specific DNA
5 element and a barcode element means that a specific DNA element and a barcode element are always contained within the same genetic construct. Accordingly, the presence or detection of a specific barcode element within a genetic construct indicates that the associated specific DNA element(s) is also present within the same genetic construct.

In a host cell, the DNA element comprising a CRISPR guide sequence and a scaffold
10 sequence is transcribed and forms a CRISPR small-guide RNA (sgRNA) that functions to recruit an endonuclease to a specific target nucleic acid in a host cell, which may result in site-specific CRISPR activity. As used herein, a “CRISPR guide sequence” refers to a nucleic acid sequence that is complementary to a target nucleic acid sequence in a host cell. The CRISPR guide sequence targets the sgRNA to a target nucleic acid sequence, also
15 referred to as a target site. The CRISPR guide sequence that is complementary to the target nucleic acid may be between 15-25 nucleotides, 18-22 nucleotides, or 19-21 nucleotides in length. In some embodiments, the CRISPR guide sequence that is complementary to the target nucleic acid is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In some embodiments, the CRISPR guide sequence that is complementary to the target nucleic
20 acid is 20 nucleotides in length.

It will be appreciated that a CRISPR guide sequence is complementary to a target nucleic acid in a host cell if the CRISPR guide sequence is capable of hybridizing to the target nucleic acid. In some embodiments, the CRISPR guide sequence is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or at least 100%
25 complementary to a target nucleic acid (see also US Patent 8,697,359, which is incorporated by reference for its teaching of complementarity of a CRISPR guide sequence with a target polynucleotide sequence). It has been demonstrated that mismatches between a CRISPR guide sequence and the target nucleic acid near the 3' end of the target nucleic acid may abolish nuclease cleavage activity (Upadhyay, et al. *Genes Genome Genetics* (2013)
30 3(12):2233-2238). In some embodiments, the CRISPR guide sequence is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or at least 100% complementary to the 3' end of the target nucleic acid (e.g., the last 5, 6, 7, 8, 9, or 10 nucleotides of the 3' end of the target nucleic acid).

The CRISPR guide sequence may be obtained from any source known in the art. For example, the CRISPR guide sequence may be any nucleic acid sequence of the indicated length present in the nucleic acid of a host cell (*e.g.*, genomic nucleic acid and/or extra-genomic nucleic acid). In some embodiments, CRISPR guide sequences may be designed and synthesized to target desired nucleic acids, such as nucleic acids encoding transcription factors, signaling proteins, transporters, etc. In some embodiments, the CRISPR guide sequences are designed and synthesized to target epigenetic genes. For example, the CRISPR guide sequences may be designed to target any of the combinations of epigenetic genes presented in Table 2. In some embodiments, the CRISPR guide sequences comprise any of the example CRISPR guide sequences provided in Table 1.

As used herein, a “scaffold sequence,” also referred to as a tracrRNA, refers to a nucleic acid sequence that recruits an endonuclease to a target nucleic acid bound (hybridized) to a complementary CRISPR guide sequence. Any scaffold sequence that comprises at least one stem loop structure and recruits an endonuclease may be used in the genetic elements and vectors described herein. Exemplary scaffold sequences will be evident to one of skill in the art and can be found for example in Jinek, et al. *Science* (2012) 337(6096):816-821, Ran, et al. *Nature Protocols* (2013) 8:2281-2308, PCT Application No. WO2014/093694, and PCT Application No. WO2013/176772.

The terms “target nucleic acid,” “target site,” and “target sequence” may be used interchangeably throughout and refer to any nucleic acid sequence in a host cell that may be targeted by the CRISPR guide sequences described herein. The target nucleic acid is flanked downstream (on the 3' side) by a protospacer adjacent motif (PAM) that may interact with the endonuclease and be further involved in targeting the endonuclease activity to the target nucleic acid. It is generally thought that the PAM sequence flanking the target nucleic acid depends on the endonuclease and the source from which the endonuclease is derived. For example, for Cas9 endonucleases that are derived from *Streptococcus pyogenes*, the PAM sequence is NGG. For Cas9 endonucleases derived from *Staphylococcus aureus*, the PAM sequence is NNGRRT. For Cas9 endonucleases that are derived from *Neisseria meningitidis*, the PAM sequence is NNNNGATT. For Cas9 endonucleases derived from *Streptococcus thermophilus*, the PAM sequence is NNAGAA. For Cas9 endonuclease derived from *Treponema denticola*, the PAM sequence is NAAAAC. For a Cpf1 nuclease, the PAM sequence is TTN.

In some embodiments, the CRISPR guide sequence and the scaffold sequence are expressed as separate transcripts. In such embodiments, the CRISPR guide sequence further

comprises an additional sequence that is complementary to a portion of the scaffold sequence and functions to bind (hybridize) the scaffold sequence and recruit the endonuclease to the target nucleic acid. In other embodiments, the CRISPR guide sequence and the scaffold sequence are expressed as a single transcript, as a chimeric RNA that may be referred to as a single guide RNA (sgRNA). An sgRNA has the dual function of both binding (hybridizing) to the target nucleic acid and recruiting the endonuclease to the target nucleic acid. In such embodiments, the scaffold sequence may further comprise a linker loop sequence.

The barcode elements can be used as identifiers for a genetic construct and may indicate the presence of one or more specific CRISPR guide sequences in a vector or genetic element. Members of a set of barcode elements have a sufficiently unique nucleic acid sequence such that each barcode element is readily distinguishable from the other barcode elements of the set. Barcode elements may be any length of nucleotide but are preferably less than 30 nucleotides in length. In some embodiments, the barcode element is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, or 30 or more nucleotides in length. Detecting barcode elements and determining the nucleic acid sequence of a barcode element or plurality of barcode elements are used to determine the presence of an associated DNA element of a genetic construct. Barcode elements as described herein can be detected by any method known in the art, including sequencing or microarray methods.

FIG. 1 shows several schematics of non-limiting examples of genetic constructs associated with the invention. In FIG. 1 step 4, a DNA element comprising a CRISPR guide sequence, designated "guide sequence," and a scaffold sequence, designated "scaffold," is flanked by a first compatible end element, indicated with "BamHI," and a second compatible end element, indicated with "BglII," which are capable of annealing to each other. The genetic construct also contains a barcode element, designated as "barcode," which is flanked by a third compatible end element, indicated with "EcoRI," and a fourth compatible end element, indicated with "MfeI," which are capable of annealing to each other, but are not capable of annealing to the first and second compatible end elements. The genetic construct also contains a separation site, such that the barcode element is located on one side of the separation site and the DNA element is located on the other side of the separation site. FIG. 1 also depicts a promoter element upstream (5' relative to) the DNA element that allows for expression (transcription) of the DNA element. While FIG. 1 depicts the DNA element as being upstream (5' relative to) the barcode element, this arrangement can also be reversed.

Compatible ends can be created in a variety of ways that will be evident to one of skill in the art and can consist of a variety of different sequences. As used herein, “compatible end elements” refer to regions of DNA that are capable of ligating or annealing to each other.

Compatible end elements that are capable of ligating or annealing to each other will be

5 apparent to one of skill in the art and refers to end elements that are complementary in nucleotide sequence to one another and therefore, are capable of base-pairing to one another.

In several non-limiting embodiments, compatible end elements can be composed of

restriction sites with compatible overhangs, Gibson assembly sequences, or functional

elements of any other DNA assembly method, including recombinases, meganucleases, TAL

10 Effector/Zinc-finger nucleases, trans-cleaving ribozymes/DNAzymes or integrases.

In some embodiments, Gibson assembly is used to generate compatible overhangs.

Gibson assembly refers to an isothermal DNA end-linking technique whereby multiple DNA

fragments can be joined in a single reaction. This method is described further in, and

incorporated by reference from, Gibson et al. (2009) Nature Methods 6:343-5.

15 In other embodiments, restriction digestion is used to generate compatible ends, as

depicted in FIG. 1. Using this method, two unique restriction enzymes generate compatible

overhangs. When these overhangs are ligated, a scar is created that is no longer recognized

by either enzyme. It should be appreciated that any restriction enzymes that generate

compatible overhangs can be used. In some non-limiting embodiments, standard biological

20 parts such as BIOBRICKS® (The BioBricks Foundation) or BglBricks (Anderson et al.

(2010) Journal of Biological Engineering 4:1), and enzymes associated with such standard

biological parts, are used. The use of standard biological parts such as BIOBRICKS® or

BglBricks is routine to one of ordinary skill in the art. It should be appreciated that while

classical restriction enzymes can be used (such as Type I, II or III restriction enzymes), other

25 DNA-cleaving molecules can also be used. For example, targeted ribozymes can be used for

cleavage of specific target sites. Meganucleases can also be utilized to minimize the

possibility of interference with the inserted DNA elements. TALE or ZF nucleases can also

be used to target long DNA sites to minimize the probability of internal cleavage within

inserted DNA elements. Furthermore, TOPO® cloning can be used to accomplish restriction

30 digestions and ligations.

In some embodiments, the first compatible end element is generated by recognition

and cleavage with the restriction enzyme BamHI, and the second compatible end element is

generated by recognition and cleavage with the restriction enzyme BglII. In some

embodiments, the third compatible end element is generated by recognition and cleavage

with the restriction enzyme MfeI, and the fourth compatible end element is generated by recognition and cleavage with the restriction enzyme EcoRI.

As used herein, a “separation site” of a genetic construct refers to a region that allows linearization of the construct. It should be appreciated that the separation site is a site within the nucleic acid of a construct at which cleavage linearizes the construct and may allow for insertion of additional genetic elements. In some embodiments, the separation site is a restriction enzyme recognition site. For example, in FIG. 1 the separation site is formed by the first and fourth compatible end elements, indicated by the BamHI and EcoRI recognition sites, respectively. Cleavage of the construct using the corresponding restriction enzymes (BamHI and EcoRI) linearizes the construct, and allows for insertion of additional genetic constructs. In some embodiments, the separation site is formed by one recognition site. In some embodiments, the separation site is formed by more than one recognition site.

Aspects of the invention relate to methods for producing a combinatorial vector comprising genetic constructs described herein. As depicted in step 3 of FIG. 1, the methods involve providing a vector containing a first genetic construct comprising a CRISPR guide sequence denoted “20 bp guide sequence,” flanked by a second compatible end element indicated by “BglII,” and a first recognition site for a first restriction enzyme denoted as “BbsI;” a barcode element, denoted “barcode,” flanked by a third compatible end element indicated by “MfeI” and a second recognition site for a second restriction enzyme. In some embodiments, the vector may be generated by annealing and ligating a first genetic construct containing compatible ends with a cleaved vector, as shown in step 2 of FIG. 1. In some embodiments, the first genetic construct is synthesized, for example by oligonucleotide array synthesis. The first genetic construct can be cleaved at the first recognition site, resulting in a fifth compatible end element, and cleaved at the second recognition site, resulting in a sixth compatible end element. A scaffold element is provided comprising a scaffold sequence and a separation site, indicated by “BamHI” and “EcoRI,” flanked by a seventh compatible end element that is capable of annealing to the fifth compatible end element of the cleaved vector and an eight compatible end element that is capable of annealing to the sixth compatible end element of the cleaved vector. The scaffold element is annealed to the cleaved first genetic construct of the vector using the compatible end elements. After annealing, the scaffold element is integrated between the CRISPR guide sequence and the barcode element, and the separation site is located between the scaffold sequence and the barcode element.

It should be appreciated that a variety of different enzyme combinations can be used to cleave the first and second recognition sites. In some embodiments, the two recognition

sites located outside of the CRISPR guide sequence and the barcode element are recognized by the same restriction enzyme, which produces compatible ends with the scaffold element. In other embodiments, the two restriction sites located outside of the CRISPR guide sequence and the barcode element are recognized by two different restriction enzymes, each of which
5 produces compatible ends with the scaffold element.

Further aspects of the invention relate to combinatorial constructs, and methods for producing combinatorial constructs. As used herein, a “combinatorial construct” refers to a genetic construct that contains a plurality of DNA elements. As used herein, a plurality of DNA elements refers to more than one DNA element, each of the DNA elements comprising
10 a CRISPR guide sequence and a scaffold sequence. As shown in step 5 of FIG. 1, the generation of a combinatorial construct can involve the linearization of a vector that contains a first genetic construct associated with the invention, by cleaving the vector at the separation site within the genetic construct. A second genetic construct associated with the invention may be inserted into the cleaved vector and annealed and ligated to the vector. As used
15 herein, an “insert” refers to a genetic construct that is intended to be inserted into a cleaved vector. In some embodiments, the insert is purified from a vector, such as by PCR or restriction digestion. The insert can be ligated to the cleaved vector through the annealing of terminal compatible end elements within the insert and their compatible components within the linearized vector.

The (n)-wise guide RNA library of step 5 of FIG. 1 depicts a post-combination combinatorial construct that contains a plurality of DNA elements and a plurality of corresponding barcode elements. In the non-limiting example depicted in step 5 of FIG. 1, the genetic construct contains four different DNA elements and four corresponding barcode elements. The combinatorial construct further contains a separation site, located between the
25 plurality of barcode elements and the plurality of DNA elements.

The methods described herein for generating combinatorial constructs can be iterative. For example, the combinatorial vector depicted in FIG. 1 can be cleaved again at the separation site, and one or more further inserts can be ligated into the combinatorial construct, while maintaining a separation site for further insertions. Significantly, throughout
30 the iterative process, as the number of DNA elements within the genetic construct continues to increase, the unique barcodes associated with each DNA element are maintained within the same genetic construct as their associated DNA elements. In some embodiments, the combination process is repeated at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, times or more than 20 times. In some embodiments, the process is repeated an nth

number of times, where n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or a number greater than 20.

It should be appreciated that combinatorial constructs can contain any number of DNA elements and associated barcode elements. In some embodiments a combinatorial construct contains 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more than 100 DNA elements and associated barcode elements.

Another aspect of the present invention relates to genetic constructs and vectors comprising more than one CRISPR guide sequence associated with a single barcode element. FIG. 2 shows several schematics of non-limiting examples of genetic constructs associated with the invention. Step 1 of FIG. 2A and 2B shows a genetic construct containing three CRISPR guide sequences, denoted “20 bp guide sequence A,” “20 bp guide sequence B,” and “20 bp guide sequence C,” a barcode element indicated by “barcode” and a recognition site located between each CRISPR guide sequence and between the barcode element and the CRISPR guide sequence nearest to the barcode element. In some embodiments, the barcode element may be located downstream of the CRISPR guide sequences, as shown in FIG. 2A. In other embodiments, the barcode element may be located upstream of the CRISPR guide sequences, as shown in FIG. 2B. In some embodiments, the recognition sites located between the CRISPR guide sequences and between the barcode element and the CRISPR guide sequence nearest to the barcode element are each different recognition sites for different restriction enzymes. In some embodiments, the genetic construct comprising the at least two CRISPR guide sequences, barcode element, and recognition sites are synthesized by any method known in the art, such as by oligonucleotide array synthesis.

Also within the scope of the present invention are genetic constructs comprising a plurality of DNA elements and one barcode element. In step 3 of FIG. 2, a genetic construct comprises three DNA elements each of which contain a CRISPR guide sequence and a scaffold sequence, a barcode element, and a promoter sequence located upstream of each of the DNA elements. In some embodiments, the barcode element may be located downstream of the CRISPR guide sequences, as shown in FIG. 2A. In other embodiments, the barcode element may be located upstream of the CRISPR guide sequences, as shown in FIG. 2B.

Aspects of the invention relate to methods for producing a combinatorial vector comprising the genetic constructs described herein. In some embodiments, the methods

involve providing a vector containing a plurality of CRISPR guide sequences and a barcode element located downstream of the plurality of CRISPR guide sequences. As shown in step 1 of FIG. 2A and 2B, three CRISPR guide sequences are denoted “20 bp guide sequence A,” “20 bp guide sequence B,” and “20 bp guide sequence C,” and the barcode element is indicated by “barcode.” The vector also contains a plurality of recognition sites for a plurality of restriction enzymes. In step 1 of FIG. 2A, each of the recognition sites is located downstream of a CRISPR guide sequence and indicated by “RE1,” “RE2,” and “RE3.” In step 1 of FIG. 2B, each of the recognition sites is located upstream of a CRISPR guide sequence and indicated by “RE1,” “RE2,” and “RE3.” In some embodiments, the vector also contains a promoter sequence located upstream of at least one of the CRISPR guide sequences. Compatible end elements downstream of at least one of the CRISPR guide sequences are generated by any method known in the art. In some embodiments, the vector is cleaved at at least one of the recognition sites with a restriction enzyme resulting in a first compatible end element and a second compatible end element. A scaffold element is provided comprising a scaffold sequence, optionally a promoter sequence, and a third compatible end element and fourth compatible end element that are capable of annealing to the first compatible end element and second compatible end element of the cleaved vector, respectively. The scaffold element is annealed to the cleaved vector through the annealing of terminal compatible end elements within the scaffold element and their compatible components within the cleaved vector. The methods described herein may be iterative resulting in a combinatorial vector containing a plurality of CRISPR guide sequences and scaffold sequences and one barcode element.

It should be appreciated that combinatorial vectors can contain any number of DNA elements associated with one barcode element. In some embodiments a combinatorial construct contains 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more than 100 DNA elements and one barcode element. The number of DNA elements associated with one barcode element may depend on the length of the genetic construct containing at the CRISPR guide sequences, barcode and recognition sites that is capable of being synthesized.

In any of the constructs or vectors described herein, one or more RNA domains may be inserted into one or more CRISPR guide sequences. In some embodiments, the CRISPR

guide sequence is fused to one or more RNA domain. In some embodiments, the RNA is a non-coding RNA or fragment thereof. In such embodiments, the RNA domain may be targeted to a DNA loci. Such constructs or vectors may be used for CRISPR display.

Further aspects of the invention relate to methods for identifying one or more DNA elements within a genetic construct or vector. After a combination event, a unique barcode that is associated with a specific DNA element(s) remains within the same genetic construct as the specific DNA element. Accordingly, identification of a barcode element or plurality of barcode elements allows for the identification of the associated DNA element or plurality of DNA elements within the same genetic construct. In some embodiments, the sequence of a barcode element and/or a DNA element is determined by sequencing or by microarray analysis. It should be appreciated that any means of determining DNA sequence is compatible with identifying one or more barcode elements and corresponding DNA elements. Significantly, in a combinatorial construct, such as is depicted in step 5 of FIG. 1, the plurality of barcode elements are within close proximity to each other allowing for the rapid identification of multiple barcode elements, and accordingly multiple DNA elements, simultaneously through methods such as DNA sequencing.

Further aspects of the invention relate to libraries comprising two or more genetic constructs as described herein that are compatible with methods for Massively Parallel Combinatorial Genetics. As used herein, a library of genetic constructs refers to a collection of two or more genetic constructs. In some embodiments, a library of genetic constructs is generated in which each unique DNA element is on a plasmid. This plasmid library can be pooled to form a vector library. An insert library can be generated, for example, by conducting PCR on the vector library. In a first combination event, all of the vectors can be paired with all of the inserts, generating a full combinatorial set of pairwise combinations. Further reactions between this pairwise library and an insert library can lead to a tri-wise, quad-wise or more than quad-wise library arising from a single vector library. Libraries of combinatorial constructs can be used to conduct screens of host cells expressing said libraries of combinatorial constructs. In some embodiments, the libraries of combinatorial constructs contain DNA elements or combinations of DNA elements with CRISPR guide sequences that target epigenetic genes, such as the example CRISPR guide sequences presented in Table 1.

It should be appreciated that since the combinatorial step is conducted in vitro, this technology can be scaled to any host cell or organism that can receive DNA. In some embodiments, the host cell is a bacterial cell. In some embodiments, the organism is bacteria and the constructs are carried on plasmids or phages. In some embodiments, the host cell is a

yeast cell. In other embodiments, the organism is yeast and the constructs are carried on plasmids or shuttle vectors. In other embodiments, the host cell is a mammalian cell, such as a human cell. In such embodiments, the genetic constructs described herein can be carried on plasmids or delivered by viruses such as lentiviruses or adenoviruses.

5 The genetic constructs and vectors described herein relate to the expression of components of a CRISPR system including a CRISPR guide sequence and scaffold sequence. The host cell in which the CRISPR system is expressed may express one or more additional CRISPR components, such as an endonuclease. In some embodiments, the host cell also expresses an endonuclease, such as a Cas endonuclease. In some embodiments, the Cas
10 endonuclease is Cas1, Cas2, or Cas9 endonuclease. In some embodiments, the host cell expresses a Cas9 endonuclease derived from *Streptococcus pyogenes*, *Staphylococcus aureus*, *Neisseria meningitidis*, *Streptococcus thermophilus*, or *Treponema denticola*. In some embodiments, the nucleotide sequence encoding the Cas9 endonuclease may be codon optimized for expression in a host cell or organism. In some embodiments, the endonuclease
15 is a Cas9 homology or ortholog.

In some embodiments, the nucleotide sequence encoding the Cas9 endonuclease is further modified to alter the activity of the protein. In some embodiments, the Cas9 endonuclease is a catalytically inactive Cas9. For example, dCas9 contains mutations of catalytically active residues (D10 and H840) and does not have nuclease activity.

20 Alternatively or in addition, the Cas9 endonuclease may be fused to another protein or portion thereof. In some embodiments, dCas9 is fused to a repressor domain, such as a KRAB domain. In some embodiments, such dCas9 fusion proteins are used with the constructs described herein for multiplexed gene repression (*e.g.* CRISPR interference (CRISPRi)). In some embodiments, dCas9 is fused to an activator domain, such as VP64 or
25 VPR. In some embodiments, such dCas9 fusion proteins are used with the constructs described herein for multiplexed gene activation (*e.g.* CRISPR activation (CRISPRa)). In some embodiments, dCas9 is fused to an epigenetic modulating domain, such as a histone demethylase domain or a histone acetyltransferase domain. In some embodiments, dCas9 is fused to a LSD1 or p300, or a portion thereof. In some embodiments, the dCas9 fusion is
30 used for CRISPR-based epigenetic modulation. In some embodiments, dCas9 or Cas9 is fused to a Fok1 nuclease domain. In some embodiments, Cas9 or dCas9 fused to a Fok1 nuclease domain is used for multiplexed gene editing. In some embodiments, Cas9 or dCas9 is fused to a fluorescent protein (*e.g.*, GFP, RFP, mCherry, etc). In some embodiments,

Cas9/dCas9 proteins fused to fluorescent proteins are used for multiplexed labeling and/or visualization of genomic loci.

Alternatively or in addition, the endonuclease is a Cpf1 nuclease. In some embodiments, the host cell expresses a Cpf1 nuclease derived from *Providentia* spp. or
 5 *Francisella* spp. In some embodiments, the nucleotide sequence encoding the Cpf1 nuclease may be codon optimized for expression in a host cell or organism.

The invention encompasses any cell type in which DNA can be introduced, including prokaryotic and eukaryotic cells. In some embodiments the cell is a bacterial cell, such as
 10 *Escherichia* spp., *Streptomyces* spp., *Zyomonas* spp., *Acetobacter* spp., *Citrobacter* spp.,
Synechocystis spp., *Rhizobium* spp., *Clostridium* spp., *Corynebacterium* spp., *Streptococcus*
 spp., *Xanthomonas* spp., *Lactobacillus* spp., *Lactococcus* spp., *Bacillus* spp., *Alcaligenes*
 spp., *Pseudomonas* spp., *Aeromonas* spp., *Azotobacter* spp., *Comamonas* spp.,
Mycobacterium spp., *Rhodococcus* spp., *Gluconobacter* spp., *Ralstonia* spp.,
Acidithiobacillus spp., *Microtholunatus* spp., *Geobacter* spp., *Geobacillus* spp., *Arthrobacter*
 15 spp., *Flavobacterium* spp., *Serratia* spp., *Saccharopolyspora* spp., *Thermus* spp.,
Stenotrophomonas spp., *Chromobacterium* spp., *Sinorhizobium* spp., *Saccharopolyspora*
 spp., *Agrobacterium* spp. and *Pantoea* spp. The bacterial cell can be a Gram-negative cell
 such as an *Escherichia coli* (*E. coli*) cell, or a Gram-positive cell such as a species of
Bacillus.

20 In other embodiments, the cell is a fungal cell such as a yeast cell, e.g.,
Saccharomyces spp., *Schizosaccharomyces* spp., *Pichia* spp., *Phaffia* spp., *Kluyveromyces*
 spp., *Candida* spp., *Talaromyces* spp., *Brettanomyces* spp., *Pachysolen* spp., *Debaryomyces*
 spp., *Yarrowia* spp. and industrial polyploid yeast strains. Preferably the yeast strain is a *S.*
cerevisiae strain. Other examples of fungi include *Aspergillus* spp., *Penicillium* spp.,
 25 *Fusarium* spp., *Rhizopus* spp., *Acremonium* spp., *Neurospora* spp., *Sordaria* spp.,
Magnaporthe spp., *Allomyces* spp., *Ustilago* spp., *Botrytis* spp., and *Trichoderma* spp.

In other embodiments, the cell is an algal cell, a plant cell, an insect cell, a rodent cell
 or a mammalian cell, including a rodent cell or a human cell (e.g., a human embryonic kidney
 cell (e.g., HEK293T cell), a human dermal fibroblast, a human cancer cells, such as a
 30 OVCAR8 cell or a OVCAR8-ADR cell. In some embodiments, the cell is a human cancer
 cell, such as a human ovarian cancer cell.

Also provided herein are compositions comprising inhibitors targeting epigenetic
 genes. As used herein, the term “epigenetic gene” refers to any gene that affects epigenetic
 regulation of another molecule or process in a cell. In some embodiments, the epigenetic

gene encodes a protein that is involved in epigenetic regulation. In some embodiments, the epigenetic gene encodes a nucleic acid, such as an RNA (*e.g.*, a microRNA), that affects epigenetic regulation. In general, epigenetics refers to any alteration to a molecule or process that does not involve mutation of the genomic DNA of the cell (Jaenisch and Bird *Nat. Gene.* (2003) 33: 245-254). Epigenetic regulation involves DNA-mediated processes in a cell, such as transcription, DNA repair, and replication through mechanisms including DNA methylation, histone modification, nucleosome remodeling, and RNA-mediating targeting (Dawson and Kouzarides *Cell* (2012) 150(1): 12-27). Non-limiting examples of epigenetic genes include: DNMT1, DNMT3A, DNMT3B, DNMT3L, MBD1, MBD2, CREBBP, EP300, HDAC1, HDAC2, SIRT1, CARM1, EZH1, EZH2, MLL, MLL2, NSD1, PRMT1, PRMT2, PRMT3, PRMT5, PRMT6, PRMT7, SETD2, KDM1A-, KDM1B, KDM2A, KDM2B, KDM3A, KDM3B, KDM4A, KDM4B, KDM4C, KDM5A, KDM5B, KDM5C, KDM5D, KDM6A, KDM6B, PHF2, PHF8, BMI1, BRD1, BRD3, BRD4, ING1, ING2, ING3, ING4, and ING5.

As used herein, the term “inhibitor” refers to any molecule, such as a protein, nucleic acid, or small molecule that reduces or prevents expression of an epigenetic gene or reduces or prevents activity of a protein encoded by the epigenetic gene. In some embodiments, the combination of two or more inhibitors of epigenetic genes reduces expression of an epigenetic gene by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or at least 65% as compared to expression of the epigenetic gene in the absence of the combination of inhibitors. In some embodiments, the combination of two or more inhibitors of epigenetic genes reduces activity of a protein encoded by an epigenetic gene by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or at least 65% as compared to activity of the protein encoded by the epigenetic gene in the absence of the combination of inhibitors.

In some embodiments, the combination of inhibitors of epigenetic genes comprises at least 2, 3, 4, 5, 6, 7, 8, 9, or at least 10 or more inhibitors of epigenetic genes. In some embodiments, the combination of inhibitors of epigenetic genes comprises two inhibitors of epigenetic genes. In some embodiments, the combination of inhibitors inhibit 2, 3, 4, 5, 6, 7, 8, 9, 10 or more epigenetic genes. In some embodiments, the combination of inhibitors of epigenetic genes comprises two inhibitors that target and inhibit two epigenetic genes.

In some embodiments, at least one inhibitor of the combination of inhibitors is a protein that directly or indirectly reduces or prevents expression of an epigenetic gene or reduces or prevents activity of a protein encoded by the epigenetic gene. For example, the

protein may be a repressor that reduces or prevents expression of the epigenetic gene or an allosteric inhibitor of a protein encoded by the epigenetic gene. In some embodiments, two or more inhibitors are proteins targeting two or more epigenetic genes. In some embodiments, the two or more inhibitors are proteins that target any of the combinations of epigenetic genes presented in Table 2.

In some embodiments, at least one inhibitor of the combination of inhibitors is a nucleic acid that reduces or prevents expression of an epigenetic gene or reduces or prevents activity of a protein encoded by the epigenetic gene. In some embodiments, the nucleic acid is a CRISPR guide sequence that, along with a scaffold sequence, recruits an endonuclease to the epigenetic gene. In some embodiments, two or more inhibitors are CRISPR guide sequences targeting two or more epigenetic genes. In some embodiments, the two or more inhibitors are CRISPR guide sequences that target any of the combinations of epigenetic genes presented in Table 2. In some embodiments, the two or more inhibitors are CRISPR guide sequences selected from the example CRISPR guide sequences targeting epigenetic genes provided in Table 1. In some embodiments, the combination of epigenetic genes comprises BRD4 and KDM4C. In some embodiments, the combination of epigenetic genes comprises BRD4 and KDM6B.

In some embodiments, the nucleic acid is a shRNA that is processed by the RNA interference (RNAi) pathway of the cell to silence expression of the target gene (*e.g.*, reduce mRNA levels and/or protein production). In some embodiments, two or more inhibitors are shRNAs targeting two or more epigenetic genes. In some embodiments, the two or more inhibitors are shRNAs that target any of the combinations of epigenetic genes presented in Table 2. In some embodiments, the two or more inhibitors are shRNAs selected from the example shRNAs targeting epigenetic genes provided in Table 4. In some embodiments, the combination of epigenetic genes comprises BRD4 and KDM4C. In some embodiments, the combination of epigenetic genes comprises BRD4 and KDM6B.

In some embodiments, at least one inhibitor of the combination of inhibitors is a small molecule that reduces or prevents expression of an epigenetic gene or reduces or prevents activity of a protein encoded by the epigenetic gene. In some embodiments, two or more inhibitors are small molecules targeting two or more epigenetic genes. In some embodiments, the two or more inhibitors are small molecules that target any of the combinations of epigenetic genes presented in Table 2. In some embodiments, the combination of epigenetic genes comprises BRD4 and KDM4C. In some embodiments, the combination of epigenetic genes comprises BRD4 and KDM6B.

Any small molecule that reduces or prevents expression of BRD4 or reduces or prevents activity of a protein encoded by BRD4 may be compatible with the compositions and methods described herein. Examples of BRD4 inhibitors include, without limitation, JQ1 ((6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester), MS417 (methyl [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetate), or RVX-208 (2-[4-(2-Hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-4(3H)-quinazolinone). In some embodiments, the BRD4 inhibitor is JQ1. Additional BRD4 inhibitors will be evident to one of skill in the art and can be found, for example, in PCT
10 Publication WO 2014/154760 A1 and Vidler et al. *J. Med. Chem.* (2013) 56: 8073-8088.

Any small molecule that reduces or prevents expression of KDM4C (also referred to as JMJD2) or reduces or prevents activity of a protein encoded by KDM4C may be compatible with the compositions and methods described herein. In some embodiments, the KDM4C inhibitor is SD70 (N-(furan-2-yl(8-hydroxyquinolin-7-yl)methyl)isobutyramide) or
15 caffeic acid. Additional KDM4C inhibitors will be evident to one of skill in the art and can be found, for example, in Leurs et al. *Bioorg. & Med. Chem. Lett.* (2012) 22(12): 5811-5813 and Hamada et al. *Bioorg. & Med. Chem. Lett.* (2009) 19: 2852-2855).

Any small molecule that reduces or prevents expression of KDM6B (also referred to as JMJD3) or reduces or prevents activity of a protein encoded by KDM6B may be
20 compatible with the compositions and methods described herein. Examples of KDM6B inhibitors include, without limitation, GSK-J4 (ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride), GSK-J1 (N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine), and IOX1 (8-Hydroxy-5-quinolinecarboxylic acid; 8-Hydroxy-5-quinolinecarboxylic acid).
25 In some embodiments, the KDM6B inhibitor is GSK-J4. Additional KDM4C inhibitors will be evident to one of skill in the art.

The combination of two or more inhibitors may comprise two or more protein inhibitors, two or more CRISPR guide sequences, two or more shRNAs, or two or more small molecule inhibitors. In some embodiments, the two or more inhibitors are different types of
30 inhibitors (*e.g.*, proteins, nucleic acids, small molecules). In some embodiments, the combination comprises a protein inhibitor and one or more additional inhibitors (*e.g.*, CRISPR guide sequences, shRNAs, and/or small molecule inhibitors). In other embodiments, the combination comprises a CRISPR guide sequence and one or more additional inhibitors (*e.g.*, proteins, shRNAs, and/or small molecule inhibitors). In other

embodiments, the combination comprises a shRNA and one or more additional inhibitors (e.g., proteins, CRISPR guide sequences, and/or small molecule inhibitors). In other embodiments, the combination comprises a small molecule inhibitor and one or more additional inhibitors (e.g., proteins, shRNAs, and/or shRNAs).

5 The methods and compositions described herein may be useful for reducing proliferation of a cell, such as a cancer cell or other cell for which reduced proliferation is desired. In some embodiments, contacting a cell with a combination of two or more inhibitors of epigenetic genes (e.g., combinations of inhibitors targeting epigenetic genes presented in Table 2) partially or completely reduces proliferation of the cell. In some
10 embodiments, contacting a cell with a combination of two or more inhibitors of epigenetic genes partially or completely reduces proliferation of the cell as compared to a cell that is not contacted with the combination of inhibitors. In some embodiments, contacting cells with a combination of two or more inhibitors of epigenetic genes reduces proliferation of the cells by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or at least 65% as
15 compared to cells that were not contacted with the combination of inhibitors. In some embodiments, contacting a cell with a combination of two or more inhibitors of epigenetic genes partially or completely reduces proliferation of a cancer cell as compared to a non-cancer cell that is contacted with the combination of inhibitors. Cell proliferation may be assessed and quantified by any method known in the art, for example using cell viability
20 assays, MTT assays, or BrdU cell proliferation assays.

 Other aspects of the invention relate to methods and compositions for treating cancer in a subject. Cancer is a disease characterized by uncontrolled or aberrantly controlled cell proliferation and other malignant cellular properties. As used herein, the term “cancer” refers to any type of cancer known in the art, including without limitation, breast cancer, biliary
25 tract cancer, bladder cancer, brain cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, hematological neoplasms, T-cell acute lymphoblastic leukemia/lymphoma, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, AIDS-associated leukemias and adult T-cell leukemia/lymphoma, intraepithelial neoplasms, liver cancer, lung cancer, lymphomas, neuroblastomas, oral cancer,
30 ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcomas, skin cancer, testicular cancer, thyroid cancer, and renal cancer. The cancer cell may be a cancer cell *in vivo* (i.e., in an organism), *ex vivo* (i.e., removed from an organism and maintained *in vitro*), or *in vitro*.

The methods involve administering to a subject a combination of two or more inhibitors of epigenetic genes in an effective amount. In some embodiments, the subject is a subject having, suspected of having, or at risk of developing cancer. In some embodiments, the subject is a mammalian subject, including but not limited to a dog, cat, horse, cow, pig, sheep, goat, chicken, rodent, or primate. In some embodiments, the subject is a human subject, such as a patient. The human subject may be a pediatric or adult subject. Whether a subject is deemed “at risk” of having a cancer may be determined by a skilled practitioner.

As used herein “treating” includes ameliorating, curing, preventing it from becoming worse, slowing the rate of progression, or preventing the disorder from re-occurring (i.e., to prevent a relapse). An effective amount of a composition refers to an amount of the composition that results in a therapeutic effect. For example, in methods for treating cancer in a subject, an effective amount of a combination of inhibitors targeting epigenetic genes is any amount that provides an anti-cancer effect, such as reduces or prevents proliferation of a cancer cell or is cytotoxic towards a cancer cell. In some embodiments, the effective amount of an inhibitor targeting an epigenetic gene is reduced when an inhibitor is administered concomitantly or in combination with one or more additional inhibitors targeting epigenetic genes as compared to the effective amount of the inhibitor when administered in the absence of one or more additional inhibitors targeting epigenetic genes. In some embodiments, the inhibitor targeting an epigenetic gene does not reduce or prevent proliferation of a cancer cell when administered in the absence of one or more additional inhibitors targeting epigenetic genes.

Inhibitors targeting epigenetic genes or combinations of inhibitors targeting epigenetic genes (*e.g.*, combinations of epigenetic genes presented in Table 2) may be administered to a subject using any method known in the art. In some embodiments, the inhibitors are administered by a topical, enteral, or parenteral route of administration. In some embodiments, the inhibitors are administered intravenously, intramuscularly, or subcutaneously.

Any of the inhibitors of epigenetic genes described herein may be administered to a subject, or delivered to or contacted with a cell by any methods known in the art. In some embodiments, the inhibitors of epigenetic genes are delivered to the cell by a nanoparticle, cell-permeating peptide, polymer, liposome, or recombinant expression vector. In other embodiments, the inhibitors of epigenetic genes are conjugated to one or more nanoparticle, cell-permeating peptide, and/or polymer. In other embodiments, the inhibitors of epigenetic genes are contained within a liposome.

Also provided are methods for identifying combinations of inhibitors of epigenetic genes that reduce or prevent proliferation of a cell or population of cells. As depicted in FIG. 4A, the methods involve contacting two populations of cells with a combinatorial library of CRISPR guide sequences targeting epigenetic genes and scaffold sequences (e.g., a barcoded CRISPR library) and a Cas9 endonuclease. The two populations of cells are cultured for different durations of time. For example, one population of cells may be cultured for 15 days and the other population of cells is cultured for 20 days. The identification of the combinations of two or more CRISPR guide sequences and scaffold sequences are determined for each population of cells, *e.g.* by sequencing methods. For example, the CRISPR guide sequences and scaffold sequences may be identified by sequencing a barcode that is a unique identifier of the CRISPR guide sequence. The abundance of each combination of CRISPR guide sequences and scaffold sequences in the population of cells that was cultured for a longer duration of time is compared to the abundance of each combination of CRISPR guide sequences and scaffold sequences in the population of cells that was cultured for the shorter duration of time. Combinations of CRISPR guide sequences and scaffold sequences that reduced proliferation of the cells will be less abundant in the population of cells that was cultured for the longer duration of time compared to the abundance of the CRISPR guide sequence in the population of cells that was cultured for the shorter duration of time. Such combinations are identified as combinations of inhibitors of epigenetic genes that reduce cell proliferation.

Other methods are provided for identifying combinations of epigenetic genes that when inhibited reduce or prevent proliferation of a cell or population of cells. As depicted in FIG. 4A, the methods involve contacting two populations of cells with a combinatorial library of CRISPR guide sequences targeting epigenetic genes and scaffold sequences (e.g., a barcoded CRISPR library) and a Cas9 endonuclease. The two populations of cells are cultured for different durations of time. For example, one population of cells may be cultured for 15 days and the other population of cells is cultured for 20 days. The identification of the combinations of two or more CRISPR guide sequences and scaffold sequences are determined for each population of cells, *e.g.* by sequencing methods. For example, the CRISPR guide sequences and scaffold sequences may be identified by sequencing a barcode that is a unique identifier of the CRISPR guide sequence. The abundance of each combination of CRISPR guide sequences and scaffold sequences in the population of cells that was cultured for a longer duration of time is compared to the abundance of each combination of CRISPR guide sequences and scaffold sequences in the population of cells

that was cultured for the shorter duration of time. Combinations of CRISPR guide sequences and scaffold sequences that reduced proliferation of the cells will be less abundant in the population of cells that was cultured for the longer duration of time. Such combinations are identified as combinations of epigenetic genes that may be target by inhibitors to reduce or prevent cell proliferation.

In some embodiments, one or more of the genes or inhibitors targeting an epigenetic gene associated with the invention is expressed in a recombinant expression vector. As used herein, a “vector” may be any of a number of nucleic acids into which a desired sequence or sequences may be inserted by restriction and ligation (*e.g.*, using the CombiGEM method) or by recombination for transport between different genetic environments or for expression in a host cell (*e.g.*, a cancer cell). Vectors are typically composed of DNA, although RNA vectors are also available. Vectors include, but are not limited to: plasmids, fosmids, phagemids, virus genomes and artificial chromosomes. In some embodiments, the vector is a lentiviral vector. In some embodiments, two or more genes or inhibitors targeting epigenetic genes are expressed on the same recombinant expression vector. In some embodiments, two or more genes or inhibitors targeting epigenetic genes are expressed on two or more recombinant expression vectors.

A cloning vector is one which is able to replicate autonomously or integrated in the genome in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated or recombination sites at which an insert with compatible ends can be integrated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host cell such as a host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase.

An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation or recombination such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard

assays known in the art (e.g., β -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein, red fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be “operably” joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5’ regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript can be translated into the desired protein or polypeptide.

When the nucleic acid molecule is expressed in a cell, a variety of transcription control sequences (e.g., promoter/enhancer sequences) can be used to direct its expression. The promoter can be a native promoter, i.e., the promoter of the gene in its endogenous context, which provides normal regulation of expression of the gene. In some embodiments the promoter can be constitutive, i.e., the promoter is unregulated allowing for continual transcription of its associated gene. A variety of conditional promoters also can be used, such as promoters controlled by the presence or absence of a molecule. In some embodiments, the promoter is a RNA polymerase II promoter, such as a mammalian RNA polymerase II promoter. In some embodiments, the promoter is a human ubiquitin C promoter (UBCp). In some embodiments, the promoter is a viral promoter. In some embodiments, the promoter is a human cytomegalovirus promoter (CMVp). In some embodiments, the promoter is a RNA polymerase III promoter. Examples of RNA polymerase III promoters include, without limitation, H1 promoter, U6 promoter, mouse U6 promoter, swine U6 promoter. In some embodiments, the promoter is a U6 promoter (U6p).

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5’ non-transcribed

and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. In particular, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene.

5 Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are
10 commercially available and known to those skilled in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press, 2012. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA). That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

15 A nucleic acid molecule associated with the invention can be introduced into a cell or cells using methods and techniques that are standard in the art. For example, nucleic acid molecules can be introduced by standard protocols such as transformation including chemical transformation and electroporation, viral transduction, particle bombardment, etc. In some embodiments, the viral transduction is achieved using a lentivirus. Expressing the nucleic
20 acid molecule may also be accomplished by integrating the nucleic acid molecule into the genome.

The invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the
25 drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having," "containing," "involving," and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

30 The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference, particularly for the teachings referenced herein.

EXAMPLES

5 Example 1

As shown in FIG. 1, a high complexity combinatorial library of barcoded CRISPR molecules can be made using the methods described herein. In step 1, a massive CRISPR guide RNA (gRNA) library was generated using array-based oligonucleotide synthesis, including forward and reverse oligonucleotides for each CRISPR guide sequence (*e.g.*, Oligo F-A and Oligo R-A; Oligo F-B and Oligo R-B). The length of the oligonucleotide synthesized is independent of the complexity of the end-product library. In step 2, the pair of oligonucleotides for a gRNA are then isolated and annealed. An oligonucleotide against each gRNA contains the 20-base pair CRISPR guide sequence, two BbsI sites, and a barcode element. The oligonucleotide may also contain 5' and 3' single stranded overhang regions for ligation of the oligonucleotide into a storage vector. In step 3, annealed oligo pairs containing BbsI and MfeI overhangs were pooled together for a one-pot ligation reaction to insert the gRNA library into the AWp28 storage vector digested with BbsI and MfeI. This results in a library of AWp28 storage vectors each containing a CRISPR guide sequence, two BbsI sites, and a barcode element.

20 In step 4, the pooled library of storage vectors then underwent a single-pot digestion using BbsI to open the vector between the CRISPR guide sequence and the barcode element to allow for the insertion of gRNA scaffold element in between the CRISPR guide sequence and the barcode element. Since the insert of gRNA scaffold element contains a separation site formed by the restriction recognition sites BamHI and EcoRI at the 3' end of the scaffold element, the library of gRNA storage vectors can undergo iterative cloning steps to generate progressively more complex n-wise barcoded library encompassing multiple gRNA expression cassettes that can mediate combinatorial gene knockout, activation or repression using Cas9 nuclease or effectors, as shown in step 5. Briefly, the barcoded guide RNA library is digested using restriction enzyme complementary to the restriction recognition sites at the separation site (*e.g.*, BamHI and EcoRI). Digestion allows for insertion of additional segments encoding a CRISPR guide sequence, scaffold sequence, separation site, and barcode element. Because the same sets of restriction enzymes can be used for the multiple rounds of cloning to build an (n)-wise library, one of the advantages of this strategy is that the (n+1)-wise library does not increase the set of restriction enzymes required.

To build a (n)-wise library of (m) gRNA members, it takes (n + 2) rounds of cloning steps. An additional advantage of this strategy is that the same CRISPR guide libraries can be used to generate higher order complexity libraries.

5 Example 2:

As shown in FIG. 2A, a complex combinatorial libraries of barcoded CRISPR molecules can be made using the methods described herein. In step 1, multiple CRISPR guide sequences and a single barcode element were synthesized on a single oligonucleotide to generate a massive combinatorial gRNA library. Restriction recognition sites were present following each of the CRISPR guide sequences. Guide sequences and the barcode are linked together by the different restriction enzyme sites. The genetic construct and vector of FIG. 2A shows an exemplary oligonucleotide containing three CRISPR guide sequences and a barcode element located downstream of the CRISPR guide sequences.

In step 2, the pooled synthesized oligonucleotides were ligated into a destination vector in a single-pot assembly. The destination vector may contain an promoter to drive expression of at least one of the CRISPR guide sequences. As shown in step 3, the vector was sequentially digested at each of the restriction recognition sites following each CRISPR guide sequence with different restriction enzymes, allowing for insertion of a scaffold element, and in some cases a promoter element to drive expression of a downstream CRISPR guide sequence. The method resulted in the generation of a barcoded combinatorial RNA library encoding multiple CRISPR guide sequences and scaffold sequences with a single barcode element for combinatorial gene knockout, activation or repression using Cas9 nuclease or effectors.

FIG. 2B depicts an alternative strategy to generate a complex combinatorial libraries of barcoded CRISPR molecules. In step 1, multiple CRISPR guide sequences and a single barcode element were synthesized on a single oligonucleotide to generate a massive combinatorial gRNA library. Restriction recognition sites were present following each of the CRISPR guide sequences as well as a restriction recognition site upstream of the first CRISPR guide sequence for insertion of a promoter element. Guide sequences and the barcode are linked together by the different restriction enzyme sites. The genetic construct and vector of FIG. 2B shows an exemplary oligonucleotide containing three CRISPR guide sequences and a barcode element located upstream of the CRISPR guide sequences.

In step 2, the pooled synthesized oligonucleotides were ligated into a destination vector in a single-pot assembly. The destination vector may contain an promoter to drive

expression of at least one of the CRISPR guide sequences. As shown in step 3, the vector was sequentially digested at each of the restriction recognition sites following each CRISPR guide sequence with different restriction enzymes, allowing for insertion of a scaffold element, and in some cases a promoter element to drive expression of a downstream CRISPR

5 guide sequence. The method resulted in the generation of a barcoded combinatorial guide RNA library encoding multiple CRISPR guide sequences and scaffold sequences with a single barcode element for combinatorial gene knockout, activation or repression using Cas9 nuclease or effectors.

Using the strategies depicted in FIGs. 2A and 2B, a (n)-wise library of (m) gRNA

10 members can be built with (n+1) rounds of cloning steps. The complexity of the library generated is dependent on the length of the oligonucleotide synthesized in step 1. Because the restriction recognition sites that allow for insertion of the scaffold sequence are different for each CRISPR guide sequence as well as promoter elements, increasing the complexity of the oligonucleotide (*i.e.*, number of CRISPR guide sequences) also increases the number of

15 restriction enzymes necessary for the digestion steps.

Example 3:

The CombiGEM-based DNA assembly method was used for the efficient and scalable assembly of barcoded combinatorial gRNA libraries. The libraries were delivered into

20 human cells by lentiviruses in order to create genetically ultra-diverse cell populations harboring unique gRNA combinations that may be tracked via barcode sequencing in pooled assays. This strategy, termed CombiGEM-CRISPR, uses simple one-pot cloning steps to enable the scalable assembly of high-order combinatorial gRNA libraries, thus simplifying and accelerating the workflow towards systematic analysis of combinatorial gene functions.

To create the initial barcoded sgRNA library, an array of oligo pairs encoding a

25 library of barcoded gRNA target sequences was first synthesized, annealed, and pooled in equal ratios for cloning downstream of a U6 promoter in the storage vector (FIG. 1). Subsequently, the scaffold sequence for the gRNAs was inserted into the storage vector library in a single-pot ligation reaction. The CombiGEM method was applied for scalable

30 assembly of higher-order combinatorial gRNA libraries (FIG. 1). Within the barcoded sgRNA construct, BamHI and EcoRI sites were positioned in between the gRNA sequence and its barcode, while BglII and MfeI sites were located at the ends. Strategic positioning of these restriction enzyme sites results in the segregation of the barcode from its gRNA sequence upon enzymatic digestion and the concatenation of barcodes representing their

respective gRNAs upon ligation of inserts. To construct the one-wise library, pooled inserts of the barcoded sgRNA expression units were prepared by restriction digestion of the storage vectors with BglII and MfeI and joined to their compatible DNA ends in the lentiviral destination vector, which was digested with BamHI and EcoRI. The one-wise library then served as the destination vector for the next round of pooled insertion of the barcoded sgRNA expression units to generate the two-wise library, in which barcodes representing each sgRNA were localized to one end of each lentiviral construct. This process may be iteratively repeated to generate higher-order barcoded combinatorial gRNA libraries. The identity of the combinatorial gRNAs can be tracked by detection of the concatenated barcodes, which are unique for each combination (*e.g.*, by high-throughput sequencing).

To evaluate the functionality of our lentiviral combinatorial gRNA expression system, gRNA combinations were constructed targeting sequences encoding green fluorescent protein (GFP) and red fluorescent protein (RFP) (Table 1). The combinatorial gene perturbation phenotypes were determined by using flow cytometry (FIGs. 6A and 6B) and fluorescence microscopy (FIG. 6E). Lentiviruses carrying dual RFP and GFP reporters together with the barcoded combinatorial gRNA expression units were used to infect human ovarian cancer cells (OVCAR8-ADR) (Honma, et al. *Nat. Med.* (2008) 14: 939-948) stably expressing human codon-optimized Cas9 nuclease (OVCAR8-ADR-Cas9) (FIG. 6A). It was anticipated that active gRNAs would target the sequences encoding GFP and RFP, and generate indels to knockout the expression of GFP and RFP. Efficient repression of GFP and RFP fluorescence levels was observed, as the GFP and RFP double-negative population was the major population observed in cells carrying Cas9 nuclease and gRNA expression units targeting both RFP and GFP at both day 4 and 8 post-infection (~83 to 97% of the total population), compared with < 0.7% in the vector control (FIGs. 6C and 6D). This repression was not observed in control cell lines expressing the gRNAs targeting GFP and/or RFP but without Cas9 nuclease (FIG. 6B). The specificity of gene perturbation was confirmed, as cells only harboring GFP-targeting sgRNA exhibited loss of the GFP signal but not the RFP signal. Similarly, cells containing the RFP-targeting sgRNAs exhibited a reduction in RFP expression, but there was not effect on GFP expression (FIG. 6E). These results demonstrate the ability of lentiviral vectors to encode combinatorial gRNA constructs that can repress the expression of multiple genes simultaneously within a single human cell.

Diverse epigenetic modifications tend to act cooperatively to regulate gene expression patterns (Wang, et al. *Nat. Genet.* (2008) 40:897-903), and combinatorial epigenetic modulation is emerging as a promising strategy for effective cancer therapeutics (Dawson, et

al. *Cell* (2012) 150: 12-27; Juergens, et al. *Cancer Discov.* (2011) 1: 598-607). Using the CombiGEM-CRISPR methods and compositions described herein, the combinatorial effects of epigenetic gene perturbations on anti-cancer phenotypes were systematically evaluated. A library was constructed containing 153 barcoded sgRNAs targeting a set of 50 epigenetic genes (3 sgRNAs per gene) and 3 control sgRNAs based on the GeCKOv2 library (Shalem, et al. *Science* (2014) 343:84-87)(Table 1).

Table 1: sgRNA target sequences

sgRNA ID	sgRNA target sequence
GFP-sg1	GGGCGAGGAGCTGTTACCG (SEQ ID NO: 7)
RFP-sg1	CACCCAGACCATGAAGATCA (SEQ ID NO: 8)
RFP-sg2	CCACTTCAAGTGCACATCCG (SEQ ID NO: 9)
Control-sg1	ATCGTTTCCGCTTAACGGCG (SEQ ID NO: 10)
Control-sg2	AAACGGTACGACAGCGTGTG (SEQ ID NO: 11)
Control-sg3	CCATCACCGATCGTGAGCCT (SEQ ID NO: 12)
DNMT1-sg1	CTAGACGTCCATTCCTTCC (SEQ ID NO: 13)
DNMT1-sg2	TTTCCAAACCTCGCACGCC (SEQ ID NO: 14)
DNMT1-sg3	ACGTAAAGAAGAATTATCCG (SEQ ID NO: 15)
DNMT3A-sg1	CCGCCCCACCTTCCGTGCCG (SEQ ID NO: 16)
DNMT3A-sg2	TGGCGCTCCTCCTTGCCACG (SEQ ID NO: 17)
DNMT3A-sg3	CCGCTCCGCAGCAGAGCTGC (SEQ ID NO: 18)
DNMT3B-sg1	AGAGTCGCGAGCTTGATCTT (SEQ ID NO: 19)
DNMT3B-sg2	ATCCGCACCCCGGAGATCAG (SEQ ID NO: 20)
DNMT3B-sg3	GAAGACTCGATCCTCGTCAA (SEQ ID NO: 21)
DNMT3L-sg1	AGGGATCTGCGCCCCATGTA (SEQ ID NO: 22)
DNMT3L-sg2	ACTCACCTTCTATATTTTCGC (SEQ ID NO: 23)
DNMT3L-sg3	CACCAAATCACGTCCATGC (SEQ ID NO: 24)
MBD1-sg1	TCACCCGTAGGCAACGTCGC (SEQ ID NO: 25)
MBD1-sg2	GTGTCCAGCGACGTTGCCTA (SEQ ID NO: 26)
MBD1-sg3	ACGTTGTGCAAAGACTGTTCG (SEQ ID NO: 27)
MBD2-sg1	CGGCGACTCCGCCATAGAGC (SEQ ID NO: 28)
MBD2-sg2	GGAGCCGGTCCCTTTCCCGT (SEQ ID NO: 29)
MBD2-sg3	AGTCTTGAAAGCGCATGCCA (SEQ ID NO: 30)
CREBBP-sg1	AGCGGCTCTAGTATCAACCC (SEQ ID NO: 31)
CREBBP-sg2	GAATCACATGACGCATTGTC (SEQ ID NO: 32)
CREBBP-sg3	CCCGCAAATGACTGGTCACG (SEQ ID NO: 33)
EP300-sg1	CTGTCAGAATTGCTGCGATC (SEQ ID NO: 34)
EP300-sg2	CTTGGCAAGACTTGCCTGAC (SEQ ID NO: 35)
EP300-sg3	TAGTTCCCCTAACCTCAATA (SEQ ID NO: 36)
HDAC1-sg1	ACACCATTCGTAACGTTGCC (SEQ ID NO: 37)
HDAC1-sg2	TCACTCGAGATGCGCTTGTC (SEQ ID NO: 38)
HDAC1-sg3	AGAATGCTGCCGCACGCACC (SEQ ID NO: 39)
HDAC2-sg1	TCCGTAATGTTGCTCGATGT (SEQ ID NO: 40)

HDAC2-sg2	TCCAACATCGAGCAACATTA (SEQ ID NO: 41)
HDAC2-sg3	TACAACAGATCGTGTAATGA (SEQ ID NO: 42)
SIRT1-sg1	GTTGACTGTGAAGCTGTACG (SEQ ID NO: 43)
SIRT1-sg2	AACAGGTTGCGGGAATCCAA (SEQ ID NO: 44)
SIRT1-sg3	TACCCAGAACATAGACACGC (SEQ ID NO: 45)
CARM1-sg1	CTCGCCGTTTCGCGTCGCCGA (SEQ ID NO: 46)
CARM1-sg2	CCCGTACTCACGGCTGTAGA (SEQ ID NO: 47)
CARM1-sg3	GGGCCACGTACCGTTGGGTG (SEQ ID NO: 48)
EZH1-sg1	ACAGGCTTCATTGACTGAAC (SEQ ID NO: 49)
EZH1-sg2	AGCTGATCAATAACTATGAT (SEQ ID NO: 50)
EZH1-sg3	CCTCATCTGAGTACTGATTC (SEQ ID NO: 51)
EZH2-sg1	ACACGCTTCCGCCAACAAAC (SEQ ID NO: 52)
EZH2-sg2	TGCGACTGAGACAGCTCAAG (SEQ ID NO: 53)
EZH2-sg3	AAAACCTCATCTCCCATATA (SEQ ID NO: 54)
MLL-sg1	GTACAAATTGTACGACGGAG (SEQ ID NO: 55)
MLL-sg2	GACCCCTCGGCGGTTTATAG (SEQ ID NO: 56)
MLL-sg3	TATATTGCGACCACCAAAC (SEQ ID NO: 57)
MLL2-sg1	CAGAGAGCACAACGCCGCAC (SEQ ID NO: 58)
MLL2-sg2	GGAACCGCTGGCAGTCGCGC (SEQ ID NO: 59)
MLL2-sg3	CTCCCGCTGCCCGTGTAGAC (SEQ ID NO: 60)
NSD1-sg1	CTGGCTCGAGATTTAGCGCA (SEQ ID NO: 61)
NSD1-sg2	AATCTGTTCATGCGCTTACG (SEQ ID NO: 62)
NSD1-sg3	GATTCCAGTACCAGTACATT (SEQ ID NO: 63)
PRMT1-sg1	CTCACCGTGGTCTAACTTGT (SEQ ID NO: 64)
PRMT1-sg2	GGATGTCATGTCTCAGCGT (SEQ ID NO: 65)
PRMT1-sg3	TTGACTCCTACGCACACTT (SEQ ID NO: 66)
PRMT2-sg1	CGTGGATGAGTACGACCCCG (SEQ ID NO: 67)
PRMT2-sg2	TCTTCTGTGCACACTATGCG (SEQ ID NO: 68)
PRMT2-sg3	CTGTCCCAGAAGTGAATCGC (SEQ ID NO: 69)
PRMT3-sg1	GCCATGTGCTCGTTAGCGTC (SEQ ID NO: 70)
PRMT3-sg2	GCCTGACGCTAACGAGCACA (SEQ ID NO: 71)
PRMT3-sg3	GAATTCATGTACTCAACTGT (SEQ ID NO: 72)
PRMT5-sg1	CGGAATGCGGGGTCCGAAC (SEQ ID NO: 73)
PRMT5-sg2	CAGCATAACAGCTTTATCCGC (SEQ ID NO: 74)
PRMT5-sg3	ATGAACTCCCTCTTGAAACG (SEQ ID NO: 75)
PRMT6-sg1	ATTGTCCGGCGAGGACGTGC (SEQ ID NO: 76)
PRMT6-sg2	CTTCGCCACGCGCTGTCTCA (SEQ ID NO: 77)
PRMT6-sg3	GACGGTACTGGACGTGGGCG (SEQ ID NO: 78)
PRMT7-sg1	CAATCCGACCACGGGGTCTG (SEQ ID NO: 79)
PRMT7-sg2	GAGGTTCAAACCGCCTGCTA (SEQ ID NO: 80)
PRMT7-sg3	TAAAGTCGGCTGGTGACACC (SEQ ID NO: 81)
SETD2-sg1	AGTTCTTCTCGGTGTCCAAA (SEQ ID NO: 82)
SETD2-sg2	GACTATCAGTTCCAGAGATA (SEQ ID NO: 83)
SETD2-sg3	AACTTACGAAGGAAGGTCTT (SEQ ID NO: 84)
KDM1A-sg1	TTACCTTCGCCCGCTTGCGC (SEQ ID NO: 85)

KDM1A-sg2	CCGGCCCTACTGTCGTGCCT (SEQ ID NO: 86)
KDM1A-sg3	AGAGCCGACTTCCTCATGAC (SEQ ID NO: 87)
KDM1B-sg1	CATACCGCATCGATAAGTCT (SEQ ID NO: 88)
KDM1B-sg2	ATAGCCAAGACTTATCGATG (SEQ ID NO: 89)
KDM1B-sg3	GAACATACCTTCTGTAGTAA (SEQ ID NO: 90)
KDM2A-sg1	ACGCTACTATGAGACCCAG (SEQ ID NO: 91)
KDM2A-sg2	TATGGCAGGGAGTCGTGCGA (SEQ ID NO: 92)
KDM2A-sg3	GTAACGAATCCTTTCTTCTT (SEQ ID NO: 93)
KDM2B-sg1	CCTCGTTCTCGTCGTATCGC (SEQ ID NO: 94)
KDM2B-sg2	GCGTACTACGAGACGCCCG (SEQ ID NO: 95)
KDM2B-sg3	CTTGGTCAAGCGTCCGACTG (SEQ ID NO: 96)
KDM3A-sg1	TAAATGCCGAGAGTGTCGCT (SEQ ID NO: 97)
KDM3A-sg2	GTCTGTCAAACCGACTTCC (SEQ ID NO: 98)
KDM3A-sg3	GATACTGCTTGGCTGTAAGT (SEQ ID NO: 99)
KDM3B-sg1	TCTTGTATGGGCGCCCCGTG (SEQ ID NO: 100)
KDM3B-sg2	GCCTTGACTGTTACCGGCTC (SEQ ID NO: 101)
KDM3B-sg3	TCCTGAGCCGGTAACAGTCA (SEQ ID NO: 102)
KDM4A-sg1	ACTCCGCACAGTTAAAACCA (SEQ ID NO: 103)
KDM4A-sg2	GCGGAACTCTCGAACAGTCA (SEQ ID NO: 104)
KDM4A-sg3	TTCCACTCACTTATCGCTAT (SEQ ID NO: 105)
KDM4B-sg1	CCCCGCGTACTTCTCGCTGT (SEQ ID NO: 106)
KDM4B-sg2	GTATGATGACATCGACGACG (SEQ ID NO: 107)
KDM4B-sg3	TCACCAGGTACTGTACCCCG (SEQ ID NO: 108)
KDM4C-sg1	CCTTTGCAAGACCCGCACGA (SEQ ID NO: 109)
KDM4C-sg2	AGTAGGCTTCGTGTGATCAA (SEQ ID NO: 110)
KDM4C-sg3	GTCTAAAGGAGCCCATCGTG (SEQ ID NO: 111)
KDM5A-sg1	CATGAACCCCAACGTGCTAA (SEQ ID NO: 112)
KDM5A-sg2	CTGGGATTCAAATAACTCGG (SEQ ID NO: 113)
KDM5A-sg3	TCTCTGGTATGAAAGTGCCG (SEQ ID NO: 114)
KDM5B-sg1	GTCCGCGAACTCTTCCAGC (SEQ ID NO: 115)
KDM5B-sg2	TCGAAGACCGGGCACTCGGG (SEQ ID NO: 116)
KDM5B-sg3	GGACTTATTTTCACTTAATA (SEQ ID NO: 117)
KDM5C-sg1	CTTACCGCCATGACACACTT (SEQ ID NO: 118)
KDM5C-sg2	GATAACAATGCGTTCGTAG (SEQ ID NO: 119)
KDM5C-sg3	GGGCTACCCGAGCCCACCGA (SEQ ID NO: 120)
KDM5D-sg1	GATTTACTCCTCGCGTCCAA (SEQ ID NO: 121)
KDM5D-sg2	AAAGACTTACCGCGGGTGGG (SEQ ID NO: 122)
KDM5D-sg3	TAAGCCCCGACATGGAACCG (SEQ ID NO: 123)
KDM6A-sg1	ACTGTAAACTGTAGTACCTC (SEQ ID NO: 124)
KDM6A-sg2	CAGCATTATCTGCATAACAG (SEQ ID NO: 125)
KDM6A-sg3	AGACTATGAGTCTAGTTTAA (SEQ ID NO: 126)
KDM6B-sg1	TACCACAGCGCCCTTCGATA (SEQ ID NO: 127)
KDM6B-sg2	ATCCCCCTCCTCGTAGCGCA (SEQ ID NO: 128)
KDM6B-sg3	CAAAGGCTTCCCGTGCAGCG (SEQ ID NO: 129)
PHF2-sg1	TTCTGCACGGGCTTGACGTC (SEQ ID NO: 130)

PHF2-sg2	GACGTCAAGCCCGTGCAGAA (SEQ ID NO: 131)
PHF2-sg3	CAGTGACGTTCGAGAACTACG (SEQ ID NO: 132)
PHF8-sg1	TCTGACGAACGTAGGGCTCC (SEQ ID NO: 133)
PHF8-sg2	GGCTTAGTGAAAAACGCCG (SEQ ID NO: 134)
PHF8-sg3	CCTCGCCATCATTCACTGTG (SEQ ID NO: 135)
BMI1-sg1	AACGTGTATTGTTTCGTTACC (SEQ ID NO: 136)
BMI1-sg2	TCCTACCTTATATTCAGTAG (SEQ ID NO: 137)
BMI1-sg3	AAAGGTTTACCATCAGCAGA (SEQ ID NO: 138)
BRD1-sg1	CACCGTGTCTATAGAGCCG (SEQ ID NO: 139)
BRD1-sg2	CGGCGGAGGTGGACAGCAT (SEQ ID NO: 140)
BRD1-sg3	CGACTCACCGGCTGCGATCC (SEQ ID NO: 141)
BRD3-sg1	CGACGTGACGTTTGCAGTGA (SEQ ID NO: 142)
BRD3-sg2	CAAAGGTCGGAAGCCGGCTG (SEQ ID NO: 143)
BRD3-sg3	CATCACTGCAAACGTCACGT (SEQ ID NO: 144)
BRD4-sg1	ACTAGCATGTCTGCGGAGAG (SEQ ID NO: 145)
BRD4-sg2	TCTAGTCCATCCCCATTAC (SEQ ID NO: 146)
BRD4-sg3	GGGAACAATAAAGAAGCGCT (SEQ ID NO: 147)
ING1-sg1	GAGATCGACGCGAAATACCA (SEQ ID NO: 148)
ING1-sg2	TATAAATCCGCGCCCGAAAG (SEQ ID NO: 149)
ING1-sg3	CCCATAACCAGTTATTGCGCT (SEQ ID NO: 150)
ING2-sg1	GCAGCAGCAACTGTACTCGT (SEQ ID NO: 151)
ING2-sg2	GCAGCGACTCCACGCACTCA (SEQ ID NO: 152)
ING2-sg3	GATCTTCAAGAAGACCCCGC (SEQ ID NO: 153)
ING3-sg1	TCTCGCGCATTTCGTTGAAG (SEQ ID NO: 154)
ING3-sg2	CTTCACGGAAATGCGCGAGA (SEQ ID NO: 155)
ING3-sg3	TCGATACTGCATTTGTAATC (SEQ ID NO: 156)
ING4-sg1	GCTGCTCGTGCTCGTTCCAA (SEQ ID NO: 157)
ING4-sg2	CCTAGAAGGCCGGACTCAA (SEQ ID NO: 158)
ING4-sg3	GGCACTACTCATATACTCAG (SEQ ID NO: 159)
ING5-sg1	GATCTGCTTCAAAGCGCGCC (SEQ ID NO: 160)
ING5-sg2	CTTCCAGCTGATGCGAGAGC (SEQ ID NO: 161)
ING5-sg3	GAAGTTCCTCTGAAGTTCGC (SEQ ID NO: 162)

Expression of these 50 epigenetic genes was evaluated in OVCAR8-ADR cells using qRT-PCR. A two-wise (153 x 153 sgRNAs = 23,409 total combinations) pooled barcoded gRNA library was generated using the CombiGEM method. Lentiviral pools were produced to deliver the library into OVCAR8-ADR-Cas9 cells. Genomic DNA from the pooled cell populations was isolated for unbiased barcode amplification by polymerase chain reaction (PCR). The representation of individual barcoded combinations in the plasmid pools stored in *Escherichia coli* and also in the infected human cell pools was quantified using Illumina HiSeq sequencing (FIGs. 3A-3D). Near-full coverage for the two-wise library was achieved within both the plasmid and infected cell pools with between ~23 to 34 million reads per

sample (FIG. 3B), and a relatively even distribution of barcoded gRNA combinations was observed (FIGs. 3A and 3B). Furthermore, there was a high correlation between barcode representation in the plasmid and infected cell pools (FIG. 3C), as well as high reproducibility in barcodes represented in biological replicates for infected cell pools (FIG. 3D). Thus, CombiGEM-CRISPR can be used to efficiently assemble and deliver barcoded combinatorial gRNA libraries into human cells.

To confirm the function of gRNAs to edit endogenous genes in OVCAR8-ADR-Cas9 cells, Surveyor assays were performed to estimate the cleavage efficiency at 8 randomly picked loci targeted by the gRNAs from the library. Indel generation efficiencies ranging from 1.9% to 26.2% were observed at day 12 post-infection (FIGs. 7A-7C). Cleavage of DNA mismatches for all of the gRNA-targeted loci at day 12 post-infection were detected (FIGs. 7A and 8A). The simultaneous cleavage efficiency was determined at multiple loci in our dual-gRNA system, and comparable levels of cleavage were observed in cells expressing individual gRNAs or double gRNAs (FIGs. 7A and 8A). Depletion of targeted protein levels in individual gRNA- and double gRNA-expressing cells was also detected (FIG. 8B). These results indicated that the multiplexed system did not hamper the activity of the gRNAs. To distinguish dual-cleavage events directed by double gRNAs within a single cell from the whole infected population, clones derived from single cells infected with the double gRNAs were isolated and cells with insertions, deletions, or mutations in both targeted genomic loci were detected using Sanger sequencing (FIGs. 9A and 9B).

Indel generation efficiency was also estimated by performing deep sequencing at targeted genomic loci. Large variations in the rates of generating indels were observed (i.e., 14 to 93%; FIG. 16A) and frameshift mutations (i.e., 52 to 95% out of all indels; FIG. S5B) among different gRNAs. In addition, gRNAs that were validated in a previous study with A375 melanoma cells (Shalem et al. 2014 *Science* 343:84-7) displayed reduced activity (e.g., for NF1-sg4 and MED12-sg1 sgRNAs) and differential indel generation preferences (e.g., for the NF1-sg1 sgRNA) in OVCAR8-ADR-Cas9 cells (Fig. 16C). Such discrepancies may be partially due to variations in chromatin accessibility at target loci (Wu et al. (2014) *Nat. Biotechnol.* 32: 670-6) and DNA break repair mechanisms (Ghezraoui et al (2014) *Mol Cell* 55:829-42) that can vary among cell types. Continual efforts in gRNA design optimization, including improving on-target cleavage rates (Donesch et al (2014) *Nat Biotechnol* 32:1262-7) and minimizing off-target cleavage, should enable the creation of more efficient gRNA sets that will improve their applicability for large-scale genetic perturbation screening in a broad range of cell types. Indel generation was further assessed by gRNAs in the multiplexed

system. The deep sequencing analysis detected largely comparable indel generation frequencies and preferences for the same gRNA expressed under the sgRNA or double gRNA systems (FIG. 16D). To distinguish dual-cleavage events directed by double gRNAs within a single cell from cleavage events distributed across the population, clones derived from single cells infected with double gRNA constructs were isolated. Cells with insertions, deletions, or mutations in both targeted genomic loci were detected (Fig. 9A-9C; Table 6). Our results indicate that the CombiGEM combinatorial gRNA library can be used to generate double genetic mutants in OVCAR8-ADR-Cas9 cells.

A pooled combinatorial genetic screen with OVCAR8-ADR-Cas9 cells was initiated to identify gRNA combinations that regulate cancer cell proliferation. A mathematical model was constructed to map out how relative changes in abundances of each library member within a population depend on various parameters (see Methods below; FIGs. 17A and 17B). Populations containing heterogeneous subpopulations that harbor different gRNA combinations were simulated. Specifically, specific percentages of the overall population were defined at the start of the simulation as harboring subpopulations with anti-proliferative (f_s) and pro-proliferative (f_f) gRNA combinations. Within each subpopulation, a fraction of cells was mutated by the CRISPR-Cas9 system (p) at the start of the simulation, resulting in a modified doubling time ($T_{doubling,m}$). The model indicated that the representation of barcoded cells with an anti-proliferative gRNA set in the entire cell population can be depleted by about 23 to 97% under simulated conditions (i.e., f_s , and $f_f = 2, 5, \text{ or } 10\%$; $p = 0.2, 0.4, 0.6, 0.8, \text{ or } 1.0$; $T_{doubling,m} = 36, 48, \text{ or } 60$ hours) (FIG. 17B). In general, increasing mutation efficiencies, increasing doubling times for anti-proliferative cells, decreasing doubling times for pro-proliferative cells, as well as increasing the percentage of pro-proliferative combinations in the population (FIG. 17C), are expected to result in greater barcode depletion of anti-proliferative barcodes in the overall population.

In the experimental screen, to identify gRNA combinations that regulate cancer cell proliferation, the OVCAR8-ADR-Cas9 cell populations infected with the two-wise combinatorial gRNA library were cultured for 15 and 20 days, then genomic DNA was isolated from the cells for unbiased amplification and quantification of the integrated barcodes (FIGs. 4A, 10A and 10B). Comparison of the barcode abundances (normalized per million reads) between the day 20 and day 15 groups yielded \log_2 (barcode count ratios) values (FIGs. 4A, 10A, and 10B). Guide RNA combinations inhibiting cell proliferation were expected to yield negative \log_2 ratios, while those conferring cells with growth advantages were expected to have positive \log_2 ratios. To reduce variability, combinations

with less than ~100 absolute reads in the day 15 group were filtered out, and the \log_2 ratios of the two potential arrangements for each gRNA pair (i.e., *sgRNA-A* + *sgRNA-B* and *sgRNA-B* + *sgRNA-A*) were averaged (FIG. 11). \log_2 ratios for each gRNA combination were determined for two biological replicates and ranked (FIGs. 5B and 12A). The majority of the gRNA combinations did not exhibit significant changes in barcode representations between the day 15 and day 20 groups, including three control gRNAs from the GeCKOv2 library (Shalem et al (2014) *Science* 343: 84-7) that do not have on-target loci in the human genome as internal controls. Sixty-one gRNA combinations were shown to exert considerable anti-proliferative effects (\log_2 ratio < -0.90) in both biological replicates (Q-value < 0.01, Table 2 and FIG. 12B), yielding potential sets of genes to investigate further for their ability to suppress the growth of cancer cells.

Table 2: Two-wise sgRNA hits that inhibit OVCAR8-ADR cell proliferation based on pooled screening

sgRNA-A	sgRNA-B	Log ₂ ratio – Day 20/Day15 Replicate 1	Log ₂ ratio – Day 20/Day15 Replicate 2	Z-score Replicate 1	Z-score Replicate 2	Q value
BRD4_sg3	MLL_sg3	-2.61	-3.32	-8.45	-10.72	7.01E-33
BMI1_sg2	HDAC2_sg3	-3.91	-1.93	-12.62	-6.29	3.41E-32
BMI1_sg2	KDM1B_sg3	-1.34	-3.71	-4.39	-11.99	1.20E-23
ING3_sg3	BMI1_sg1	-3.68	-1.11	-11.87	-3.64	4.57E-21
BRD4_sg3	KDM6A_sg2	-2.30	-2.20	-7.45	-7.15	1.52E-18
BRD4_sg3	PHF2_sg2	-1.57	-2.88	-5.12	-9.31	4.05E-18
BMI1_sg2	PRMT6_sg1	-2.80	-1.59	-9.05	-5.19	1.19E-17
ING3_sg2	KDM5A_sg2	-2.28	-2.04	-7.40	-6.65	3.48E-17
KDM5B_sg3	MLL_sg3	-3.17	-1.05	-10.23	-3.47	2.61E-16
KDM6A_sg3	KDM6A_sg2	-1.95	-2.26	-6.35	-7.33	2.61E-16
BRD4_sg3	KDM4C_sg1	-1.48	-2.28	-4.84	-7.40	7.88E-13
KDM6B_sg1	KDM3A_sg2	-0.98	-2.70	-3.23	-8.74	3.00E-12
ING3_sg3	KDM6A_sg2	-1.46	-2.10	-4.79	-6.81	2.02E-11
PRMT5_sg3	PRMT5_sg3	-1.54	-1.92	-5.04	-6.26	9.13E-11
BRD4_sg3	BRD4_sg2	-2.45	-1.00	-7.93	-3.30	1.24E-10
BMI1_sg2	NSD1_sg3	-2.19	-1.20	-7.13	-3.94	2.68E-10
BMI1_sg2	MBD2_sg3	-1.44	-1.93	-4.70	-6.27	3.94E-10
BMI1_sg2	KDM1A_sg1	-1.62	-1.40	-5.29	-4.59	5.85E-08
KDM3A_sg2	PRMT5_sg3	-1.28	-1.72	-4.21	-5.62	6.62E-08
BRD4_sg3	EP300_sg3	-1.28	-1.71	-4.22	-5.58	7.28E-08
BMI1_sg2	KDM3A_sg1	-1.47	-1.48	-4.79	-4.85	1.32E-07
BRD4_sg3	KDM6B_sg1	-1.20	-1.64	-3.94	-5.35	5.58E-07

PHF8_sg2	KDM1A_sg1	-1.11	-1.69	-3.65	-5.52	8.77E-07
KDM6A_sg3	HDAC2_sg3	-1.03	-1.77	-3.40	-5.77	8.77E-07
BRD4_sg3	KDM6B_sg2	-0.92	-1.86	-3.05	-6.05	1.13E-06
PRMT5_sg3	HDAC1_sg1	-1.26	-1.43	-4.15	-4.68	3.14E-06
PHF8_sg2	PRMT5_sg3	-1.60	-1.08	-5.23	-3.57	3.50E-06
BRD4_sg3	PHF2_sg1	-1.51	-1.13	-4.94	-3.71	5.35E-06
BRD4_sg3	EZH2_sg3	-1.02	-1.57	-3.38	-5.12	8.80E-06
PRMT5_sg3	EZH1_sg1	-0.96	-1.62	-3.19	-5.28	9.53E-06
KDM6A_sg2	KDM5A_sg2	-1.48	-1.04	-4.86	-3.44	1.72E-05
BRD4_sg3	KDM2B_sg2	-1.00	-1.49	-3.30	-4.88	2.59E-05
KDM6B_sg3	PRMT5_sg3	-1.03	-1.43	-3.41	-4.67	3.60E-05
BRD4_sg1	KDM6B_sg1	-1.30	-1.15	-4.27	-3.79	3.74E-05
KDM1A_sg3	PRMT5_sg3	-1.52	-0.91	-4.96	-3.01	4.81E-05
PRMT5_sg3	EP300_sg2	-1.41	-1.00	-4.61	-3.31	5.44E-05
BRD4_sg3	PRMT5_sg2	-1.46	-0.91	-4.79	-3.02	7.59E-05
KDM5D_sg2	MLL_sg3	-1.01	-1.34	-3.35	-4.40	9.28E-05
BRD4_sg3	PRMT5_sg3	-1.03	-1.33	-3.39	-4.35	9.28E-05
PHF2_sg1	PRMT5_sg3	-1.19	-1.13	-3.92	-3.71	1.32E-04
PRMT5_sg2	DNMT1_sg1	-1.28	-1.02	-4.21	-3.37	1.54E-04
KDM6A_sg2	KDM5C_sg1	-1.28	-1.01	-4.19	-3.34	1.73E-04
BMI1_sg2	KDM6A_sg2	-0.96	-1.30	-3.17	-4.25	2.47E-04
KDM1A_sg1	PRMT5_sg3	-0.95	-1.29	-3.15	-4.24	2.68E-04
BRD4_sg2	KDM2B_sg1	-1.06	-1.17	-3.51	-3.85	2.82E-04
KDM4A_sg2	PRMT5_sg3	-1.07	-1.16	-3.52	-3.81	3.18E-04
PRMT6_sg2	PRMT5_sg2	-1.02	-1.13	-3.37	-3.74	6.20E-04
KDM2B_sg3	PRMT5_sg3	-1.13	-1.01	-3.73	-3.34	6.95E-04
KDM6B_sg1	MLL_sg3	-0.92	-1.19	-3.05	-3.90	9.39E-04
BRD4_sg3	BMI1_sg2	-0.94	-1.14	-3.11	-3.76	1.10E-03
KDM5A_sg3	NSD1_sg3	-0.91	-1.14	-3.03	-3.75	1.37E-03
BRD4_sg3	KDM3A_sg2	-0.92	-1.13	-3.04	-3.74	1.37E-03
KDM6B_sg3	PRMT7_sg3	-1.11	-0.90	-3.65	-3.00	1.85E-03
BRD3_sg3	KDM4C_sg1	-0.99	-1.01	-3.27	-3.33	2.13E-03
KDM4C_sg1	PRMT5_sg3	-0.93	-1.06	-3.08	-3.51	2.15E-03
KDM3B_sg1	PRMT5_sg3	-1.00	-0.99	-3.31	-3.28	2.15E-03
PRMT5_sg2	MBD1_sg1	-0.94	-1.04	-3.11	-3.42	2.47E-03
EP300_sg3	MBD1_sg3	-0.92	-1.03	-3.05	-3.41	2.93E-03
ING3_sg1	BRD4_sg3	-0.99	-0.96	-3.28	-3.17	2.93E-03
KDM1A_sg1	HDAC2_sg3	-0.94	-0.95	-3.12	-3.14	4.71E-03
PRMT5_sg2	CARM1_sg1	-0.95	-0.91	-3.14	-3.02	5.78E-03

Hits from the screen were validated by evaluating the ability of the gRNA pair to inhibit the proliferation of OVCAR8-ADR-Cas9 cells (i.e., by ~33% within 5 days) in individual (non-pooled) cell growth assays using the corresponding gRNA pairs delivered via lentiviruses (FIG. 4C). There was high consistency between data collected from the pooled

screen and individual validation assays (FIG. 13). Collectively, the methods described herein provide an experimental pipeline for the systematic screening of barcoded combinatorial gRNAs that are capable of exerting anti-proliferative effects on ovarian cancer cells.

5 Many gRNAs targeting epigenetic genes exhibited stronger anti-proliferative effects when used in combination with other epigenetic-gene-targeting gRNAs than when used in combination with control gRNAs (FIGs. 4B and 12A).

Off-target activity of the gRNAs was assessed by deep sequencing, which revealed a low indel generation rate (*i.e.*, 0.15 to 0.38%) at all exonic off-target genomic loci computationally predicted by the CRISPR design and CCTop tools for the two gRNAs (FIG. 10 19). Collectively, an experimental pipeline was established and validated for the systematic screening of barcoded combinatorial gRNAs that are capable of exerting anti-proliferative effects on ovarian cancer cells.

The gRNA pairs were confirmed with validation assays (FIGs. 5A and 8) and shRNA pairs (FIGs. 5B and 14) targeting KDM4C and BRD4 simultaneously led to synergistic 15 reductions in cancer cell growth. Furthermore, co-treatment with the small-molecule KDM4C inhibitor SD70 (Jin, et al. *PNAS* (2014) 111:9235-9240) and small-molecule BRD4 inhibitor JQ1 (Asangani, et al. *Nature* (2014) 510:278-282)(FIG. 5C) inhibited the proliferation of OVCAR8-ADR cells synergistically. Similarly, gRNA pairs (FIGs. 5A and 8) and shRNA pairs (FIGs. 5B and 14) that simultaneously targeted KDM6B and BRD4 20 exhibited synergy, as did co-treatment with the KDM6B/6A inhibitor GSK-J4 (Kruidenier, et al. *Nature* (2012) 488: 404-408) and JQ1 (FIG. 5D). Synergy between both of these pairwise combinations of small-molecule drugs was confirmed by both the Bliss independence (Bliss *Ann. Appl. Biol.* (1939) 6: 585-615) and the Highest Single Agent (Borisy, et al. *PNAS* (2003) 100: 7977-7982) models (FIGs. 5C and 5D).

25 The methods described herein allow for the identification of novel epigenetic target gene pairs that inhibit cancer cell proliferation and the potential development of synergistic drug therapies. The methods also expand the utility of CRISPR-Cas9-based systems for performing systemic multiplexed genetic perturbation screens in a high-throughput capacity.

These methods can also help identify new areas for biological inquiry, such as studies 30 into the mechanisms that underlie observed phenotypes. For example, gene expression patterns were evaluated in cell populations infected with lentiviruses encoding gRNAs targeting both KDM4C and BRD4, or KDM6B and BRD4 (FIG. 21A). Significantly perturbed genes were associated with gene sets involved in cancer-related pathways, including TNF α /NF κ B signaling, p53 pathways, and apoptosis (Fig. 21B). In addition, the

combinatorial effects of epigenetic perturbations are complex and can vary across different cell types (FIGs. 22A and 22B).

5 Methods

Vector construction

The vectors were constructed using standard molecular cloning techniques, including restriction enzyme digestion, ligation, PCR, and Gibson assembly (Table 3). Custom oligonucleotides were purchased from Integrated DNA Technologies. The vector constructs were transformed into *E. coli* strain DH5 α , and 50 μ g/ml of carbenicillin (Teknova) was used to isolate colonies harboring the constructs. DNA was extracted and purified using Plasmid Mini or Midi Kits (Qiagen). Sequences of the vector constructs were verified with Genewiz's DNA sequencing service.

15 Table 3: Constructs

Construct ID	Design
pAWp28	pBT264-U6p-{2xBbsI}-sgRNA scaffold-{MfeI}
pAWp28-1	pBT264-U6p-GFP-sg1
pAWp28-2	pBT264-U6p-RFP-sg1
pAWp28-3	pBT264-U6p-RFP-sg2
pAWp28-4	pBT264-U6p-KDM4C-sg1
pAWp28-5	pBT264-U6p-PHF2-sg1
pAWp28-6	pBT264-U6p-KDM6B-sg2
pAWp28-7	pBT264-U6p-PHF2-sg2
pAWp28-8	pBT264-U6p-DNMT1-sg1
pAWp28-9	pBT264-U6p-DNMT3B-sg1
pAWp28-10	pBT264-U6p-PRMT2-sg3
pAWp28-11	pBT264-U6p-HDAC2-sg1
pAWp28-12	pBT264-U6p-ING4-sg1
pAWp28-13	pBT264-U6p-KDM1B-sg3
pAWp28-14	pBT264-U6p-KDM2A-sg3
pAWp28-15	pBT264-U6p-PRMT6-sg1
pAWp28-16	pBT264-U6p-BMI1-sg2
pAWp28-17	pBT264-U6p-PHF8-sg2
pAWp9	pFUGW-UBCp- <i>RFP</i> -CMVp- <i>GFP</i> -{BamHI+EcoRI}
pAWp9-1	pFUGW-UBCp- <i>RFP</i> -CMVp- <i>GFP</i> -U6p-GFP-sg1
pAWp9-2	pFUGW-UBCp- <i>RFP</i> -CMVp- <i>GFP</i> -U6p-RFP-sg1
pAWp9-3	pFUGW-UBCp- <i>RFP</i> -CMVp- <i>GFP</i> -U6p-RFP-sg2
pAWp9-4	pFUGW-UBCp- <i>RFP</i> -CMVp- <i>GFP</i> -U6p-RFP-sg1-U6p-GFP-sg1
pAWp9-5	pFUGW-UBCp- <i>RFP</i> -CMVp- <i>GFP</i> -U6p-RFP-sg2-U6p-GFP-sg1

pAWp11	pFUGW-CMVp
pAWp12	pFUGW-CMVp- <i>GFP</i>
pAWp12-1	pFUGW-CMVp- <i>GFP</i> -[U6p-BRD4-sg3]-[U6p-PHF2-sg1]
pAWp12-2	pFUGW-CMVp- <i>GFP</i> -[U6p-BRD4-sg3]-[U6p-KDM6B-sg2]
pAWp12-3	pFUGW-CMVp- <i>GFP</i> -[U6p-BRD4-sg3]-[U6p-KDM4C-sg1]
pAWp12-4	pFUGW-CMVp- <i>GFP</i> -[U6p-BRD4-sg3]-[U6p-PHF2-sg2]
pAWp12-5	pFUGW-CMVp- <i>GFP</i> -[U6p-BRD4-sg3]
pAWp12-6	pFUGW-CMVp- <i>GFP</i> -[U6p-KDM4C-sg1]
pAWp12-7	pFUGW-CMVp- <i>GFP</i> -[U6p-KDM6B-sg2]
pAWp12-8	pFUGW-CMVp- <i>GFP</i> -[U6p-DNMT1-sg1]
pAWp12-9	pFUGW-CMVp- <i>GFP</i> -[U6p-DNMT3B-sg1]
pAWp12-10	pFUGW-CMVp- <i>GFP</i> -[U6p-PRMT2-sg3]
pAWp12-11	pFUGW-CMVp- <i>GFP</i> -[U6p-HDAC2-sg1]
pAWp12-12	pFUGW-CMVp- <i>GFP</i> -[U6p-ING4-sg1]
pAWp12-13	pFUGW-CMVp- <i>GFP</i> -[U6p-KDM1B-sg3]
pAWp12-14	pFUGW-CMVp- <i>GFP</i> -[U6p-KDM2A-sg3]
pAWp12-15	pFUGW-CMVp- <i>GFP</i> -[U6p-PRMT6-sg1]
pAWp12-16	pFUGW-CMVp- <i>GFP</i> -[U6p-BMI1-sg2]-[U6p-PHF8-sg2]
pAWp21	pLKO.1-Control sh
pAWp21-1	pLKO.1-KDM4C-sh1
pAWp21-2	pLKO.1-KDM4C-sh2
pAWp21-3	pLKO.1-KDM6B-sh
pAWp21-4	pLKO.1-BRD4-sh1
pAWp21-5	pLKO.1-BRD4-sh2
pAWp30	pFUGW-EFSp- <i>Cas9-P2A-Zeo</i>

To generate a lentiviral vector encoding an shRNA that targeted a specific gene, oligonucleotide pairs harboring the sense and antisense sequences were synthesized, annealed, and cloned in the AgeI- and EcoRI-digested pLKO.1 vector²⁹ (Addgene plasmid #10879) by ligation. The shRNA sense and antisense sequences were designed and constructed based on the siRNA Selection Program (sirna.wi.mit.edu/) (Table 4).

Table 4: shRNA antisense sequences used for individual validation assays

shRNA ID	shRNA antisense sequence
Control-sh	CGAGGGCGACTTAACCTTAGG (SEQ ID NO: 163)
KDM4C-sh1	AAATCTTCGTAATCCAAGTAT (SEQ ID NO: 164)
KDM4C-sh2	GTAATACCGGGTGTTCGGATG (SEQ ID NO: 165)
KDM6B-sh	ATTAATCCACACGAGGTCTCC (SEQ ID NO: 166)
BRD4-sh1	TATAGTAATCAGGGAGGTCA (SEQ ID NO: 167)
BRD4-sh2	TTTAGACTTGATTGTGCTCAT (SEQ ID NO: 168)

To generate the pAWp30 lentiviral expression vector encoding Cas9 protein and Zeocin resistance as the selection marker, the EFS promoter and Cas9 sequences were amplified from Addgene plasmid #49535, while the Zeocin sequence was amplified from Addgene plasmid #25736, by PCR using Phusion DNA polymerase (New England Biolabs).

5 The PCR products were cloned into the pAWp11 lentiviral vector backbone using Gibson Assembly Master Mix (New England Biolabs).

To construct a storage vector containing U6 promoter (U6p)-driven expression of sgRNA that targeted a specific gene, oligo pairs with the 20 bp sgRNA target sequences were synthesized, annealed, and cloned in the BbsI-digested pAWp28 vector using T4 ligase (New
10 England Biolabs). To construct a lentiviral vector for U6p-driven expression of single or combinatorial sgRNA(s), U6p-sgRNA expression cassettes were prepared from digestion of the storage vector with BglIII and MfeI enzymes (Thermo Scientific), and inserted into the pAWp12 vector backbone or the single sgRNA expression vector, respectively, using ligation
15 via the compatible sticky ends generated by digestion of the vector with BamHI and EcoRI enzymes (Thermo Scientific). To express the sgRNAs together with the dual RFP and GFP fluorescent protein reporters, the U6p-driven sgRNA expression cassettes were inserted into the pAWp9, instead of pAWp12, lentiviral vector backbone using the same strategy described
20 above. The pAWp9 vector was modified from the pAWp7 vector backbone by introducing unique BamHI and EcoRI sites into the vector to enable the insertion of the U6p-sgRNA expression cassettes.

Assembly of the barcoded combinatorial sgRNA library pool

An array of 153 oligo pairs (Oligo F-(x) and Oligo R-(x), where $x = 1$ to 153) harboring the barcoded sgRNA sequences were synthesized, and annealed to generate
25 double-stranded inserts harboring the 20 bp sgRNA target sequences, two BbsI restriction sites, 8 bp barcodes unique to each sgRNA while differed from each other by at least two bases, and 5' overhangs at their ends. To generate the pooled storage vector library, the 153 annealed inserts were mixed at equal ratios and cloned in the pAWp28 storage vector (digested with BbsI and MfeI) via a single pot of ligation reaction via their compatible ends.
30 To build the barcoded sgRNA library, another one-pot ligation reaction was performed with the pooled storage vector library digested with BbsI, and an insert containing the sgRNA scaffold sequence, BamHI and EcoRI restriction sites, and 5' overhangs at their ends that was prepared via synthesis and annealing of an oligo pair S1 and S2. The pooled storage vector

and the barcoded sgRNA libraries were both prepared in Endura competent cells (Lucigen) and purified by the Plasmid Midi kit (Qiagen).

Pooled lentiviral vector libraries harboring single or combinatorial gRNA(s) were constructed with same strategy as for the generation of single and combinatorial sgRNA constructs described above, except that the assembly was performed with pooled inserts and vectors, instead of individual ones. Briefly, the pooled U6p-sgRNA inserts were generated by a single-pot digestion of the pooled storage vector library with BglIII and MfeI. The destination lentiviral vector (pAWp12) was digested with BamHI and EcoRI. The digested inserts and vectors were ligated via their compatible ends (i.e., BamHI + BglIII & EcoRI + MfeI) to create the pooled one-wise sgRNA library (153 sgRNAs) in lentiviral vector. The one-wise sgRNA vector library was digested again with BamHI and EcoRI, and ligated with the same U6p-sgRNA insert pool to assemble the two-wise sgRNA library (153 x 153 sgRNAs = 23,409 total combinations). After the pooled assembly steps, the sgRNAs were localized to one end of the vector construct and their respective barcodes were concatenated at the other end. The lentiviral sgRNA library pools were prepared in XL10-Gold ultracompetent cells (Agilent Technologies) and purified by Plasmid Midi kit (Qiagen).

Cell culture

HEK293T cells were obtained from ATC, and were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum and 1X antibiotic-antimycotic (Life Technologies) at 37°C with 5% CO₂. OVCAR8-ADR cells were a gift from T. Ochiya (Japanese National Cancer Center Research Institute, Japan). The identity of the OVCAR8-ADR cells was authenticated (Genetica DNA Laboratories). OVCAR8-ADR cells stably expressing Cas9 protein (OVCAR-ADR-Cas9) were generated by lentiviral infection of OVCAR8-ADR cells with the pAWp30 vector and selected for three weeks in the presence of 200 µg/ml Zeocin (Life Technologies). OVCAR8-ADR and OVCAR8-ADR-Cas9 cells were cultured in RPMI supplemented with 10% heat-inactivated fetal bovine serum and 1X antibiotic-antimycotic at 37°C with 5% CO₂. For drug treatment, SD70 (Xcessbio #M60194), GSK-J4 (Cayman Chemical #12073), and/or (+)-JQ1 (Cayman Chemical #11187) were used to treat OVCAR8-ADR cells at indicated drug doses prior to the cell viability assays.

Lentivirus production and transduction

Lentiviruses were produced and packaged in HEK283T cells in 6-well format. HEK293T cells were maintained at ~70% confluency before transfection. FuGENE HD

transfection reagents (Promega) were mixed with 0.5 µg of lentiviral vector, 1 µg of pCMV-dR8.2-dvpr vector, and 0.5 µg of pCMV-VSV-G vector in 100 µl of OptiMEM medium (Life Technologies), and were incubated for 15 minutes at room temperature before adding to cell culture. Culture medium was replaced the next day. Supernatant containing newly produced
5 viruses were collected at 48-hour and 96-hour post-transfection, and filtered through a 0.45 µm polyethersulfone membrane (Pall). 500 µl of filtered viral supernatant was used to infect 250,000 cells in the presence of 8 µg/ml polybrene (Sigma) overnight for transduction with individual vector constructs. For pooled lentiviral library production used in the screens, lentivirus production and transduction were scaled up using the same experimental
10 procedures. Filtered viral supernatant was concentrated using Amicon Ultra Centrifugal Filter Unit (Millipore). Cells were infected in the presence of 8 µg/ml polybrene at a multiplicity of infection of 0.3 to 0.5 to ensure single copy integration in most cells, which corresponded to an infection efficiency of 30-40%. The total number of cells used in the screening was approximately 300-fold more than the library sizes in order to maintain library
15 coverage and reduce any spurious effects due to random lentiviral integration into the genome. Cell culture medium was replaced the next day after infection and cultured for indicated time periods prior to experiments.

Sample preparation for barcode sequencing

20 To prepare samples from cultured cells for barcode sequencing, genomic DNA was extracted and prepared using DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer's protocol. For the barcoded sgRNA plasmid libraries, plasmid DNA transformed into *E. coli* was extracted using the Plasmid Midi Kit (Qiagen). DNA concentrations were determined using Quant-iT PicoGreen dsDNA Assay Kit (Life
25 Technologies).

A ~360 bp fragment containing unique barcode representing each combination within the pooled vector and infected cell libraries was PCR amplified from the plasmid/genomic DNA samples using Kapa Hotstart Ready Mix (Kapa Biosystems). For plasmid DNA, 1 ng of DNA template was added for a 25-µl PCR reaction. For genomic DNA, 800 ng of DNA
30 was added for a 50-µl PCR reaction and a total of 64 PCR reactions were performed for each genomic DNA sample to ensure that the number of cell genomes being amplified was more than 100 times the library size. Moreover, the PCR parameters were optimized to ensure that PCR amplification steps were maintained in the exponential phase to avoid PCR bias. The Illumina anchor sequences and an 8 base-pair indexing barcode were added during the PCR

for multiplexed sequencing. The primer pair sequences used to amplify barcode sequence were: 5'-AATGATACGGCGACCACCGAGATCTACACGGATCCGCAACGGAATTC-3' (SEQ ID NO: 1) and

5'CAAGCAGAAGACGGCATAACGAGATNNNNNNNNGGTTGCGTCAGCAAACACAG-3' (SEQ ID NO: 2), where NNNNNNNN indicates a specific indexing barcode assigned for each experimental sample.

The PCR products containing the barcode sequences were then purified based on fragment size by running on a 1.5% agarose gel and further extracted using the QIAquick Gel Extraction Kit (Qiagen). The PCR product concentrations were determined by quantitative PCR using KAPA SYBR Fast qPCR Master Mix (Kapa Biosystems) and the Illumina Library Quantification Kit (Kapa Biosystems). The forward and reverse primer used for quantitative PCR were 5'-AATGATACGGCGACCACCGA-3' (SEQ ID NO: 3) and 5'-CAAGCAGAAGACGGCATAACGA-3' (SEQ ID NO: 4), respectively. The PCR products from different samples were then pooled at a desired ratio for multiplexed sample sequencing and loaded on the Illumina HiSeq system with CombiGEM barcode primer (5'-CCACCGAGATCTACACGGATCCGCAACGGAATTC-3' (SEQ ID NO: 5)) and indexing barcode primer (5'-GTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACC-3' (SEQ ID NO: 6)).

20 Barcode sequencing data analysis

Barcode reads for each sgRNA combinations were processed from the Illumina sequencing data. Barcode reads representing each combination were normalized per million reads for each sample categorized by the indexing barcodes. As measures of cell proliferation, barcode count ratios of normalized barcode reads comparing day 20 against day 15 groups were calculated as fold changes. Pro-proliferation and anti-proliferation phenotypes had fold changes of normalized barcode reads of > 1 and < 1 respectively, while no phenotypic change resulted in a fold change = 1. Barcodes that gave less than ~100 absolute reads in the day 15 group were filtered out to improve data reliability. The fold changes of the different possible orders of each same sgRNA combination were averaged, and high consistency in the fold-changes was observed (i.e., coefficient of variation (CV) < 0.2 and < 0.4 for over 82% and 95% of the combinations, respectively (FIG. 11). The calculated fold change was log transformed to give the log₂ ratio. Screens were performed in two biological replicates with independent infections of the same lentiviral libraries. Combinations were ranked by the log₂ ratio across all experimental conditions. The set of top

hits (open circles) were defined as those with a \log_2 ratio that was at least three standard deviations from the mean of sgRNA combinations harboring only the control sgRNAs (open triangles) in both biological replicates (FIGs. 4B, 12A, and 12B).

5 Cell viability assay

The MTT colorimetric assay was performed to assess cell viability. For each 96 well, 100 μ l of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (Sigma) was added to the cell cultures. Cells were incubated for 3 hours at 37°C with 5% CO₂. Viable cells convert the soluble MTT salt to insoluble blue formazan crystals.

10 Formazan crystals were dissolved with 100 μ l of solubilization buffer at 37°C. Absorbance reading at an optical density (OD) of 570nm and 650nm (reference) were measured using a Synergy H1 Microplate Reader (BioTek).

Drug synergy quantification

15 The Bliss independence (BI) model (*Bliss Ann. Appl. Biol.* (1939) 26: 585-615) and the Highest Single Agent (HSA) model (Borisys, et al. *PNAS* (2003) 100: 7977-7982) are commonly used methods to evaluate synergy between drug combinations.

Based on the BI model, the expected effect (E_{Exp}) is given by:

$$20 \quad E_{Exp} = E_A + E_B - (E_A \times E_B),$$

where E_A is the growth inhibition effect observed at a certain concentration of drug A alone, and E_B is the growth inhibition effect observed at a certain concentration of drug B alone. E_{Obs} is the observed growth inhibition effect for the drug combination (A + B), each at 25 the same concentration as in E_A and E_B , respectively. Each effect is expressed as a fractional inhibition between 0 and 1. When $E_{Obs} - E_{Exp} > 0$, the two drugs are considered to be interacting synergistically.

The HSA model is similar to the BI model except, according to the HSA model, E_{Exp} is equal to the larger of the growth inhibition effect produced by the combination's single 30 drug agents (E_A or E_B) at the same concentrations as in the drug combination (A + B).

Two drugs were considered to be synergistic if $E_{Obs} - E_{Exp} > 0.1$ (i.e. > 10% of excess inhibition over the predicted BI and HSA models in FIGs. 5C and 5D) for at least two different concentration combinations in both models to enhance the stringency of our criteria.

Flow cytometry

Cells were collected at 4-day and 8-day post infection. Samples were washed and resuspended in 1x PBS supplemented with 2% fetal bovine serum. To remove any clumps of cells, the resuspended cells were passed through cell strainers before loading onto the LSRII
5 Fortessa flow cytometer (Becton Dickinson). At least 20,000 events were acquired per sample. Proper laser sets and filters were selected based on cell samples. Forward scatter and side scatter were used to identify appropriate cell populations. Data were analyzed using manufacturer's build-in software.

10 Fluorescence microscopy

Cultured cell were directly observed under an inverted fluorescent microscope (Zeiss) three days post-lentiviral infection. Images were captured using the Zeiss built-in software.

Immunoblot analysis

15 Cells were lysed in 2X RIPA buffer supplemented with protease inhibitors. Lysates were homogenized using a pestle motor mixer (Agros) for 30 seconds, and then centrifuged at 15,000 rpm for 15 min at 4°C. Supernatants were quantified using the BCA assay (Thermo Scientific). Protein was denatured at 99°C for 5 minutes before gel electrophoresis on a 4-15% polyacrylamide gel (Bio-Rad). Proteins were transferred to nitrocellulose membranes at
20 80V for 2 hours at 4°C. Primary antibodies used were: anti-BRD4 (1:2,000, Cell Signaling #13440), anti-KDM4C (1:1,000, Abcam ab85454) anti-KDM6B (1:1,000, Abcam ab85392), and anti-beta-actin (1:4,000, Abcam ab6276). Secondary antibodies used were: HRP-linked anti-rabbit IgG (1:2,000, Cell Signaling #7074), and HRP-linked anti-mouse IgG (1:4,000, Cell Signaling #7076). Membranes were developed by SuperSignal West Pico
25 chemiluminescent substrate (Thermo Scientific) and imaged using a ChemiDoc Touch imaging system (BioRad).

Surveyor assay and sequencing analysis for genome modification

The Surveyor assay was carried out to evaluate DNA cleavage efficiency. Genomic
30 DNA was extracted from cell cultures using QuickExtract DNA extraction solution (Epicentre) according to the manufacturer's protocol. Amplicons harboring the targeted loci were generated by PCR using Phusion DNA polymerase and primers listed in Table 5. About 200 ng of the PCR amplicons were denatured, self-annealed, and incubated with 1.5 µl of

Surveyor Nuclease (Transgenomic) at 42°C for 30 minutes. The samples were then analyzed on a 2% agarose gel. The DNA band intensities were quantified using ImageJ software, and the indel occurrence was estimated with the following formula (Ran et al. *Nat. Protoc.* (2013) 8:2281-2308):

5

$$\text{Indel (\%)} = 100 \times (1 - \text{square root of } (1 - f_{\text{cut}})),$$

with $f_{\text{cut}} = (b + c)/(a + b + c)$, where a is the band intensity for the uncleaved PCR amplicon while b and c are the intensities for each cleaved band. The expected uncleaved and

10

cleaved bands for the targeted alleles are listed in FIGs. 7 and 8.

Sanger sequencing was performed to analyze the genome modifications generated by the expression of combinatorial sgRNAs. Cells infected with the combinatorial sgRNA constructs were cultured for 12 days, and re-plated in 96-well plates as single cells by serial dilution of the cultures. Genomic DNA was extracted from the isolated single cell-expanded

15

clones after culturing for 5 to 21 days using QuickExtract DNA extraction solution, and amplicons harboring the targeted alleles were prepared by PCR as described above. The PCR amplicons were cloned into a TOPO vector using TA Cloning Kit (Life Technologies) according to the manufacturer's protocol, and the nucleotide mutations, insertions, and deletions were identified using Sanger sequencing.

20

Table 5: List of PCR primers used in Surveyor assay and Sanger sequencing

Target sgRNA ID	Forward primer (5' to 3')	Reverse primer (5' to 3')
BMI1-sg2	AGAAATTAAACGGCTACCTCCA (SEQ ID NO: 169)	GTTGGTACAAAGTGGTGAAGGC (SEQ ID NO: 183)
BRD4-sg2	TCCATAGTGTCTTGAGCACCAC (SEQ ID NO: 170)	ACGTGGCTTCATTGTACATCCT (SEQ ID NO: 184)
BRD4-sg3	CACTTGCTGATGCCAGTAGGAG (SEQ ID NO: 171)	AAGCACATGCTTCAGGCTAACA (SEQ ID NO: 185)
DNMT1-sg1	GTGAATAGCTTGGGAATGTGGG (SEQ ID NO: 172)	TCATCTGCTCTTACGCTTAGCC (SEQ ID NO: 186)
DNMT3B-sg1	GCCACACTCTACATGGGAGC (SEQ ID NO: 173)	CTCGGCAACCCTCCATACAT (SEQ ID NO: 187)
HDAC2-sg1	GACTTTTCCATCAGGGACACCT (SEQ ID NO: 174)	AACCATGCACAGAATCCAGATTTA (SEQ ID NO: 188)
ING4-sg1	GGTGGACAAACACATTCGGC (SEQ ID NO: 175)	AAGAGTTCTTGGCGCAGACA (SEQ ID NO: 189)
KDM1B-sg3	CCTATCATTGCCCAAGGAGTC (SEQ ID NO: 176)	TCGTCCAAGTTACAGTCATCACA (SEQ ID NO: 190)
KDM2A-sg3	CTAGGCCTCCGACAGTTGTAAT (SEQ ID NO: 177)	TCCTCTGGTGCACAGAAAAGTC (SEQ ID NO: 191)

KDM4C-sg1	AGCCACCCTTGGTTGGTTTT (SEQ ID NO: 178)	TTCTCTCCAGACACTGCCCT (SEQ ID NO: 192)
KDM6B-sg2	GGTAAGGGAAACTCTGGGGC (SEQ ID NO: 179)	GTGCCCAGAACTACTGCCAT (SEQ ID NO: 193)
PHF8-sg2	CTCCCTCCCTTCCCTAAGGCT (SEQ ID NO: 180)	GAGGTGAGTTCCAGCTTCCC (SEQ ID NO: 194)
PRMT2-sg3	ATTGCCTTAAGTCGACACCTGAT (SEQ ID NO: 181)	CACCTTACAGGCACTGCGTT (SEQ ID NO: 195)
PRMT6-sg1	GACTGTAGAGTTGCCGGAACAG (SEQ ID NO: 182)	CTCCCTCCCTAGAGGCTATGAG (SEQ ID NO: 196)

Table 6: Sequence of the targeted alleles in OVCAR8-ADR-Cas9 single cells harboring BMI1-sg2 and PHF8-sg2 expression construct. Nucleotides in boldface indicate the PAM sequence; and underlined nucleotides refer to base pair insertions or mutations.

Single Cell	sgRNA ID	Sequence (5' to 3')	SEQ ID NO.	Indel
1	BMI1-sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAG----- GTCTTGTGAACTTGGACATCACAAATAGGAC	231	-10bp
1	BMI1-sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAG----- GTCTTGTGAACTTGGACATCACAAATAGGAC	231	-10bp
1	PHF8-sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAAC----- TTCAAAGGGGCATGATACACACAAGGGGAAACC AGTGAAGACC	232	-10bp
1	PHF8-sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAAC----- TTCAAAGGGGCATGATACACACAAGGGGAAACC AGTGAAGACC	232	-10bp
2	BMI1-sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATA----- GGTCTGGTCTTGTGAACTTGGACATCACAAATAG GAC	233	-9bp
2	BMI1-sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGT--- GGTCTGGTCTTGTGAACTTGGACATCACAAATAG GAC	234	-3bp
2	PHF8-sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA- CGCCG TGGATCTTCAAAGGGGCATGATACACAC AAGGGGAAACCAGTGAAGACC	235	-1bp
2	PHF8-sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA-C--- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	236	-5bp
3	BMI1-sg2	ACTCCAATAATAATTACAAACAAGGAATTTCAAC AGTTTCCTACCTTATATTC CTGTGATCTGTGGTCTG GTCTTGTGAACTTGGACATCACAAATAGGAC	237	2mut & +4bp

3	BMI1- sg2	ACTCCAATAATAATTACAAACAAGGAATTTCAAC AGTTTCCTACCTTATATTCIGTGATCTGTGGTCTG GTCTTGTGAACTTGGACATCACAAATAGGAC	237	2mut & +4bp
3	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	238	-3bp
3	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	238	-3bp
4	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
4	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
4	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
4	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
5	BMI1- sg2	ATTTCAACAGTTTCCTACCTTATATACTATACTAT <u>ATATATATATATACTATATATATAGTGGTCTG</u> GTCTTGTGAACTTGGACATCACAAATAGGAC	241	+30bp
5	BMI1- sg2	ATTTCAACAGTTTCCTACCTTATATACTATACTAT <u>ATATATATATATACTATATATATAGTGGTCTG</u> GTCTTGTGAACTTGGACATCACAAATAGGAC	241	+30bp
5	PHF8- sg2	CTCTCATGTTTTTCTGGCTTAGTGAAAAAACTTCA <u>CTAAGTTTTACTTAGTGGATCTTCAAAGGGGCA</u> TGATACACACAAGGGGAAACCAGTGAAGACC	242	+16bp & 2mut
5	PHF8- sg2	CTCTCATGTTTTTCTGGCTTAGTGAAAAAACTTCA <u>CTAAGTTTTACTTAGTGGATCTTCAAAGGGGCA</u> TGATACACACAAGGGGAAACCAGTGAAGACC	242	+16bp & 2mut
6	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC----- TGGTCTGGTCTTGTGAACTTGGACATCACAAATA GGAC	243	-5bp
6	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTAC----- TTGTGAACTTGGACATCACAAATAGGAC	244	-24bp
6	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA---- C <u>ATGGATCTTCAAAGGGGCATGATACACACAAG</u> GGGAAACCAGTGAAGACC	245	-4bp & 1mut
6	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACG--- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	246	-3bp

7	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCT----- AGTGGTCTGGTCTTGTGAACTTGGACATCACAAA TAGGAC	247	-10bp
7	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCT----- AGTGGTCTGGTCTTGTGAACTTGGACATCACAAA TAGGAC	247	-10bp
7	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
7	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
8	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCT--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	248	1mut & -3bp
8	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCT--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	248	1mut & -3bp
8	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
8	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
9	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
9	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC----- TGGTCTGGTCTTGTGAACTTGGACATCACAAATA GGAC	243	-5bp
9	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA---- CATGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	245	-4bp & 1mut
9	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
10	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
10	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT

10	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACTAAGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	249	3mut
10	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
11	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
11	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTAC----- TAGTGGTCTGGTCTTGTGAACTTGGACATCACAA ATAGGAC	250	-11bp
11	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
11	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
12	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
12	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
12	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
12	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
13	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
13	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
13	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGA----- ATCTTCAAAGGGGCATGATACACACAAGGGGAA ACCAGTGAAGACC	251	-13bp
13	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGA----- ATCTTCAAAGGGGCATGATACACACAAGGGGAA ACCAGTGAAGACC	251	-13bp
14	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT

14	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
14	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACG--- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	246	-3bp
14	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACG--- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	246	-3bp
15	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
15	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
15	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
15	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
16	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
16	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC---- TGGTCTGGTCTTGTGAACTTGGACATCACAAATA GGAC	243	-5bp
16	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA---- CATGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	245	-4bp & 1mut
16	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
17	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	234	-3bp
17	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	234	-3bp
17	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCC TGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT

17	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
18	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
18	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
18	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
18	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
19	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
19	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCA----- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	252	-14bp & 1mut
19	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGAAACCAGTGAAGACC	246	-3bp
19	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA---- CATGGATCTTCAAAGGGGCATGATACACACAAG GGAAACCAGTGAAGACC	245	-4bp & 1mut
20	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
20	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
20	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAAC--- GTGGATCTTCAAAGGGGCATGATACACACAAGG GAAACCAGTGAAGACC	253	-3bp
20	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAAC--- GTGGATCTTCAAAGGGGCATGATACACACAAGG GAAACCAGTGAAGACC	253	-3bp
21	BMI1- sg2	ACAACCTCCAATAATAATTACAAACAAGGAATTT AACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	254	+1bp
21	BMI1- sg2	ACAACCTCCAATAATAATTACAAACAAGGAATTT AACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	254	+1bp

21	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
21	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACG--- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	246	-3bp
22	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTA----- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	255	-14bp
22	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC--TAG- GGTCTGGTCTTGTGAACTTGGACATCACAAATAG GAC	256	-3bp
22	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
22	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
23	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAG----- TGTGAACTTGGACATCACAAATAGGAC	257	-13bp
23	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATA---- TAGTGGTCTGGTCTTGTGAACTTGGACATCACAA ATAGGAC	258	-5bp
23	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
23	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
24	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	239	-3bp
24	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTA----- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	255	-14bp
24	PHF8- sg2	TCTGACTCACAATCTCTCATGTTTTTCTGGCTTAG TGAAAAACATGCCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	259	+3bp & 2mut
24	PHF8- sg2	TCTGACTCACAATCTCTCATGTTTTTCTGGCTTAG TGAAAAACATGCCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	259	+3bp & 2mut

25	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCA--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	239	-3bp
25	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCA--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	239	-3bp
25	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
25	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
26	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATT CAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
26	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATT CAGT--- GGTCTGGTCTTGTGAACTTGGACATCACAAATAG GAC	234	-3bp
26	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
26	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
27	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTAT----- TGGTCTGGTCTTGTGAACTTGGACATCACAAATA GGAC	260	-9bp
27	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTAT----- TGGTCTGGTCTTGTGAACTTGGACATCACAAATA GGAC	260	-9bp
27	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACG CGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
27	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACG--- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	246	-3bp
28	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACA----- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	261	-22bp
28	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACA----- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	261	-22bp

28	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
28	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
29	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
29	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC----- TGGTCTGGTCTTGTGAACTTGGACATCACAAATA GGAC	243	-5bp
29	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA---- C <u>A</u> TGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	245	-4bp & 1mut
29	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
30	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
30	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
30	PHF8- sg2	TCTCATGTTTTTCTGGCTTAGTGAAAT <u>C</u> TAAGC <u>T</u> <u>A</u> GTGAAATCTAAGCCG <u>T</u> GGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	262	+17bp & 1mut
30	PHF8- sg2	TCTCATGTTTTTCTGGCTTAGTGAAAT <u>C</u> TAAGC <u>T</u> <u>A</u> GTGAAATCTAAGCCG <u>T</u> GGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	262	+17bp & 1mut
31	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC <u>T</u> TATATGGTCTG GTCTTGTGAACTTGGACATCACAAATAGGAC	263	5mut
31	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTA----- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	255	-14bp
31	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp
31	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA--- CGTGGATCTTCAAAGGGGCATGATACACACAAG GGGAAACCAGTGAAGACC	246	-3bp

32	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
32	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATA--- TAGTGGTCTGGTCTTGTGAACTTGGACATCACAA ATAGGAC	264	-3bp & 1mut
32	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
32	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
33	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTAG----- AACTTGGACATCACAAATAGGAC	265	-18bp
33	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTAG----- AACTTGGACATCACAAATAGGAC	265	-18bp
33	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
33	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
34	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
34	BMI1- sg2	TCAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
34	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
34	PHF8- sg2	GTTCTGACTCACAATCTCTCATGTTTTTCTGGCT AGTGAAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	266	+1bp
35	BMI1- sg2	TAATTACAAACAAGGAATTTCAACAGTTTCCTAC CTTATATTAGTAGTATAATATATTATTAGTGGTCTG GTCTTGTGAACTTGGACATCACAAATAGGAC	267	+14bp
35	BMI1- sg2	TAATTACAAACAAGGAATTTCAACAGTTTCCTAC CTTATATTAGTAGTATAATATATTATTAGTGGTCTG GTCTTGTGAACTTGGACATCACAAATAGGAC	267	+14bp
35	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTG----- GATCTTCAAAGGGGCATGATACACACAAGGGGA AACCAGTGAAGACC	268	-13bp

35	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTG----- GATCTTCAAAGGGGCATGATACACACAAGGGGA AACCAGTGAAGACC	268	-13bp
36	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC-- TAGTGGTCTGGTCTTGTGAACTTGGACATCACAA ATAGGAC	269	-2bp
36	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC-- TAGTGGTCTGGTCTTGTGAACTTGGACATCACAA ATAGGAC	269	-2bp
36	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAACG--- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	246	-3bp
36	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
37	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTATATAGTGGTCTG GTCTTGTGAACTTGGACATCACAAATAGGAC	270	3mut
37	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCAGTAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	239	WT
37	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA-C---- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	236	-5bp
37	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAA-C---- TGGATCTTCAAAGGGGCATGATACACACAAGGG GAAACCAGTGAAGACC	236	-5bp
38	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTC--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	239	-3bp
38	BMI1- sg2	TAATTACAAACAAGGAATTTCAACAGTTTCCTAC CTTATATTCAGGTAGTGAATCTGAATAGTGGTCT GGTCTTGTGAACTTGGACATCACAAATAGGAC	271	+14bp
38	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAAC--- GTGGATCTTCAAAGGGGCATGATACACACAAGG GAAACCAGTGAAGACC	253	-3bp
38	PHF8- sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAAC--- GTGGATCTTCAAAGGGGCATGATACACACAAGG GAAACCAGTGAAGACC	253	-3bp
39	BMI1- sg2	TACAACTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTT----- CTGGTCTTGTGAACTTGGACATCACAAATAGGAC	272	-15bp

39	BMI1-sg2	TACAACCTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCA--- GTGGTCTGGTCTTGTGAACTTGGACATCACAAAT AGGAC	239	-3bp
39	PHF8-sg2	ACAATCTCTCATGTTTTTCTGGCTTAGTGAATCCTT <u>CAAAGGGATCTTCAAAA</u> GGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	273	+11bp & 4mut
39	PHF8-sg2	ACAATCTCTCATGTTTTTCTGGCTTAGTGAATCCTT <u>CAAAGGGATCTTCAAAA</u> GGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	273	+11bp & 4mut
40	BMI1-sg2	TACAACCTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATT----- GTGAACTTGGACATCACAAATAGGAC	274	-18bp
40	BMI1-sg2	TACAACCTCCAATAATAATTACAAACAAGGAATTT CAACAGTTTCCTACCTTATATTCA--- AGTGGTCTGGTCTTGTGAACTTGGACATCACAAA TAGGAC	275	-3bp
40	PHF8-sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT
40	PHF8-sg2	CGTTCTGACTCACAATCTCTCATGTTTTTCTGGCT TAGTGAAAAAACGCCGTGGATCTTCAAAGGGGC ATGATACACACAAGGGGAAACCAGTGAAGACC	240	WT

RNA extraction and quantitative RT-PCR (qRT-PCR)

RNA were extracted from cells using TRIzol Plus RNA Purification Kit (Life Technologies) according to manufacturer's protocol and treated with PureLink on-column DNase kit (Life Technologies). RNA quality and concentration was determined using NanoDrop Spectrophotometer. RNA samples were reverse-transcribed using SuperScript III Reverse Transcriptase (Life Technologies), Random Primer Mix (New England Biolabs) and RNase OUT (Invitrogen). To evaluate gene expression level, quantitative PCR was conducted using SYBR FAST qPCR MasterMix (KAPA) on the LightCycler480 system (Roche). Data was quantified and analyzed using LifeCycler480 SW 1.1 build-in software. PCR primers were designed and evaluated using PrimerBlast (NCBI). Primer sequences are listed in Table 7.

Table 6: PCR primers used in qRT-PCR

Target gene ID	Forward primer (5' to 3')	Reverse primer (5' to 3')
BRD4	GTTGATGTGATTGCCGGCTC (SEQ ID NO: 197)	TTAGGCAGGACCTGTTTCGG (SEQ ID NO: 200)
KDM4C	CGTACGGGTTTCATGCAAGTT (SEQ ID NO: 198)	CGTTTGCTTAAGAGCACCTCC (SEQ ID NO: 201)
KDM6B	CCCCTCACCGCCTATCAGTA	TCTTGAACAAGTCGGGGTTCG

(SEQ ID NO: 199)	(SEQ ID NO: 202)
------------------	------------------

Table 8: PCR primers used in deep sequencing for indel detection

Target gRNA ID	Type of target site	20 bp gRNA targeting sequence (5' to 3')	SEQ ID NO.	Forward primer (5' to 3')	SEQ ID NO.	Reverse primer (5' to 3')	SEQ ID NO.
NF1- sg1	On- target	GTIGT GCTCA GTA CT GACTT	276	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GGTATCTGTGGTT GATGCAGTTTCC	304	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- AGTAGTGAGGCC GCTTATAACC	332
NF1- sg4	On- target	TTTCA GCTTC CAATA AAAAC	277	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GGTATCTGTGGTT GATGCAGTTTCC	304	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- AGTAGTGAGGCC GCTTATAACC	332
NF2- sg2	On- target	ATICC ACGGG AAGGA GATCT	278	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GCACAGAGCTGC TGCTTGGAGTG	305	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- TAACAAGGAGAT GCCCTGGCTGG	333
MED1 2-sg1	On- target	AGGAT TGAAG CTGAC GTICT	279	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CGTTTCTGCCT CAGGATGAAC	306	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- AGGTCATGAAGG CAAACCTCAGCC	334
PHF8- sg2	On- target	GGCTT AGTGA AAAAA CGCCG	280	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- TTGGAAGAGAAG GATCTGCTGAGG C	307	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- CACCTGTCAAAA GTCCTACTCCGG	335
BMI- sg2	On- target	TCCTA CCTTAT ATTCA GTAG	281	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GCTACCCTCCACA AAGCACACAC	308	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- CCTGGAGACCAG CAAGTATTGTCC	336
KDM4 C-sg1	On- target	CCTTTG CAAGA CCC GC ACGA	109	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CCTTCAGAAACA ATGTCCCAAATCG	309	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- GTCCTCTGAACCC CAGCTGTAAG	337
KDM4 C-sg1	Off- target	GCTTT GCCC G AACCG CACGA	282	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- AGCCTTTCTGAGA GCGGGCTAG	310	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- CAAACAGAGGCC AAAGGGTGTCCC	338
KDM4 C-sg1	Off- target	CCTAG GCCAG ACCTG CACGA	283	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GCCTCCCTCATC CTCTCGCTTC	311	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- ACAGGAGGTCGT GGTGCAGTCTC	339

KDM4 C-sg1	Off- target	GCTCT GGAAG ACCCG CACCA	284	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GATTGGCTCCAA GCGGCCATCAAA C	312	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- TTGTGTGAGGAA CGTTGACGCTACC	340
KDM4 C-sg1	Off- target	CCTTAT CAAGA CCCAC ACCA	285	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- TTGAACTCAAGG CTCAGCCAACAG GC	313	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- GAGCGTAGGTCC TCTGCATGGAG	341
KDM6 B-sg2	On- target	ATCCC CCTCCT CGTAG CGCA	286	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CAACTCAGGCTG GATGCATCGG	314	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- CCACAGAATGAC AGGAACCCATGG	342
KDM6 B-sg2	Off- target	CTGCT CCTCCT CGTAG CGCT	287	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- TTGGTGGCCGCTG AGTGTGTGTAC	315	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- ACTGAGCAGAGC CTAGGAGGCAG	343
KDM6 B-sg2	Off- target	TGCGC CCTCCT CCTAG CGCA	288	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CAGCATGTTGAC ATAGCGGC	316	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- TGTTGCCAGATCC AGAGGCGTC	344
KDM6 B-sg2	Off- target	CTCCTC CTCCG CGTAG CGCT	289	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- TGAGAGGAGATG AGTCGGGGTC	317	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- AACTGGCCCGAG TAGTCGGAGCAG	345
KDM6 B-sg2	Off- target	CTGCC CCTCCT GGTAG CGCC	290	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GACGGGTCAAAG CCTCAGGAGAG	318	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- TCCTCAGAGTGTG TGGAAGTGCTGG	346
KDM6 B-sg2	Off- target	AACCA GCTCC TCGTA GCTCA	291	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- TTAGCTGCCCAGC TCACAGCTACC	319	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- AAGAGCTCCTAG GGGAGGATCAG	347
KDM6 B-sg2	Off- target	ACCGC CCTCCT CCTAG CTCA	292	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GAGCCCCAAGAG CGAGACAA	320	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- TGGCAGGAGCAC AGCCTAAGGA	348
KDM6 B-sg2	Off- target	AGCCC GCTCC TCGTG GGCA	293	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GGCGCTCAGAAG GCTGTGCAG	321	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- ACACCCGCTCG GAGATCAACAC	349
BRD4- sg3	On- target	GGGAA CAATA AAGAA	294	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT-	322	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT-	350

		GCGCT		CCTAGGTGACACT GGACTTTTGC		CCACCCCTACATC TCACCTTGTTG	
BRD4- sg3	Off- target	TGGAA AAACA AAGAA GAGCT	295	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- AGGTTACCTCAG GCTGCTCAGAAG	323	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- GTGAGGTTTCCAC GTGCCAGC	351
BRD4- sg3	Off- target	GGGAA GTATA AGGAA GAGCT	296	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CGTCTCTCCAT GTGAGCTTGTG	324	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- CCAACAATTCCA GGTATGAAACTC CC	352
BRD4- sg3	Off- target	GTGAG CAATA AAGCA GCCCT	297	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GGAAAGATCATC TGATCAGGCCCAT C	325	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- CTCCCCACTTGTA GGTTCCTAATCC	353
BRD4- sg2	On- target	TCTAG TCCAT CCCC ATTAC	298	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CTTGTTAGGGTTG GAGGTCTCTGG	326	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- GTAGAGTGCCTG GTGAAGAATGTG	354
BRD4- sg2	Off- target	AATAT TCCATT CCCCA TTAC	299	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- AAGGCCCGTAAA GGGCAAGTTCAG	327	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- TCCAGACTGTTGT TCAGTCCTGT	355
BRD4- sg2	Off- target	TGTTGT CCATA CCTCA TTAC	300	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- GGTGACAGGAAG CTGTGCGGAACAT	328	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- CTCTGGATTTGCC CACACCTAGTC	356
BRD4- sg2	Off- target	TCTAG GTCAT GCACC ATTAC	301	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CTCACTGTGATCT GACACCAAACAC	329	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- GCATGCTTGCTTT CTGAAGGTGGC	357
BRD4- sg2	Off- target	CCCAT TCCTTC CCCCA TTAC	302	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CTAGTTGCCTTCA TGCCTTACAGAC	330	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- TTCCAAGCAAGT GAGCTTCAGCAC C	358
BRD4- sg2	Off- target	TCCAC ACCCT CCCC ATTAC	303	ACACTCTTTCCCT ACACGACGCTCTT CCGATCT- CTGCTCCCCTCC AGACTACCC	331	GTGACTGGAGTTC AGACGTGTGCTCT TCCGATCT- CCACCCATGACA CAGGAGGG	359

Table 9: PCR primers used in whole genome amplification for indel detection

Target sgRNA ID	Forward primer (5' to 3')	Reverse primer (5' to 3')
--------------------	---------------------------	---------------------------

BMI1-sg2	GTCTCGTGGGCTCGGAGATGTGTAT AAGAGACAGGCTACCCTCCACAAA GCACACAC (SEQ ID NO: 360)	TCGTCGGCAGCGTCAGATGTGTATA AGAGACAGCCTGGAGACCAGCAAGT ATTGTCC (SEQ ID NO: 362)
PHF8-sg2	GTCTCGTGGGCTCGGAGATGTGTAT AAGAGACAGTTGGAAGAGAAGGAT CTGCTGAGGC (SEQ ID NO: 361)	TCGTCGGCAGCGTCAGATGTGTATA AGAGACAGCACCTGTCAAAAAGTCCT ACTCCGG (SEQ ID NO: 363)

RNA-Seq and data analysis

RNA was extracted from cells using TRIzol Plus RNA Purification Kit (Life Technologies) according to the manufacturer's protocol and treated with PureLink on-column DNase kit (Life Technologies). RNA quality and concentration was determined using NanoDrop Spectrophotometer. RNA samples were reverse-transcribed using SuperScript III Reverse Transcriptase (Life Technologies), Random Primer Mix (New England Biolabs) and RNase OUT (Invitrogen). Sequencing libraries were prepared using the Illumina Library Prep Kit, starting with an input amount of 1 μ g total RNA and following the manufacturer's recommendations. After PCR amplification, the libraries were size-selected to 300 +/- 25 bp on a 2% agarose gel (E-Gel EX, Invitrogen) and submitted to single-end sequencing on an Illumina HiSeq 2000 instrument. RNA-Seq experiments were performed in two biological replicates.

15

Raw single-end reads of the cDNA fragments were aligned to the human transcriptome (RefSeq, hg19) using TopHat2 (Kim, et al. *Genome Biol* (2013) 14:R36) and Bowtie (Langmead, et al. *Genome Biol* (2009) 10:R25). Differentially expressed genes between samples were called using Cuffdiff2 (Trapnell, et al. *Nat Biotechnol* (2013) 31:46-53) with the bias correction option, masking reads mapping to mitochondrial and ribosomal RNA transcripts. Genes were called differentially expressed if they met a minimum of 0.1 fragments per kilobase per million reads (FPKM) in at least one of the conditions tested, the absolute log₂-fold-change was at least 0.5, and the P-value after multiple hypothesis correction (Q-value) was less than 0.05. Gene set enrichment analysis was performed using MSigDB database (broadinstitute.org/gsea/index.jsp) (Subramanian, et al. *Proc Natl Acad Sci USA* (2005) 102:15545-50).

25

Mathematical modeling of cell proliferation in a mixed population

To estimate how different parameters affect results in our pooled screens, we simulated cell proliferation in a mixed cell population harboring gRNA combinations that

30

exhibit different growth rates. At a given time (t), the total cell count (C_N) in the population is represented by the summation of individual cell counts containing different combinations (C_i ; 1 to N , where N is the total number of combinations), such that $C_N(t) = \sum_{i=1}^N C_i(t)$.

5 For each individual gRNA combination, cell growth is represented by Eq. (1). Based on an exponential cell growth model, cells with each gRNA combination consist of two populations: one with a modified growth rate (k_m) due to gene disruption by the CRISPR-Cas9 system, and the other (unmodified cells) with the wild-type growth rate (k_{wt}). The former population is defined as a fraction of cells, p , which is limited by the cleavage
10 efficiency of the CRISPR-Cas9 system. For simplicity, we assumed that p was constant throughout the duration of the assay.

$$C_i(t) = p C_i(t) + (1 - p)C_i(t) = pC_0e^{k_mt} + (1 - p)C_0e^{k_{wt}t} \quad (\text{Eq. 1})$$

15 where p represents the fraction of mutated cells with a modified growth rate, and C_0 represents the initial number of cells carrying the same barcoded gRNA combination. The cell growth rate (k) is evaluated from the cell's doubling time ($T_{doubling}$) following Eq. 2. The doubling time for wild-type OVCAR8-ADR-Cas9 cells was experimentally determined to be ~24 hours (data not shown).

20

$$k = \ln 2 / T_{doubling} \quad (\text{Eq. 2})$$

For simplicity in modeling, we segregated the total cell population into three sub-populations with different growth phenotypes as described in Eq. (3).

25

$$C_N(t) = \sum_{i=1}^N C_i(t) \approx f_{wt}N \times C_0e^{k_{wt}t} + f_sN \times C_{i,slow}(t) + f_fN \times C_{i,fast}(t) \quad (\text{Eq. 3})$$

where $C_{i,slow}(t)$ and $C_{i,fast}(t)$ represent the average growth profiles of cells with anti-proliferative gRNAs and pro-proliferative gRNAs, respectively, which are determined by Eq.
30 (1). At the start of the experiment, the percentages of the overall population that behave as wild type or that contain anti-proliferative gRNAs and pro-proliferative gRNAs are represented by f_{wt} , f_s and f_f , respectively.

Based on this mixed cell growth model, we modeled the relative frequency ($R. F.$) of a

pro-proliferative gRNA's and an anti-proliferative gRNA's representation in the whole population. The relative frequency is defined as the barcode abundance at a given time compared to the initial time point (i. e., $R.F. = \frac{F(t)}{F(t=0)}$, where $F = C_i(t)/C_N(t)$). The total

number of combinations in a pool, N and the initial number of cells, C_0 , do not impact the

5 relative frequency results. After running the simulation with defined parameters, we observed enrichment and depletion of a pro-proliferative gRNA and anti-proliferative gRNA in the population, respectively (FIG. 17A). The degree of enrichment and depletion was observed to change with different percentages (i.e., 2, 5, or 10%) of initial gRNA combinations defined to have an anti-proliferative (f_s) and pro-proliferative (f_f) response (FIG. 17A). We further

10 evaluated the relative frequency of an anti-proliferative gRNA's representation by modulating the doubling time of modified cells ($T_{doubling,m}$) and the fraction of cells with the modified growth rate (p) for the anti-proliferative gRNA. Assuming that p stayed constant throughout the experiment, the representation of an anti-proliferative clone in the entire cell population could be depleted by ~23% to 97% under the parameter ranges shown in FIGs. 17B-17C.

15 This model represents a simplified version of cell growth dynamics by segregating cell populations into sub-populations with average growth rates and does not account for potential interactions between cells. Based on our model, the sensitivity of our screen could be enhanced with improved gRNA efficiencies to increase the fraction of cells with modified growth rates and by increasing the assay time.

20

Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention.

25 Accordingly, the foregoing description and drawings are by way of example only.

References

1. Shalem, O. *et al.* Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* **343**, 84–7 (2014).
2. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. *Science* **343**, 80–4 (2014).
3. Zhou, Y. *et al.* High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. *Nature* **509**, 487–491 (2014).

4. Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C. & Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. *Nat. Biotechnol.* **32**, 267–73 (2014).
5. Gilbert, L. A. *et al.* Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. *Cell* **159**, 647–661 (2014).
6. Konermann, S. *et al.* Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. *Nature* doi:10.1038/nature14136 (2014).
7. Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–23 (2013).
- 10 8. Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science* **339**, 823–6 (2013).
9. Gilbert, L. A. *et al.* CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* **154**, 442–451 (2013).
10. Cheng, A. A., Ding, H. & Lu, T. K. Enhanced killing of antibiotic-resistant bacteria enabled by massively parallel combinatorial genetics. *Proc. Natl. Acad. Sci.* **111**, 12462–7 (2014).
- 15 11. Honma, K. *et al.* RPN2 gene confers docetaxel resistance in breast cancer. *Nat. Med.* **14**, 939–948 (2008).
12. Wang, Z. *et al.* Combinatorial patterns of histone acetylations and methylations in the human genome. *Nat. Genet.* **40**, 897–903 (2008).
- 20 13. Dawson, M. A. & Kouzarides, T. Cancer epigenetics: From mechanism to therapy. *Cell* **150**, 12–27 (2012).
14. Juergens, R. A. *et al.* Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. *Cancer Discov.* **1**, 598–607 (2011).
- 25 15. Jones, P. A. & Baylin, S. B. The Epigenomics of Cancer. *Cell* **128**, 683–692 (2007).
16. Yoo, C. B. & Jones, P. A. Epigenetic therapy of cancer: past, present and future. *Nat. Rev. Drug Discov.* **5**, 37–50 (2006).
17. Jin, C. *et al.* Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 9235–40 (2014).
- 30 18. Asangani, I. a *et al.* Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. *Nature* **510**, 278–82 (2014).
19. Kruidenier, L. *et al.* A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. *Nature* **488**, 404–408 (2012).

20. Bliss, C. I. THE TOXICITY OF POISONS APPLIED JOINTLY1. *Ann. Appl. Biol.* **26**, 585–615 (1939).
21. Borisy, A. A. *et al.* Systematic discovery of multicomponent therapeutics. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 7977–7982 (2003).
- 5 22. Pattanayak, V. *et al.* High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. *Nat. Biotechnol.* **31**, 839–43 (2013).
23. Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. *Nat. Biotechnol.* **32**, 677–683 (2014).
- 10 24. Wu, X. *et al.* Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. *Nat. Biotechnol.* **32**, 670–676 (2014).
25. Doench, J. G. *et al.* Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. *Nat. Biotechnol.* **32**, 1262–1267 (2014).
26. Essletzbichler, P. *et al.* Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. *Genome Res.* **24**, 2059–2065 (2014).
- 15 27. Blasco, R. B. *et al.* Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. *Cell Rep.* **9**, 1219–1227 (2014).
28. Choi, P. S. & Meyerson, M. Targeted genomic rearrangements using CRISPR/Cas technology. *Nat. Commun.* **5**, 3728 (2014).
- 20 29. Moffat, J. *et al.* A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen. *Cell* **124**, 1283–1298 (2006).
30. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**, 2281–308 (2013).
31. Kim D, *et al.* (2013) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* 14:R36.
- 25 32. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10:R25.
33. Trapnell C, *et al.* (2013) Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nat Biotechnol* 31:46–53.
- 30 34. Subramanian A, *et al.* (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 102:15545–50.
35. Stemmer M (2015) CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool. *PLoS One* 10(4):e0124633.

EQUIVALENTS

While several inventive embodiments have been described and illustrated herein,
5 those of ordinary skill in the art will readily envision a variety of other means and/or
structures for performing the function and/or obtaining the results and/or one or more of the
advantages described herein, and each of such variations and/or modifications is deemed to
be within the scope of the inventive embodiments described herein. More generally, those
skilled in the art will readily appreciate that all parameters, dimensions, materials, and
10 configurations described herein are meant to be exemplary and that the actual parameters,
dimensions, materials, and/or configurations will depend upon the specific application or
applications for which the inventive teachings is/are used. Those skilled in the art will
recognize, or be able to ascertain using no more than routine experimentation, many
equivalents to the specific inventive embodiments described herein. It is, therefore, to be
15 understood that the foregoing embodiments are presented by way of example only and that,
within the scope of the appended claims and equivalents thereto, inventive embodiments may
be practiced otherwise than as specifically described and claimed. Inventive embodiments of
the present disclosure are directed to each individual feature, system, article, material, kit,
and/or method described herein. In addition, any combination of two or more such features,
20 systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials,
kits, and/or methods are not mutually inconsistent, is included within the inventive scope of
the present disclosure.

All definitions, as defined and used herein, should be understood to control over
dictionary definitions, definitions in documents incorporated by reference, and/or ordinary
25 meanings of the defined terms.

The indefinite articles “a” and “an,” as used herein in the specification and in the
claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”

The phrase “and/or,” as used herein in the specification and in the claims, should be
understood to mean “either or both” of the elements so conjoined, i.e., elements that are
30 conjunctively present in some cases and disjunctively present in other cases. Multiple
elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of
the elements so conjoined. Other elements may optionally be present other than the elements
specifically identified by the “and/or” clause, whether related or unrelated to those elements
specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when

used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

5 As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or,” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of”
10 or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary
15 meaning as used in the field of patent law.

 As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements
20 and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A
25 and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one,
30 B (and optionally including other elements); etc.

 It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.

5 In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

10

What is claimed is:

CLAIMS

- 5 1. A genetic construct comprising
a first DNA element comprising
a CRISPR guide sequence and
a scaffold sequence;
a first compatible end element and a second compatible end element flanking the first
10 DNA element, wherein the first and second compatible end elements are capable of annealing
to each other;
a barcode element;
a third compatible end element and a fourth compatible end element flanking the
barcode element, wherein the third and fourth compatible end elements are capable of
15 annealing to each other but are not capable of annealing to the first or second compatible end
elements; and
a separation site located between the fourth compatible end element and the first
compatible end element, wherein the DNA element, first compatible end element, and second
compatible end element are on one side of the separation site, and the barcode element, the
20 third compatible end element, and the fourth compatible end element are on the other side of
the separation site.
2. The genetic construct of claim 1, further comprising a promoter element upstream of
the first DNA element.
- 25 3. A vector comprising a genetic construct according to claim 1 or 2.
4. A genetic construct comprising:
a plurality of DNA elements, wherein each DNA element of the plurality of DNA
30 element comprises a CRISPR guide sequence and a scaffold sequence;
a first compatible end element and a second compatible end element flanking the
plurality of DNA elements, wherein the first and second compatible end elements are capable
of annealing to each other;
a plurality of barcode elements;

a third compatible end element and a fourth compatible end element flanking the plurality of barcode elements, wherein the third and fourth compatible end elements are capable of annealing to each other but are not capable of annealing to the first or second compatible end elements; and

5 a separation site located between the plurality of DNA elements and the plurality of barcode elements.

5. A vector comprising

a genetic construct according to claim 4 and

10 a promoter sequence located upstream of each of the CRISPR guide sequences.

6. A method for generating a combinatorial vector, comprising:

(a) providing a vector containing a first genetic construct comprising:

a CRISPR guide sequence;

15 a second compatible end element and a first recognition site for a first restriction enzyme flanking the CRISPR guide sequence;

a barcode element; and

a third compatible end element and a second recognition site for a second restriction enzyme flanking the barcode element;

20 (b) cleaving the first genetic construct at the first recognition site, resulting in a fifth compatible end element, and cleaving the vector at the second recognition site, resulting in a sixth compatible end element;

(c) providing a scaffold element comprising

a scaffold sequence;

25 a separation site comprising a first compatible end element and a fourth compatible end element; and

a seventh compatible end element and an eighth compatible end element flanking the scaffold element, wherein the seventh compatible end element is capable of annealing to the fifth compatible end element and the eighth compatible end element is capable of annealing to the sixth compatible end element;

30 (d) annealing the scaffold element to the cleaved first genetic construct, wherein the annealing occurs at compatible end elements within the vector and the scaffold element that are capable of annealing to each other, and wherein after the annealing, the scaffold element is integrated between the CRISPR guide sequence

and the barcode element, and wherein the separation site is located between the scaffold sequence and the barcode element, creating a combinatorial vector.

7. The method of claim 6, further comprising:

5 (a) providing a combinatorial vector according to claim C1;

(b) cleaving the vector at the separation site within the scaffold element, resulting in a first compatible end element and a fourth compatible end element;

(c) providing a second genetic construct comprising

a CRISPR guide sequence;

10 a scaffold sequence;

a barcode element; and

a second compatible end element and a third compatible end element flanking the second genetic construct, wherein the second compatible end element of the second genetic construct is capable of annealing with the first compatible end element of the vector and the third compatible end element of the second genetic construct is capable of annealing to the fourth compatible end element of the vector;

15

(d) annealing the second genetic construct to the cleaved vector, wherein the annealing occurs at compatible end elements within the second genetic construct and the vector that are capable of annealing to each other, and wherein after annealing, the second genetic construct is integrated into the vector, creating a combinatorial vector comprising concatenated barcode elements and concatenated CRISPR guide and scaffold sequences.

20

25 8. The method of claim 7, wherein the combinatorial vector further comprises a promoter element upstream of the CRISPR guide sequences.

9. The method of claim 7 or 8, wherein the method is iterative.

30 10. The method of any one of claims 6-9, wherein the first recognition site and the second recognition sites have the same recognition site sequence, and the first restriction enzyme and the second restriction enzyme are the same restriction enzymes.

11. A genetic construct comprising
at least two CRISPR guide sequences;
a barcode element; and
a restriction recognition site located between each CRISPR guide sequence and
5 between the barcode element and the CRISPR guide sequence nearest to the barcode element.
12. A genetic construct comprising
a plurality of DNA elements, each comprising
a CRISPR guide sequence and
10 a scaffold sequence;
a barcode element; and
a promoter sequence located upstream of each of the DNA elements of the plurality of
DNA elements.
- 15 13. The genetic construct of claim 11 or 12, wherein the barcode element is located at the
5' end of the genetic construct.
14. The genetic construct of claim 11 or 12, wherein the barcode element is located at the
3' end of the genetic construct.
- 20 15. A vector comprising any of the genetic constructs according to claims 11-14.
16. A method for generating a combinatorial vector, comprising
(a) providing a vector comprising:
25 a plurality of CRISPR guide sequences;
a barcode element, wherein the barcode element is located downstream of the
plurality of CRISPR guide sequences;
optionally a promoter sequence located upstream of at least one of the
plurality of CRISPR guide sequences; and
30 a plurality of recognition sites for a plurality of restriction enzymes, wherein
each of the plurality of recognition sites is located downstream of one of the plurality
of CRISPR guide sequences;

- (b) cleaving the vector at at least one of the plurality of recognition sites with at least one of the plurality of restriction enzymes, resulting in a first compatible end element and a second compatible end element;
- (c) providing a first scaffold element comprising:
- 5 a scaffold sequence,
 optionally a promoter sequence, and
 a third compatible end element and fourth compatible end element flanking the first scaffold element, wherein the third compatible end element is capable of annealing to the first compatible end element of the cleaved vector and the fourth
- 10 compatible end element is capable of annealing to the second compatible end element of the cleaved vector;
- (d) annealing the first scaffold element to the cleaved vector, wherein the annealing occurs at compatible end elements within the first scaffold element and the cleaved vector, and wherein after annealing, the first scaffold element is integrated
- 15 downstream of one of the plurality of CRISPR guide sequences, thereby producing a combinatorial vector.

17. The method of claim 16, wherein the method is iterative.

20 18. A method for generating a combinatorial vector, comprising

- (a) providing a vector comprising:
- a plurality of CRISPR guide sequences,
 a barcode element, wherein the barcode element is located upstream of the plurality of CRISPR guide sequences;
- 25 optionally a promoter sequence located upstream of at least one of the plurality of CRISPR guide sequences; and
 a plurality of recognition sites for a plurality of restriction enzymes, wherein each of the plurality of recognition sites is located upstream of one of the plurality of CRISPR guide sequences;
- 30 (b) cleaving the vector at least one of the plurality of recognition sites with at least one of the plurality of restriction enzymes, resulting in a first compatible end element and a second compatible end element;
- (c) providing a first scaffold element comprising:
 optionally a scaffold sequence,

a promoter sequence, and

a third compatible end element and fourth compatible end element flanking the first scaffold element, wherein the third compatible end element is capable of annealing to the first compatible end element of the cleaved vector and the fourth compatible end element is capable of annealing to the second compatible end element of the cleaved vector;

(d) annealing the first scaffold element to the cleaved vector, wherein the annealing occurs at compatible end elements within the first scaffold element and the cleaved vector, and wherein after annealing, the first scaffold element is integrated upstream of one of the plurality of CRISPR guide sequences, thereby producing a combinatorial vector.

19. The method of claim 18, wherein the method is iterative.

20. A composition comprising two or more inhibitors targeting two or more epigenetic genes selected from the combinations of epigenetic genes set forth in Table 2.

21. The composition of claim 20, wherein each of the two or more inhibitors reduce or prevent expression of an epigenetic gene or reduce or prevent activity of a protein encoded by the epigenetic gene.

22. The composition of claim 20 or 21, wherein each of the inhibitors is selected from the group consisting of a CRISPR guide sequence and scaffold sequence; an shRNA; and a small molecule.

23. The composition of claim 22, wherein at least one of the inhibitors is a CRISPR guide sequence and scaffold sequence; and the composition further comprises or encodes a Cas9 endonuclease.

24. The composition of claim 22 or 23, wherein the CRISPR guide sequence or shRNA is expressed from a recombinant expression vector.

25. The composition of any one of claims 20-24, wherein the combination of epigenetic genes comprises BRD4 and KDM4C or BRD4 and KDM6B.

26. The composition of claim 25, wherein the inhibitor of BRD4 is JQ1 ((6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester).

5

27. The composition of claim 25 or 26, wherein the inhibitor of KDM4C is SD70 (N-(furan-2-yl(8-hydroxyquinolin-7-yl)methyl)isobutyramide).

28. The composition of claim 25 or 26, wherein the inhibitor of KDM6B is GSK-J4 (ethyl
10 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride).

29. A method for reducing proliferation of a cell, comprising contacting the cell with a combination of two or more inhibitors targeting two or more epigenetic genes selected from
15 the combinations of epigenetic genes set forth in Table 2.

30. The method of claim 29, wherein the cell is a cancer cell.

31. The method of claim 30, wherein the cancer cell is an ovarian cancer cell.

20

32. The composition of any one of claims 29-31, wherein each of the two or more inhibitors reduce or prevent expression of an epigenetic gene or reduce or prevent activity of a protein encoded by the epigenetic gene.

25 33. The composition of any one of claims 29-32, wherein each of the inhibitors is selected from the group consisting of a CRISPR guide sequence and scaffold sequence; an shRNA; and a small molecule.

34. The composition of claim 33, wherein at least one of the inhibitors is a CRISPR guide
30 sequence and scaffold sequence; and the composition further comprises or encodes a Cas9 endonuclease.

35. The composition of claim 33 or 34, wherein the CRISPR guide sequence or shRNA is expressed from a recombinant expression vector.

36. The composition of any one of claims 29-35, wherein the combination of epigenetic genes comprises BRD4 and KDM4C or BRD4 and KDM6B.

5 37. The composition of claim 36, wherein the inhibitor of BRD4 is JQ1 ((6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester).

10 38. The composition of claim 36 or 37, wherein the inhibitor of KDM4C is SD70 (N-(furan-2-yl(8-hydroxyquinolin-7-yl)methyl)isobutyramide).

39. The composition of claim 36 or 37, wherein the inhibitor of KDM6B is GSK-J4 (ethyl 3-(((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride).

15

40. A method for treating cancer in a subject, comprising administering to the subject a combination of two or more inhibitors targeting two or more epigenetic genes selected from the combinations of epigenetic genes set forth in Table 2, wherein each of the two or more inhibitors are administered in an effective amount.

20

41. The method of claim 40, wherein each of the inhibitors is selected from the group consisting of a CRISPR guide sequence, an shRNA, and a small molecule.

25 42. The method of claim 41, wherein the effective amount of each of the two or more inhibitors administered in the combination is less than the effective amount of the inhibitor when not administered in the combination.

30 43. The composition of any one of claims 40-42, wherein each of the two or more inhibitors reduce or prevent expression of an epigenetic gene or reduce or prevent activity of a protein encoded by the epigenetic gene.

44. The composition of any one of claims 40-43, wherein each of the inhibitors is selected from the group consisting of a CRISPR guide sequence and scaffold sequence; an shRNA; and a small molecule.

45. The composition of claim 44, wherein at least one of the inhibitors is a CRISPR guide sequence and scaffold sequence; and the composition further comprises or encodes a Cas9 endonuclease.

5

46. The composition of claim 44 or 45, wherein the CRISPR guide sequence or shRNA is expressed from a recombinant expression vector.

10

47. The composition of any one of claims 40-46, wherein the combination of epigenetic genes comprises BRD4 and KDM4C or BRD4 and KDM6B.

48. The composition of claim 47, wherein the inhibitor of BRD4 is JQ1 ((6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester).

15

49. The composition of claim 47 or 48, wherein the inhibitor of KDM4C is SD70 (N-(furan-2-yl(8-hydroxyquinolin-7-yl)methyl)isobutyramide).

20

50. The composition of claim 47 or 48, wherein the inhibitor of KDM6B is GSK-J4 (ethyl 3-(((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride).

51. A method for identifying a combination of inhibitors of epigenetic genes that reduces proliferation of a cell, the method comprising:

25

contacting a first population of cells and a second population of cells with a plurality of combinations of two or more CRISPR guide sequences and scaffold sequences and a Cas9 endonuclease;

culturing the first population of cells and the second population of cells such that the second population of cells is cultured for a longer duration compared to the first population of cells;

30

identifying the combinations of two or more CRISPR guide sequences and scaffold sequences in the first population of cells and the combinations of two or more CRISPR guide sequences and scaffold sequences in the second population of cells;

comparing the abundance of each combination of two or more CRISPR guide sequences and scaffold sequences in the first population of cells to the abundance of each combination of two or more CRISPR guide sequences and scaffold sequences in the second population of cells; and

5 identifying a combination of two or more CRISPR guide sequences and scaffold sequences that is absent from or in reduced abundance in the second population of cells but present in or in increased abundance in the first population of cells as a combination of CRISPR guide sequences and scaffold sequences that reduces cell proliferation.

10 52. A method for identifying a combination of genes to be inhibited to reduce proliferation of a cell, the method comprising:

contacting a first population of cells and a second population of cells with a plurality of combinations of two or more CRISPR guide sequences and scaffold sequences and a Cas9 endonuclease;

15 culturing the first population of cells and the second population of cells such that the second population of cells is cultured for a longer duration compared to the first population of cells;

identifying the combinations of two or more CRISPR guide sequences and scaffold sequences in the first population of cells and the combinations of two or more CRISPR guide sequences and scaffold sequences in the second population of cells;

20 comparing the abundance of each combination of two or more CRISPR guide sequences and scaffold sequences in the first population of cells to the abundance of each combination of two or more CRISPR guide sequences and scaffold sequences in the second population of cells; and

25 identifying a combination of two or more CRISPR guide sequences and scaffold sequences that is absent from or in reduced abundance in the second population of cells but present in or in increased abundance in the first population of cells as a combination of genes to be inhibited to reduce proliferation.

30

FROM FIG. 1A

4. Pooled ligation of storage vectors digested with BbsI and an annealed oligo containing gRNA scaffold sequence




FIG. 1A (CONT.)




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3D

FIG. 3C




FIG. 4A

9/47




FIG. 4B




FIG. 4C




FIG. 5B




FIG. 5A

11/47

JQ1 (μM)	% inhibition			Excess over Bliss independence model			Excess over HSA model		
	SD70 (μM)			SD70 (μM)			SD70 (μM)		
	0	1.25	2.5	0	1.25	2.5	0	1.25	2.5
0	0±7	24±5	50±4	0	0	0	0	0	0
0.1	8±17	26±13	61±6	0	-5	6	0	2	11
0.2	4±8	38±4	63±6	0	11	11	0	14	13




FIG. 5C





FIG. 5D




FIG. 6A




FIG. 6B




FIG. 6D

FIG. 6C




FIG. 6E

17/47

sgRNA	Uncleaved band	Cleaved bands
DNMT1-sg1	600	450/150
DNMT3B-sg1	544	400/150
PRMT2-sg3	559	370/170
HDAC2-sg1	871	500/300
ING4-sg1	502	300/200
KDM1B-sg3	499	350/150
KDM2A-sg3	455	300/150
PRMT6-sg1	849	550/300
KDM4C-sg1	419	264/155
KDM6B-sg2	489	273/216
BRD4-sg3	541	341/200

FIG. 7A




FIG. 7B




FIG. 7C

sgRNA	Uncleaved band	Cleaved bands
KDM4C-sg1	419	264/155
KDM6B-sg2	489	273/216
BRD4-sg3	541	341/200




FIG. 8A




FIG. 8B

BMI1-sg2 + PHF8-sg2

	WT	BMI1	PHF8
Single cell-derived clone #1	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TGACTCACAAATCTCTCATGTTTTTTCTGGCCTTAGTGAAAAAACCAGCCGGTGGATCTTCAAAGGGG -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'
Single cell-derived clone #2	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'
Single cell-derived clone #3	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'
Single cell-derived clone #4	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'
Single cell-derived clone #5	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'	5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3' 5' - TTTC AACAGTTTCCTACCTTATATATTCAGTAGTGGGCTGGCTTGTGAACCTGGACATCACAA -3'

21/47

FIG. 9A

BMI1-sg2 + PHF8-sg2

Single cell-derived clone #	5' -	3' -	WT	BM11
Single cell-derived clone #6	5' - TTTC AACAGTTTCCTACCTTATATATTC - - - - - TAGTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	5' - TTTC AACAGTTTCCTACCTTATATATTC - - - - - IG TGAACCTTGGACATCACA A - 3'	WT -13 bp	BM11
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	+1 bp	PHF8
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	+1 bp	PHF8
Single cell-derived clone #7	5' - TTTC AACAGTTTCCTACCTTATATTC - - - - - AGTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	5' - TTTC AACAGTTTCCTACCTTATATTC - - - - - AGTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	-3 bp	BM11
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	1 mut.; +3 bp	PHF8
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	1 mut.; +3 bp	PHF8
Single cell-derived clone #8	5' - TTTC AACAGTTTCCTACCTTATATTC - - - - - TAGTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	5' - TTTC AACAGTTTCCTACCTTATATTC - - - - - TCTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	-6 bp	BM11
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	-10 bp	PHF8
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	WT	PHF8
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	WT	PHF8
Single cell-derived clone #9	5' - TTTC AACAGTTTCCTACCTTATATTC - - - - - TAGTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	5' - TTTC AACAGTTTCCTACCTTATATTC - - - - - TAGTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	-2 bp	BM11
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	1 mut.; -7 bp	PHF8
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	WT	PHF8
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	WT	PHF8
Single cell-derived clone #10	5' - TTTC AACAGTTTCCTACCTTATATTC - - - - - TAGTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	5' - TTTC AACAGTTTCCTACCTTATATTC - - - - - TAGTGGTCTGGTCTTGTGAACCTTGGACATCACA A - 3'	WT	BM11
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	WT	PHF8
	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	5' - TGACTCACA AATCTCTCA TGTGTTTCTGGCTTAGTGA AAAAAACGGCCGTGGATCTTCAAAGGGG - 3'	WT	PHF8

FIG. 9A (CONT.)

BRD4-sg2 + KDM4C-sg1

Single cell-derived clone #6	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	BRD4
	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	
Single cell-derived clone #7	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	1 mut; +1 bp	KDM4C
	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+1 bp	
Single cell-derived clone #8	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	BRD4
	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	
Single cell-derived clone #9	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+1 bp	KDM4C
	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	-5 bp	
Single cell-derived clone #10	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	BRD4
	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	
Single cell-derived clone #11	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+1 bp	KDM4C
	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+2 bp	
Single cell-derived clone #6	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	BRD4
	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	
Single cell-derived clone #7	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+2 bp	KDM4C
	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+1 bp	
Single cell-derived clone #8	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	BRD4
	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	
Single cell-derived clone #9	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+1 bp	KDM4C
	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+2 bp	
Single cell-derived clone #10	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	BRD4
	5' - TAGACATTTGGGAAGTTTCTAGTCCATCCCCCAATTACTGGCAGATTTCTCAATCTCGTCC - 3'	WT	
Single cell-derived clone #11	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	-21 bp	KDM4C
	5' - GAAGGATAATCACCTTTGCAAGACCCCGCAACGATGGGCTCCTTTAGACTCCATGTATGCA - 3'	+1 bp	

FIG. 9B (CONT.)

25/47

BMI1-sg2 + PHF8-sg2




FIG. 9C




FIG. 10A




FIG. 10B

26/47




FIG. 11




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13




FIG. 14A




FIG. 14B




FIG. 14C





FIG. 14D





FIG. 14E

31/47





FIG. 14F




FIG. 15

33/47




FIG. 16A





FIG. 16B

34/47

NF1-sg1



NF2-sg2




FIG. 16C

35/47





FIG. 16C (CONT.)





FIG. 16D



37/47

FIG. 16E




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 18

	<u>Guide Sequence</u>	<u>PAM</u>		
KDM4C-sg1	CCTTTGCAAGACCCGCACGA	TGG	80.85%	

	GCTTTGCCCGAACCGCACGA	GAG	0.29%	
	CCTAGGCCAGACCTGCACGA	TGG	0.23%	
	GCTCTGGAAGACCCGCACCA	GGG	0.21%	exonic
CCTTATCAAGACCCACACCA	GAG	0.15%		
	ATCCCCCTCCTCGTAGCGCA	TGG	52.74%	

KDM6B-sg2	TGCGCCCTCCTCCTAGCGCA	TGG	3.74%	
	CTGCCCTCCTGGTAGCGCC	TGG	1.01%	
	CTGCTCCTCCTCGTAGCGCT	GGG	0.43%	
	AACCAGCTCCTCGTAGCTCA	GGG	0.32%	
	AGCCCGCTCCTCGTGGGGCA	CGG	0.19%	exonic
	ACCGCCCTCCTCCTAGCTCA	GGG	0.17%	
	CTCCTCCTCCGCGTAGCGCT	TGG	0.14%	
	CTCCTCCTCCTCCTACCGCA	AGG	n.d.	
	ATTCTCCTCCTGGTACCGCA	AGG	n.d.	
	CTCACCTCCTCCTAGCACA	TAG	n.d.	
	GGGAACAATAAAGAAGCGCT	TGG	61.97%	

BRD4-sg3	TGGAAAACAAAGAAGAGCT	TGG	0.38%	
	GGGAAGTATAAGGAAGAGCT	CAG	0.26%	exonic
	GTGAGCAATAAAGCAGCCCT	AAG	0.18%	
	TCTAGTCCATCCCCATTAC	TGG	16.65%	

BRD4-sg2	AATATTCCATTCCCCATTAC	TGG	0.33%	
	TGTTGTCCATACCTCATTAC	TGG	0.19%	exonic
	TCTAGGTCATGCACCATTAC	TGG	0.19%	

	TCCACACCCTCCCCATTAC	TAG	0.25%	intronic
	CCCATTCTTCCCCATTAC	CAG	0.21%	

FIG. 19

43/47




FIG. 20A




FIG. 20B




FIG. 21A





FIG. 21B




FIG. 22A

47/47




FIG. 22B